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1.	  INTRODUCTION	  
1.1	  Actin	  and	  myosins	  in	  cell	  motility	  
1.1.1	  How	  the	  cell	  move:	  an	  overview	  Different	   type	   of	   protein	   filaments,	   known	   as	  microtubules,	   intermediate	   filaments,	  and	  microfilaments,	   form	   the	   cytoskeleton.	   The	   cytoskeleton	   supports	   and	   actively	  participates	   in	   various	   processes	   such	   as	   internalization	   of	   molecules	   and	   vesicles	  from	   the	   plasma	   membrane	   [Smythe	   et	   al.,	   2006],	   exocytosis	   [Porat-­‐Shliom	   et	   al.,	  2013],	  and	  last,	  but	  not	  least	  cells	  movement.	  This	  dynamic	  system	  is	  indeed	  essential	  in	   order	   to	   generate	   the	   force	   necessary	   to	  move	   cells.	  Movement	   is	   the	   results	   of	  different	   stimuli	   transmitted	   from	  grow	   factors	   receptors	   such	  as	   receptor	   tyrosine	  kinases	   (RTKs)	   or	   G	   protein–coupled	   receptors	   (GPCRs)	   to	   the	   cytoplasmic	  environment	   through	   adhesion	   molecules	   such	   as	   integrins	   and	   cadherins.	   Such	  molecules	   can	   elicit	   and	   control	   signal	   cascades,	   causing	   major	   cytoskeleton	  rearrangements,	  which	  ultimately	  lead	  to	  cell	  movement.	  	  Physiological	   processes	   such	   as	   embryonic	   development,	   wound	   healing,	   and	  immune	  responses	  exploit	  single-­‐	  and/or	  multiple-­‐cell	  migration	  and	  both	  processes	  are	  highly	  regulated	  [Ridley,	  2011].	  In	  normal	  condition	  the	  movement	  ceases	  when	  the	   cell	   reaches	   its	   final	   destination,	   terminal	   differentiates,	   or	   ends	   its	   functions.	  Lack	  of	  movement,	  or	  uncontrolled	  motility	   leads	  to	  diverse	  pathological	  conditions	  such	   as	   cancer-­‐cell	   dissemination	   (metastasis),	   developmental	   defects,	  immunosuppression	   of	   autoimmune	   reactions	   [Yamaguchi	   et	   al.,	   2007]	   [Ridley,	  2011].	  To	  achieve	  cell	  movement,	  several	  processes	  occur	  in	  a	  coordinate	  fashion.	  	  The	  first	  step	  begins	  with	  the	  extension	  of	  the	  protrusions	  mediated	  by	  actin-­‐structures	  at	  the	  leading	  edge	  [Nurnberg	  et	  al.,	  2011].	  These	  structures	  contain	  actin	  filaments	  and	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are	   called	   lamellipodia	   and	   filopodia	   (Figure	   1).	  Then,	   adhesions	   at	   the	   rear	  of	   the	  cell	  must	  be	  disassembled	  and	  internalized,	  while	  new	  adhesions	  should	  be	  formed	  at	  the	  front	  through	  exocytosis	  processes	  [Ridley	  et	  al.,	  2003].	  	  	  
	  	  
Figure	   1	   Steps	   in	   cell	  migration.	  a)	   Formation	  of	   actin	  protrusions	   at	   the	   leading	   edge	  drives	   the	  process.	   b)	   Establishment	   of	   new	   adhesive	   sites	   stabilizes	   the	   protrusions	   c)	   The	   tensile	   forces	  between	  adhesions	  and	  actin-­‐	  cytoskeleton	  lead	  the	  nucleus	  and	  the	  cell	  body	  to	  translocate	  forward	  in	  the	  direction	  of	  migration	  d)	  At	  the	  cell	  rear,	  old	  adhesions	  disassemble,	  and	  the	  trailing	  edge	  retracts	  Adapted	  from	  [Mattila	  et	  al.,	  2008].	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1.1.2	  Actin	  and	  the	  microfilament	  system	  Actin	  together	  with	  different	  motor	  proteins	  (myosins),	  and	  actin	  regulatory	  proteins	  form	  the	  microfilament	  system,	  the	  most	  dynamic	  component	  of	  the	  cytoskeleton	  and	  the	  major	  responsible	  for	  cell	  motility.	  	  Actin	  polymers	   (filamentous,	   F-­‐actin)	   are	   formed	  by	   single	  42	  kDa	  monomers	  (globular	   G-­‐actin)	   that	   posses	   the	   ability	   to	   bind	   ATP	   and	   ADP.	   	   Polymerization	   of	  molecules	   to	   form	   F-­‐actin	   is	   the	   major	   driving	   responsible	   for	   formation	   of	  protrusions.	   This	   was	   demonstrated	   to	   be	   an	   autocatalytic	   process	   in	   vitro.	   When	  assembled,	   actin	   filaments	   resemble	   a	   twisted	   string	  of	   approximately	  7	  nm	  with	   a	  structural	  and	  functional	  polarization.	  A	  fast	  polymerizing	  or	  barbed	  end	  (plus	  or	  “+”	  end)	  represents	  one	  terminus,	  while	  a	  slow	  polymerizing	  or	  pointed	  end	  (minus	  or	  “–“	  end)	  forms	  the	  other	  terminus	  of	  the	  filament.	  Most	  of	  the	  large-­‐scale	  rearrangements	  of	  actin	  cytoskeleton,	  during	  protrusions	  formation	  are	  due	  to	  actin	  polymerization,	  and	  take	  place	  just	  beneath	  the	  plasma	  membrane	  where	  the	  vast	  majority	  of	  barbed-­‐ends	   are	   positioned	   [Carlier	   et	   al.,	   2015].	   Spatial	   and	   temporal	   regulation	   of	   actin	  polymerization	  are	  obtained	  through	  the	  action	  of	  a	  plethora	  of	  actin	  binding	  proteins	  (ABPs)	   such	   as	   profilin,	   which	   maintain	   a	   pool	   of	   ready-­‐to-­‐polymerize	   actin,	   or	  capping	  proteins	  that	  can	  bind	  and	  block	  both	  barbed-­‐	  and	  pointed-­‐end	  of	  filaments.	  Other	   ABPs	   affect	   F-­‐actin	   formation	   through	   their	   severing,	   bundling	   or	   nucleating	  factors,	   thus	   resulting	   in	   filaments	   disruption,	   reinforcement	   or	   de	   novo	  polymerization,	   respectively	   (Figure	   2).	  The	  combined	  activity	  of	  all	   these	  proteins	  generates	   cell	   movement,	   thanks	   to	   constant	   actin	   polymerization	   and	   filaments-­‐network	  assembly	  at	  the	  cell	  front	  while	  depolymerization	  of	  filaments,	  together	  with	  disassembly	  of	  cell/surface	  adhesions	  occurs	  at	  the	  cell	  rear.	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Figure	   2	   Actin	   nucleation	   and	   polymerization.	   Simplified	   representation	   of	   actin	   polymerization	  dynamics.	  Spontaneous,	  ATP-­‐bound	  actin	  oligomers	  (or	  nuclei)	  formation	  is	  kinetically	  unfavourable,	  and	   this	   slows	   down	   the	   whole	   actin	   filaments	   formation.	   Once	   this	   stage	   is	   overcome,	   actin	  polymerization	   is	   fast,	  especially	  at	   the	  plus-­‐end.	  ATP	   is	  quickly	  hydrolysed	  by	  F-­‐actin	   forming	  ADP-­‐actin,	   which	   favours	   depolymerization	   of	   filaments.	   Both	   polymer	   formation	   and	   dissociation	   are	  influenced	  by	  several	  actin-­‐binding	  proteins	  such	  as	  ADF/cofilin	   (favouring	  dissociation),	  or	  capping	  proteins	  (stabilizing	  and	  thus	  blocking	  one	  of	  the	  two	  ends	  of	  the	  filament).	  ADP	  to	  ATP	  exchange	  on	  actin	   is	  catalysed	  by	  profilin,	  which	  maintain	  a	  pool	  of	  ready-­‐to-­‐polymerize	  actin.	  From	  [Nurnberg	  et	  
al.,	  2011]. 
	  
1.1.3	  The	  myosin	  superfamily	  of	  motor	  proteins	  Several	  molecular	  motors	   exploit	  microfilaments	   and	  microtubules	   to	   travel	  within	  the	   cell.	   In	   the	   case	   of	   actin	   filaments,	   diverse	   ATPases	   known	   as	   myosins	   have	  evolved	   in	   all	   eukaryotes	   [Foth	   et	   al.,	   2006].	   This	   large	   family	   of	   motor-­‐proteins	  participates	   in	   every	   aspect	   of	   the	   motility	   of	   living	   beings,	   being	   involved	   in	  macroscopic	   processes	   such	   as	   muscle	   contraction	   [Geeves,	   1991],	   as	   well	   as	   in	  microscopic	   phenomena	   such	   as	   vesicle	   internalization	   [Chandrasekar	   et	  al.,	   2014].	  Muscle	  class	  II	  myosin	  has	  been	  the	  first	  identified	  and	  the	  most	  studied	  one	  among	  the	   actin-­‐based	   molecular	   motors	   [Geeves,	   1991].	   It	   forms	   macromolecular,	   rod-­‐
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shaped	   complexes,	   which	   are	   tightly	   interconnected	   with	   actin	   filaments.	   By	  reciprocal	   sliding,	   actin	   filaments	   and	   myosin	   class	   II	   complexes	   cause	   muscle	  shortening,	   and	   thus	   contraction.	   We	   refer	   to	   these	   class	   II	   molecules	   as	   the	  conventional	   myosins.	   The	   later	   discovery	   of	   class	   I	   myosin	   [Pollard	   et	   al.,	   1973]	  opened	   the	   route	   to	   the	   identification	   of	   novel	   myosin	   classes,	   which,	   with	   the	  advance	  in	  genome	  sequencing	  raised	  the	  number	  of	  known	  classes	  to	  37	  [Richards	  et	  
al.,	   2005]	   (Figure	   3).	   All	   myosins,	   a	   part	   from	   muscle	   myosin	   II,	   are	   known	   as	  unconventional	  myosins	  [Woolner	  et	  al.,	  2009].	  	  	  	  
	  
	  
Figure	   3	   Myosins	   differentiation	   tree.	   Unrooted	   phylogenetic	   tree	   of	   the	   myosin	   superfamily	   is	  derived	  from	  an	  alignment	  of	  139	  members	  of	   the	  myosin	  superfamily.	  The	  alignment	  compared	  the	  core	   motor	   domains	   (equivalent	   to	   residues	   88-­‐780	   of	   chicken	   skeletal	   myosin	   II)	   of	   each	   myosin,	  using	  distance	  matrix	  analysis	  performed	  with	  the	  Clustal-­‐W	  package	  [Hodge	  et	  al.,	  2000] 	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The	   overall	   domain	   organization	   of	   all	   actin-­‐based	  molecular	  motors	   is	   quite	  conserved.	  At	   the	  N-­‐terminal	  region	   is	   the	  ATP-­‐	  and	  actin-­‐binding	  region,	  known	  as	  motor	  domain,	  which	  spans	  700	  to	  800	  amino	  acids.	  This	  part	  of	  the	  protein	  allows	  myosins	   to	   travel	   along	   the	  microfilament	   system	   to	   exert	   their	   functions	   (further	  described	  below).	  The	  motor	  domain	  is	  the	  most	  conserved	  region	  of	  the	  protein	  and	  allows	  the	  classification	  of	  the	  myosins’	  classes.	  	  Towards	  the	  C-­‐terminus	  a	  converter	  and	  neck	  (or	   lever)	  domains	  are	  found	  in	  all	   known	   myosins.	   The	   filament-­‐bound	   motor	   head	   cause	   the	   rotation	   of	   the	  converter	   region;	   the	   lever	   then	   amplifies	   such	   rearrangements	   and	   allows	   the	  reciprocal	   movement	   of	   the	   motor	   heads.	   The	   neck	   encompasses	   from	   one	   to	   six	  basic-­‐	  and	  hydrophobic-­‐rich	   (IQXXXRGXXXR)	   IQ	  motifs,	  which	  confer	   to	   the	  myosin	  molecule	  the	  ability	  to	  interact	  with	  proteins	  such	  as	  troponin	  or	  myosin	  light	  chains	  that	  regulate	  myosin	  activity	  [Tyska	  et	  al.,	  2002].	  	  The	  C-­‐terminal	  part	  of	  the	  myosin	  molecules	  is	  known	  as	  the	  tail	  domain	  and	  is	  responsible	   for	   the	   specific	   functions	   of	   the	   different	   myosin.	   Indeed	   sequence	  analysis	   of	   myosins	   tails	   point	   to	   low	   levels	   of	   conservation	   through	   evolution.	   In	  general,	  myosin	  tails	  are	  composed	  of	  various	  interaction	  surfaces	  that	  allow	  them	  to	  dimerize,	   to	   bind	   lipids	   (i.e.	   myosin	   I	   and	   VI)	   and/or	   specific	   binding	   partners.	  Because	   of	   these	   interactions	   this	   region	   is	   also	   acknowledged	   as	   cargo-­‐binding	  domain	  (CBD).	  Binding	  surfaces	  on	  myosins	  might	  include	  FERM	  (4.1	  protein,	  Ezrin,	  Radixin	   and	  Moesin	   containing)	   domain,	  MyTH4	   (Myosin	  Tail	  Homology),	   SH3	   (Src	  Homology	  3	  domain),	  PH	  (Pleckstrin	  Homology)	  domain	   [Krendel.	  et	  al.,	  2005],	  and	  MIU	  (inverted	  Ubiquitin	  Interacting	  Motif)	  [Penengo	  et	  al.,	  2006],	  (Figure	  4).	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Figure	  4	  Myosins	  domains	  organization.	  Schematic	  representation	  of	  the	  diverse	  myosin	  structures.	  The	  blue	  region	  highlight	  the	  motor	  domain,	  inserts	  are	  shown	  as	  diagonally	  hatched	  boxes.	  Coloured	  boxes	  in	  the	  tail	  domains	  represent	  different	  regions	  predicted	  by	  sequence	  homology:	  GPQ	  identifies	  a	  glycine-­‐,	   proline-­‐,	   and	   glutamine-­‐rich	   region;	   +	   +	   ,	   positively	   charged	   regions;	   SH3,	   SRC	   homology	   3	  domains;	  CC,	  coiled-­‐coil	  domains;	  MyTH4,	  myosin	  tail	  homology	  4	  domains;	  DLC,	  presumptive	  dynein	  light	   chain	   binding	   domain;	   talin,	   talin	   homology	   domain;	   Zn2+,	   zinc	   binding	   domain;	   rhoGAP,	   rho	  GTPase-­‐activating	  protein	  domain;	  and	  PH,	  pleckstrin	  homology	  domain.	  From	  [Krendel.	  et	  al.,	  2005].	  
Myosin	   translocation	   along	   actin	   filaments	   depends	   on	   structural	  rearrangements	  of	  the	  motor	  domain	  caused	  by	  ATP	  hydrolysis.	  The	  classical	  myosin	  cycle	  starts	  with	  the	  detachment	  of	  the	  motor	  protein	  from	  actin	  upon	  ATP-­‐binding.	  Successive	   formation	   of	   the	   intermediate	   myosin-­‐ADP-­‐Pi	   allows	   reattachment	   to	  actin,	   which	   is	   followed	   by	   the	   release	   of	   ADP	   and	   Pi,	   the	   final	   step	   that	   causes	  conformational	   changes	   and	   thus	   force	   generation,	   as	   well	   as	   the	   clearance	   of	   the	  ATP-­‐binding	   cleft,	   ready	   for	   a	   new	   cycle.	   Such	   conformational	   changes	   are	   then	  amplified	  by	   the	   converter	  and	   lever	  arm	  domains,	  which	  direct	   the	  motion	   (swing	  lever	  arm	  hypothesis).	  	  
electrostatic interaction between actin and a high-
ly basic insert in the Myo9b motor domain, which
prevents myosin from diffusing away from an actin
filament (56, 100).
Low-duty-ratio motors may be better suited to
induce rapid contraction of actomyosin assemblies
rather than sustained movement of a cargo along a
filament. For these myosins to function efficie tly,
the probability of their encounters with actin fila-
ments has to be high. This can be achieved by
assembling individual myosin molecules into bipo-
lar filaments, as is the case for muscle and non-
muscle Myo2s, or by allowing myosins to act in the
regions of high actin-filament concentration, such
as brush-border microvilli or the leading edge of
the cell, as has been proposed for Myo1s (34, 59).
Interestingly, vertebrate nonmuscle Myo2s are rep-
resented by both a low-duty-ratio Myo2a (64) and a
high-duty-ratio Myo2b (116, 144), both of which
may be expressed in the same cell. This may allow
Myo2b to perform functions associated with main-
tenance of cortical tension, whereas Myo2a may be
responsible for rapid contractile movements.
Actin filaments possess an inherent polarity, with
plus (or barbed) and minus (or pointed) ends.
Although most myosins move t ward the plus ends
of actin filaments, Myo6 has been shown to be a
minus-end-directed motor, and Myo9b may move
toward both plus and minus ends, which suggests
that its directionality may be regulated (see Table
1). Depending on the orientation of actin filaments
within a specific intracellular region, plus- or
minus-end-directed myosins may be better able to
perform specific functions. For example, many
types of actin-rich protrusions (filopodia, microvil-
li of intestinal brush border, inner-ear hair-cell











PH domains MyTH4 FERM
CC
DLC




I Dictyostelium MyoB (124 kDa)
I Vert. myosin Ia (119 kDa)
II Vert. skeletal muscle myosin II (223 kDa)
III Drosophila ninaC long (174 kDa)
V Vert. myosin Va (212 kDa)
VI Vert. myosin VI (145 kDa)
or
or
VII Vert. myosin VIIa (250 kDa)
IX Vert. myosin IXb (230 kDa)
X Vert. myosin X (~230 kDa)
XV Vert. myosin XVa (395 kDa)  
100 amino acids = 1 IQ motif
FIGURE 1. Myosin family of molecular motors
A: structure of the heavy chains of myosin classes discussed in this review. B: schematic representations of myosin structures. Class VI and class VII
include myosins that may exist in both a dimeric and a monomeric form. Figure is redrawn from Mermall V, Post PL, and Mooseker MS.
Unconventional myosins in cell movement, embrane traffic, and signal transduction. Science 279: 527–533, 1998.
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1.1.4	  Myosins	  functions	  Intracellular	   transport	   of	  molecules,	   vesicles,	   and	   organelles	   are	   the	  most	   intuitive	  purpose	  of	  myosins	  within	  a	  cell,	  however	  diverse	  other	  functions	  have	  emerged	  with	  time.	   A	   role	   in	   mRNA	   movement	   was	   demonstrated	   for	   class	   V	   myosin	   in	   yeast,	  transporting	   mRNA	   toward	   the	   bud	   tip	   [Graydon	   B.	   Gonsalvez	   et	   al.,	   2005].	  Mitochondria	  transport	  has	  been	  instead	  ascribed	  to	  depend	  on	  myosin	  XIX	  in	  human	  [Quintero	  et	  al.,	  2009]	  as	  well	  as	  on	  myosin	  V	  and	  VI	  in	  flies	  [Pathak	  et	  al.,	  2010].	  On	  top	  of	  the	  transport	  functions,	  myosins	  can	  also	  tether	  cargoes	  to	  actin,	  such	  as	  in	  the	  case	   of	   myosin	   V	   and	   VI	   that	   can	   anchor	   melanosomes	   and	   Golgi	   membranes,	  respectively.	   	   Myosins	   not	   only	   exploit	   microfilaments	   for	   their	   motor	   or	   anchor	  activities,	  but	  also	  can	  influence	  actin	  dynamics	  itself.	  This	  is	  the	  case	  of	  yeast	  myosin	  I	   that,	   through	   the	   interaction	  with	  WASp	  and	   the	  Arp2/3	  complex,	  promotes	  actin	  polymerization	  [Sirotkin	  et	  al.,	  2005].	  	  In	  the	  complex	  process	  of	  cell	  migration	  myosins	  acquire	  more	  disparate	  roles.	  Albeit	   cell	   protrusion	   are	   primarily	   fuelled	   by	   actin	   polymerization	   at	   the	   leading	  edge,	  contraction	  forces	  generated	  by	  myosin	  II	  on	  microfilament	  bundles	  coordinate	  the	  retraction	  of	  the	  rear	  of	  the	  moving	  cell.	  While	  migrating,	  cells	  exploit	  also	  myosin	  X	  to	  form	  new	  integrin-­‐based	  adhesions	  with	  the	  ECM	  at	  the	  leading	  edge	  [Zhang	  et	  
al.,	  2004],	  and	  contemporarily	  recycle	  older	  integrin	  through	  the	  action	  of	  myosin	  VI	  [Valdembri	  et	  al.,	  2009]	  	  	  
1.1.4.1	  Myosins	  and	  cancer	  Uncontrolled	   proliferation,	   ability	   to	   prevent	   growth	   suppression,	   maintenance	   of	  replicative	   immortality,	   disruption	   of	   the	   programmed	   cell	   death	   mechanisms,	  evasion	  of	  immune	  surveillance,	  induction	  of	  angiogenesis,	  and	  the	  ability	  to	  migrate	  and	   form	  metastasis	   are	   acknowledged	   hallmarks	   of	   cancer	   [Hanahan	   et	  al.,	   2011].	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We	   previously	   stated	   the	   involvement	   of	   myosins	   in	   the	   latter	   two	   processes	   (see	  above).	   Nevertheless	   actin-­‐based	   motors,	   through	   their	   functions,	   can	   lead	   to	   the	  appearance	   of	   many	   other	   cancer	   hallmarks	   in	   cells.	   Of	   outstanding	   interest,	   p53	  posttranslational	   stability	   has	   been	   recently	   linked	   to	   the	   function	   of	   non-­‐muscle	  myosin	   IIa.	   Knockdown	   of	   such	  motor	   protein	   stimulates	   squamous	   cell	   carcinoma	  formation	   in	   tumour-­‐susceptible	   background	   [Schramek	   et	   al.,	   2014].	   Similarly,	  myosin	  VI	  was	  previously	  shown	  to	  participate	  in	  the	  p53-­‐mediated	  survival	  pathway	  [Enari	   et	   al.,	   2006].	   Programmed	   cell	   death,	   which	   allows	   cells	   to	   kill	   themselves	  before	   becoming	   tumoural,	   was	   instead	   demonstrated	   to	   be	   influenced	   class	   V	  myosin,	  through	  its	  sequestering	  action	  of	  Bmf,	  a	  pro-­‐apoptotic	  factor	  [Puthalakath	  et	  
al.,	   2001].	   Moreover	   myosins	   are	   often	   involved	   in	   the	   maintenance	   of	   apical-­‐basolateral	  polarity,	  which	  is	  lost	  in	  tumour	  cells	  undergoing	  epithelial-­‐mesenchymal	  transition.	   On	   top	   of	   this,	   myosins	   play	   in	   processes	   such	   as	   angiogenesis,	  inflammation,	  and	   immune	  response,	  often	  hijacked	   from	  cancer	  cells	   [Ouderkirk	  et	  
al.,	  2014].	  
	  
1.2	   Myosin	  VI	  Among	  all	  the	  myosin	  classes,	  myosin	  VI	  has	  the	  unique	  property	  to	  travel	  along	  actin	  filaments	   toward	   their	   minus-­‐end.	   This	   protein	   is	   ubiquitously	   expressed	   in	   all	  multicellular	  eukaryotes.	  Myosin	  VI	  was	  first	  characterized	  in	  Drosophila	  [Kellerman	  
et	  al.,	  1992]	  and	  successively	  identified	  in	  G.	  gallus,	  S.	  scrofa	  [Hasson	  et	  al.,	  1994],	  M.	  
musculus	   [Avraham.	   et	   al.,	   1995],	   in	   C.	   elegans	   [Baker	   et	   al.,	   1997]	   and	   H.	   sapiens	  [Avraham	  et	  al.,	  1997].	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1.2.1	  	   Myosin	  VI	  mechanical	  properties	  and	  structural	  organization	  At	   a	   molecular	   scale,	   myosin	   VI	   consists	   of	   a	   ≈1250-­‐1300	   amino	   acids-­‐long	  polypeptide	   with	   two	   main	   functional	   domains	   (Figure	   5),	   a	   motor–IQ	   domain	  sufficient	  for	  pointed-­‐end	  (minus-­‐end)	  directed	  movement,	  and	  a	  tail	  region.	  The	  N-­‐terminus	  motor	  domain	  can	  interact	  with	  actin	  and	  ATP	  and	  possess	  ATPase	  activity,	  which	  is	  regulated	  by	  the	  unique	  insert	  1	  [Pylypenko	  et	  al.,	  2011].	  Release	  of	  ADP	  and	  Pi,	  the	  final	  step	  of	  the	  myosin	  motor	  cycle,	  causes	  conformational	  changes	  and	  thus	  force	   generation	   that	   are	   then	   transmitted	   to	   the	   rest	   of	   the	  molecule	   through	   the	  converter	  region	  to	  the	  insert	  2,	  a	  stretch	  of	  ≈30	  amino	  acids	  that	  can	  bind	  calmodulin	  and	  bestow	  myosin	  VI	   its	  unique	  reverse	  directionality	  through	  repositioning	  of	  the	  lever	  arm	  [Bryant	  et	  al.,	  2007];	  [Park	  et	  al.,	  2007].	  Downstream	  insert	  2	  a	  canonical	  IQ	  motif	  forms	  the	  lever-­‐arm	  and	  allows	  interaction	  with	  a	  second	  calmodulin	  molecule.	  Some	  peculiarities	  of	   the	  motor	  property	  of	  myosin	  VI,	   such	  as	   its	   large	   (30-­‐36	  nm	  steps	  on	  actin	  [Nishikawa	  et	  al.,	  2002])	  were	  found	  to	  depend	  on	  the	  tail	  region.	  The	  proximal	  part	  is	  arranged	  in	  an	  extensible	  three	  alpha-­‐helix	  bundle	  [Mukherjea	  et	  al.,	  2009],	  while	  the	  distal	  part	  forms	  an	  elongated	  single	  alpha	  helix	  (or	  SAH)	  [Spink	  et	  
al.,	  2008]	  and	  terminates	  into	  a	  cargo-­‐binding	  region	  of	  about	  250	  amino	  acids.	  Both	  these	  subdomains	  are	  unique	  to	  myosin	  VI	  and	  might	  explain	  the	  long	  pace	  of	  myosin	  VI.	  Two	  alternative	  hypotheses	  on	   the	  stepping	  mechanism	  of	  myosin	  VI	  have	  been	  put	  forward.	  In	  the	  first	  scenario,	  myosin	  VI	  SAH	  act	  as	  the	  lever-­‐arm	  extension	  and	  dimerization	   occur	   between	   the	   cargo-­‐binding	   domains	   and/or	  within	   the	   adaptor	  protein	  bound	   to	   the	  cargo-­‐binding	  domain	   [Spink	  et	  al.,	  2008];	   [Yu	  et	  al.,	  2009].	   In	  the	  second	  hypothesis	  the	  unfolded	  three-­‐helix	  bundle	  works	  as	  lever	  arm	  extension	  and	  dimerization	  takes	  place	  between	  this	  region	  and	  the	  SAH	  domain	  [Mukherjea	  et	  
al.,	   2009];	   [Mukherjea	  et	  al.,	   2014].	  For	   certain	   functions	  dimerization	  of	  myosin	  VI	  seemed	   dispensable,	   as	   in	   the	   case	   of	   spermatid	   individualization,	   where	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dimerization-­‐defective	   mutants	   were	   shown	   to	   function	   as	   the	   wild-­‐type	   molecule	  [Noguchi	  et	  al.,	  2009;	  Noguchi	  et	  al.,	  2006].	  	  	  	  
	  
Figure	   5:	   Myosin	   VI	   domains	   organization.	   Scheme	   of	   the	   different	   subdomains	   of	   myosin	   VI	  reported	  with	  their	  boundaries.	  	  	  In	  the	  cargo-­‐binding	  domain	  of	  myosin	  VI	  three	  main	  interaction	  surfaces	  are	  found.	  Among	   them	  a	  MIU	   (Motif	   Interacting	  with	  Ubiquitin)	  has	  been	   identified	   in	  myosin	  VI	   to	  bind	  ubiquitin	   [Penengo	  et	  al.,	   2006].	  On	   top	  of	   this	   the	  CBD	  contains	  also	  two	  acknowledged	  myosin	  VI	  ligand	  interaction	  surfaces,	  the	  “RRL”	  and	  “WWY”	  motifs	   (reviewed	   in	   [Tumbarello	   et	  al.,	   2013]).	   The	   RRL	   triplet	   is	   reported	   to	   bind	  endocytic	   adaptors,	   including	   GAIP-­‐interacting	   protein	   C-­‐terminus	   (GIPC)	   [Bunn	   et	  
al.,	   1999;	   Spudich	   et	   al.,	   2007],	   and	   autophagy	   receptors,	   such	   as	   optineurin	  [Sahlender	  et	  al.,	  2005],	  Nuclear	  Dot	  Protein	  52	  (NDP52)	  and	  Traf6-­‐binding	  protein	  (T6BP)	  [Morriswood	  et	  al.,	  2007].	  In	  the	  CBD	  of	  myosin	  VI,	  between	  the	  MIU	  and	  the	  RRL	  domains	   (Figure	   5),	   an	  alternative	  splicing	   region	  has	  been	   identified	   [Buss	  et	  
al.,	  2001].	  This	  has	  been	  defined	  as	   large	   insert	  (LI)	  and	  encompasses	  the	  sequence	  between	   residues	   1036	   and	   1068	   (numbering	   from	   the	   longest	   isoform),	   a	   region	  codified	  by	  three	  exons	  (Figure	  13).	  A	  second	  alternatively	  spliced	  region	  is	  coded	  by	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a	   single	   exon	   and	   encompass	  9	   amino	   acids,	   known	  as	   short	   insert	   (SI).	   This	   latter	  region	  is	  positioned	  downstream	  the	  RRL	  motif	  [Buss	  et	  al.,	  2001].	  	  An	  intrinsic	  level	  of	  complexity	  in	  deciphering	  myosin	  VI	  functions	  comes	  from	  the	  presence	  of	  different	   isoforms.	  Although	  myosin	  VI	   is	  widely	  expressed	   in	  most	  tissues,	   isoforms	  containing	  the	  LI	  are	  specifically	   found	   in	  polarized	  epithelial	  cells	  with	   well-­‐developed	   apical	   microvilli	   [Au	   et	   al.,	   2007;	   Buss	   et	   al.,	   2001].	   How	   the	  presence	  of	  LI	  in	  the	  tail	  influences	  the	  functions	  and	  intracellular	  targeting	  of	  myosin	  VI	   is	   not	   known.	   Up	   to	   now,	   isoforms	   lacking	   the	   LI	   present	   no	   specific	  expression/localization	   but	   they	   are	   required	   for	   polarized	   transport	   of	   tyrosine	  motif	  containing	  basolateral	  membrane	  proteins	  [Au	  et	  al.,	  2007]	  and	  for	  maintaining	  an	   active	   pool	   of	   secretory	   granules	   near	   the	   plasma	  membrane	   of	   neurosecretory	  cells	  [Tomatis	  et	  al.,	  2013].	  	  
1.2.2	  Myosin	  VI	  functions	  In	   the	   past	   years,	   different	   animal	   and	   cellular	   models	   have	   been	   exploited	   to	  investigate	   the	   functions	  of	  myosin	  VI.	  These	   studies	  have	   revealed	   that	   this	  motor	  protein	  potentially	  influences	  a	  large	  number	  of	  processes	  including	  asymmetric	  cell	  division,	   organelles	   architectures,	   autophagy,	   endocytosis,	   exocytosis,	   and	   cell	  migration.	  	  In	   Drosophila	   melanogaster	   Jaguar	   (myosin	   VI)	   deletion	   was	   recently	  demonstrated	  to	  partially	   impact	  on	   flies	  viability	  since	   fly’s	  progeny	   lacking	   Jaguar	  are	   viable	   but	   at	   non-­‐Mendelian	   frequency	   [Morrison	   et	   al.,	   2008].	   Possible	  explanations	   for	   this	   effect	  might	   come	   from	   earlier	   studies	   where	  myosin	   VI	   was	  shown	   to	   be	   involved	   in	   oogenesis.	   During	   this	   process,	   knockdown	   of	   myosin	   VI	  revealed	  its	  importance	  in	  follicle	  cell	  morphology	  and	  migration	  [Deng	  et	  al.,	  1999].	  Myosin	   VI	   is	   also	   required	   to	   form	   and	   maintain	   the	   actin-­‐cone	   that	   drives	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cytoplasmic	   expulsion	   in	   spermatid	   individualization.	   In	   such	   process	   the	  individualization	   complex	   traverses	   the	   length	   of	   each	   spermatid	   resulting	   in	   the	  shared	  membrane	   of	   64	   spermatids.	   Jaguar	   allows	  membrane	   rearrangements	   that	  resolves	  the	  syncytium	  into	  individual	  spermatid	  [Rogat	  et	  al.,	  2002];[Noguchi	  et	  al.,	  2006];	   [Noguchi	   et	   al.,	   2009].	   Myosin	   VI	   plays	   a	   critical	   role	   also	   in	   C.	   elegans	  spermatogenesis,	  being	  required	  for	  asymmetric	  segregation	  of	  cellular	  components	  [Kelleher	  et	  al.,	  2000].	  	  During	   embryonic	   development,	   in	   the	   process	   of	   syncytial	   blastoderm	  cleavage,	   Jaguar	   was	   shown	   to	   participate	   in	   furrow	   formation	   before	   cytokinesis	  [Mermall	   et	  al.,	   1995].	   In	   later	   stages	   of	   embryogenesis	   of	  Drosophila,	  myosin	   VI	   is	  involved	  in	  asymmetric	  cell	  division	  of	  neuroblasts	  progenitors.	  In	  these	  cells	  mitotic	  spindles	   align	   with	   the	   apical-­‐basal	   axis	   and	   the	   subsequent	   asymmetric	   division	  generates	  a	  Ganglion	  Mother	  Cell	  (GMC)	  and	  a	  neuroblast.	  Accumulation	  of	  some	  cell-­‐fate	   determinants,	   such	   as	   Miranda,	   at	   the	   basal	   membrane,	   depends	   on	   Jaguar	  activity	  during	  metaphase	  [Erben	  et	  al.,	  2008].	  	  The	  intracellular	  transport	  ability	  of	  myosin	  VI	  was	  also	  shown	  in	  Drosophila	  primary	   neurons,	   where	   it	   regulates	   the	   transport	   of	   mitochondria	   [Pathak	   et	   al.,	  2010].	  In	  this	  process,	  Jaguar	  establishes	  a	  tug-­‐of-­‐war	  with	  microtubules	  based	  motor	  proteins.	  Its	  depletion	  increases	  retrograde	  transport	  of	  mitochondria	  along	  the	  axon	  [Pathak	  et	  al.,	  2010].	   In	   the	  mature	  Drosophila	  nervous	  system,	  myosin	  VI	   is	  critical	  for	  the	  correct	  localization	  of	  recycling	  vesicles	  at	  the	  synapsis.	  This	  activity	  possibly	  depends	  on	  the	  tethering	  ability	  of	  the	  protein.	  Notably,	   in	  neuromuscular	  junctions	  myosin	  VI	  depletion	  causes	  an	  increase	  vesicles	  motility	  [Kisiel	  et	  al.,	  2014].	  	  The	   first	   direct	   evidences	   of	   a	   role	   for	   myosin	   VI	   in	   cell	   migration	   were	  obtained	   in	  Drosophila.	   In	   the	  process	  of	  oogenesis,	   a	   group	  of	   follicle	   cells	   (border	  cells)	  migrate	  towards	  the	  oocyte	  in	  a	  process	  that	  requires	  a	  functional	  Jaguar,	  DE-­‐
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cadherins	   and	   armadillo,	   the	  Drosophila	   homologue	   of	   β-­‐catenin	   [Geisbrecht	   et	   al.,	  2002].	  Myosin	  VI	  knockdown	  was	  later	  found	  to	  inhibit	  ovarian	  cancer	  dissemination	  in	  nude	  mice	  [Yoshida	  et	  al.,	  2004],	  a	  process	  that	  shows	  similarities	  with	  border	  cells	  migration.	  	  	   In	  mammals,	  perturbations	  of	  myosin	  VI	  activity	  have	  been	   linked	   to	  several	  phenotypes.	  Studies	  on	  genetic-­‐linked	  deafness	  highlighted	  the	  importance	  of	  several	  myosins,	  among	  which	  myosin	  VI.	  The	  Snell’s	  waltzer	  (sv)	  mouse	  strain	  displays	  loss	  of	   hearing	   and	   balance	   in	   an	   autosomal	   and	   recessive	   way.	   Investigation	   on	   this	  mouse	  led	  to	  the	  identification	  of	  a	  truncation	  in	  the	  gene	  encoding	  for	  myosin	  VI	  as	  the	  primary	  cause	  of	  the	  phenotype	  [Avraham.	  et	  al.,	  1995].	   In	  normal	  mice,	  myosin	  VI	   is	   expressed	   at	   the	   level	   of	   the	   sensory	   hair	   cells	   of	   the	   inner	   ear.	   These	   cells	  develop	   short	   microvilli	   at	   the	   apical	   membrane,	   and	   some	   of	   them	   can	   further	  mature	   into	   elongated	   structure,	   known	   as	   stereocilia.	   Myosin	   VI	   is	   required	   to	  maintain	   the	  shape	  and	   integrity	  of	   these	  cellular	  protrusions.	   In	   the	  Snell’s	  waltzer	  (sv)	  mouse	  the	  first	  steps	  of	  development	  of	  the	  stereocilia	  are	  normal	  but	  then	  they	  often	  fuse	  together	  [Self	  et	  al.,	  1999].	  Myosin	  VI	  localizes	  at	  the	  level	  of	  the	  cuticolar	  plate	  and	  the	  pericuticolar	  necklace	  of	  sensory	  hair	  cells.	  Absence	  of	  myosin	  VI	  lead	  to	  a	   rise	   of	   the	   apical	   membrane,	   which	   detach	   from	   the	   cuticolar	   plate,	   possibily	  indicate	   an	   anchoring	   function	   of	   this	   motor	   protein	   [Hasson	   et	   al.,	   1997].	   These	  findings	   were	   successively	   reproduced	   and	   corroborated	   in	  Danio	   rerio	   and	  Homo	  
sapiens.	   In	   the	   first	   case,	   one	   of	   the	   two	   myosin	   VI-­‐coding	   genes,	   myo6b,	   is	  predominantly	  expressed	  and	   localized	  at	   the	   level	  of	   the	  sensory	  epithelium	  of	   the	  ear	  [Seiler	  et	  al.,	  2004].	  In	  human,	  genetic	  and	  sequence	  analysis	  of	  myosin	  VI	  gene	  in	  deaf	   patients	   linked	  myosin	   VI	  mutations	   to	   a	   non-­‐syndromic	   autosomal	   dominant	  form	   of	   deafness	   and	   cardiomyopathies	   [Melchionda	   et	   al.,	   2001];	   [Mohiddin	   et	   al.,	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2004],	   therefore	   proving	   for	   a	   conserved	   role	   of	   myosin	   VI	   in	   the	   development	   of	  auditory	  system.	  	  
1.2.3	  Myosin	  VI	  at	  the	  Golgi	  One	  of	  the	  first	  observation	  on	  the	  intracellular	  localization	  of	  endogenous	  myosin	  VI	  in	   cultured	   cells	   was	   its	   enrichment	   at	   the	   level	   of	   the	   Golgi	   complex	   and	   at	   the	  leading	  edge	  of	  migrating	  cells	  in	  NRK	  and	  A431	  [Buss	  et	  al.,	  1998].	  The	  Golgi	  complex	  is	  composed	  of	  a	  system	  of	  packed	  membranous	  cisternae	  that	  are	  divided	  into	  cis-­‐,	  
medial-­‐,	  and	  trans-­‐Golgi	  compartments	  (along	  the	  nucleus/periphery-­‐axis).	  From	  the	  two	  sides	  of	  the	  complex	  an	  intricate	  net	  of	  tubules	  and	  vesicles	  emerge,	  forming	  the	  
cis-­‐	   and	   trans-­‐Golgi	   networks	   [Gurel	   et	   al.,	   2014].	   Being	   a	   central	   node	   of	   vesicle	  trafficking	   in	   the	   cell,	   the	   Golgi	   complex	   receives	   and	   modifies	   proteins	   from	   the	  endoplasmic	  reticulum	  and	  those	  proteins	  are	  later	  engulfed	  into	  vesicles	  that	  might	  undergo	  exocytosis	  and/or	  fusion	  with	  other	  membranes.	  Clathrin	  cages	  coat	  vesicles	  emerging	   from	   the	   Golgi	   complex	   in	   a	   process	   similar	   to	   the	   one	   occurring	   at	   the	  plasma	  membrane	   during	   endocytosis	   [Liu	   et	  al.,	   2001].	   Early-­‐,	   late-­‐,	   and	   recycling	  endosomal	  compartments	  constantly	  exchange	  components	  with	  the	  Golgi	  [Lu	  et	  al.,	  2014a].	   Not	   surprisingly,	   this	   intricate	   system	   maintains	   its	   plasticity	   thanks	   to	  interaction	  with	   the	   cytoskeleton	   (both	  actin-­‐	  and	  microtubule	   components),	  which	  act	  as	  a	  scaffold	  and	  directly	  affect	  vesicle	  budding	  and	  fission	  processes	  [Gurel	  et	  al.,	  2014].	  Myosin	  VI	  localization	  at	  the	  Golgi	  was	  shown	  to	  influence	  the	  morphology	  of	  the	   cisternae	   as	   well	   as	   the	   secretion	   of	   proteins.	   In	   particular,	   primary	   fibroblast	  from	  Snell’s	  waltzer	  mouse	  showed	  reduced	  (~40%)	  size	  and	  altered	  morphology	  of	  the	  Golgi	   [Warner	  et	  al.,	   2003].	   Secretion	  of	  a	   soluble	  and	  secreted	   form	  of	  alkaline	  phosphatase	  (SEAP)	  was	  also	  reduced	  up	  to	  ~80%	  compared	  to	  controls	  [Warner	  et	  
al.,	   2003].	   Overexpression	   of	   full-­‐length	   myosin	   VI	   was	   able	   to	   rescue	   both	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phenotypes	  [Warner	  et	  al.,	  2003].	  These	  functional	  observations	  were	  later	  confirmed	  in	   primary	   human	   prostate	   cancer	   cells,	   where	   myosin	   VI	   and	   GOLPH2	   (a	   Golgi-­‐resident	  protein)	  colocalize	  and	  were	  proposed	  as	  possible	  prostate	  cancer	  markers	  [Wei	  et	  al.,	  2008].	  Another	  link	  between	  myosin	  VI	  and	  the	  Golgi	  complex	  was	  found	  by	  Sahlender	  and	  colleagues	  who	  showed	  that	  depletion	  of	  optineurin	  results	  in	  Golgi	  complex	   fragmentation	  and	  myosin	  VI	  de-­‐localization	   from	  the	  trans-­‐Golgi	  network.	  Optineurin	   was	   identified	   as	   myosin	   VI	   interactor	   via	   an	   yeast	   two-­‐hybrid	   assay	  [Sahlender	  et	  al.,	  2005].	  The	  authors	  could	   identify	   the	  region	  between	  amino	  acids	  412	   and	   520	   of	   optineurin	   as	   critical	   for	  myosin	   VI	   binding.	   By	   structure-­‐function	  analysis	   and	   subsequent	   mutagenesis,	   the	   interaction	   surface	   on	   myosin	   VI	   was	  mapped	   on	   the	   1116RRL1118	   sequence	   [Sahlender	   et	   al.,	   2005].	   SEAP	   secretion	   in	  fibroblast	  derived	  from	  Snell’s	  waltzer	  mice	  was	  rescued	  by	  the	  overexpression	  of	  WT	  myosin	   VI,	   but	   not	   by	   the	   one	   of	   an	   optineurin	   binding-­‐impaired	   mutant.	   Two	  threonine	   phosphorylation	   sites	   (1097TINT1100)	   on	  myosin	   VI	  were	   also	   found	   to	   be	  critical	   for	   optineurin	   binding	   [Sahlender	   et	   al.,	   2005].	   	   Trafficking	   of	   Vesicular	  Stomatitis	   Virus	   Glycoprotein	   (VSV-­‐G)	   from	   the	   Golgi	   to	   the	   plasma	  membrane,	   as	  well	   as	   co-­‐localization	   of	   myosin	   VI	   and	   Rab8	   in	   vesicles	   underneath	   the	   plasma	  membrane	  was	  reduced	  in	  optineurin-­‐depleted	  cells	  [Sahlender	  et	  al.,	  2005].	  Thus,	  in	  the	   Golgi	   optineurin	   appears	   to	   bridge	   myosin	   VI	   to	   Rab8,	   forming	   a	   tether	   that	  counteracts	  microtubule-­‐mediated	  transport	  events	   [Sahlender	  et	  al.,	  2005]	  (Figure	  
6).	  The	  deficiency	  in	  exocytosis	  described	  upon	  perturbation	  of	  myosin	  VI:optineurin	  complex	  was	  then	  more	  precisely	  ascribed	  to	  defects	  in	  the	  ER-­‐to-­‐Golgi	  transport	  and	  to	  diminished	  vesicle	  fusion	  events	  at	  the	  plasma	  membrane	  [Bond	  et	  al.,	  2011].	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Figure	  6:	  Optineurin	  bridges	  myosin	  VI	  to	  the	  Golgi	  system.	  Schematic	  representation	  proposed	  for	  the	  myosin	   VI:optineurin:Rab8	   interaction	   at	   the	   level	   of	   the	   TGN.	   The	   complex	   stabilizes	   the	   Golgi	  architecture	   in	   a	   tug-­‐of-­‐war	   with	   microtubules	   and	   microtubule-­‐based	   motor	   proteins.	   From	  [Sahlender	  et	  al.,	  2005].	  	   The	   1116RRL1118	   motif	   in	   myosin	   VI	   has	   been	   shown	   to	   be	   critical	   for	   the	  interaction	   with	   proteins	   other	   than	   optineurin,	   namely	   TRAF6-­‐binding	   protein	  (T6BP,	   also	   called	   TAXBP1),	   and	   its	   homologue	   nuclear	   dot	   protein	   52	   (NDP52)	  [Morriswood	   et	   al.,	   2007].	   These	   three	   proteins	   share	   common	   structural	   features	  [Birgisdottir	   et	   al.,	   2013]	   and	   contain	   an	   LC3-­‐interacting	   region	   (or	   LIR).	   As	   a	  consequence,	   they	   have	   been	   recently	   implicated	   in	   autophagy	   [Birgisdottir	   et	   al.,	  2013]	  and	  mitophagy	  [Heo	  et	  al.,	  2015].	  LC3	  is	  a	  ubiquitin-­‐like	  modifier	  which,	  once	  lipidated	   (LC3-­‐II),	   is	   incorporated	   into	   autophagosomes	   membrane	   and	   drives	   the	  process	  of	  fusion	  with	  endosomes	  and	  lysosomes.	  LC3-­‐receptors	  that	  bind	  the	  surface	  of	   LC3-­‐II-­‐positive	   vesicles	   influence	   their	   fate	   [Birgisdottir	   et	   al.,	   2013].	   Indeed,	  optineurin,	   T6BP,	   and	   NDP52	   [Birgisdottir	   et	   al.,	   2013],	   participate	   to	   this	   process	  (Figure	   7a).	   Recently,	   also	  myosin	  VI	   has	   been	   involved	   in	   autophagy.	   Tumbarello	  and	   colleagues	   discovered	   that	   this	   motor	   protein	   acts	   as	   a	   bridge	   between	   the	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Figure	  7	  Possible	   functions	  of	  myosin	  VI	  and	   its	   interactors	   in	  autophagy.	  a)	  Domain	  structure	  and	   interacting	   partners	   of	   T6BP,	   NDP52	   and	   optineurin.	   LIR,	   LC3-­‐interaction	   motif;	   SKICH,	   SKIP–carboxyl	  homology	  domain;	  CC,	  coiled-­‐coil	  domain;	  ZF,	  zinc-­‐finger	  domain;	  GAL-­‐8,	  galectin-­‐8.	  Adapted	  from	  [Tumbarello	  et	  al.,	  2012].	  b)	   In	  the	  process	  of	  autophagy	  myosin	  VI	  might	  extert	   its	   function	  at	  three	   different	   levels:	   1)	   Monomeric	   myosin	   VI	   tethers	   Tom1-­‐positive	   endosomes	   with	  
a)	  
b)	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autophagosomes,	   a	   process	   required	   for	   autophagosome	   maturation.	   2)	   Dimeric	   myosin	   VI	   might	  bridge	   endosomal	   and	   autophagic	   compartments	   (presenting	   LC3II)	   through	   the	   simultaneous	  interactions	   with	   Tom1	   and	   autophagy	   adaptors	   such	   as	   optineurin,	   NDP52,	   and	   T6BP.	   3)	   Tom1	  localizes	  myosin	   VI	   to	   autophagosomes	  where	   it	   interacts	  with	   the	   autophagy	   adaptors	   and	   tethers	  autophagosomes	   to	   the	   actin	   cytoskeleton	   required	   for	   fusion	  with	   the	   lysosomal	   compartment.	   E	  =	  endosome,	  L	  =	  lysosome.	  [Tumbarello	  et	  al.,	  2012].	  	  	  
1.2.4	  Myosin	  VI	  at	  the	  Clathrin	  Coated	  Pits	  (CCPs)	  As	   previously	   stated	   the	   tail	   of	   myosin	   VI	   can	   undergo	   alternative	   splicing	   in	   two	  different	   sites	   (LI	   and	   SI)	   [Buss	   et	   al.,	   2001];	   [Tomatis	   et	   al.,	   2013].	   Increasing	  evidences	   show	   that	   highly	   polarized	   tissues	   such	   as	   the	   intestine	   predominantly	  express	  the	  full	  LI	  sequence	  (myosin	  VI+LI)	  [Buss	  et	  al.,	  2001]).	  Immunofluorescence	  studies	   localized	   myosin	   VI+LI	   containing	   at	   the	   apical	   region	   of	   polarized	   Caco-­‐2	  cells,	   a	   cell	   line	   that	   recapitulates	   most	   of	   the	   intestinal	   cells	   features	   [Buss	   et	   al.,	  2001]).	  This	  isoform	  of	  myosin	  VI	  was	  shown	  to	  co-­‐localize	  with	  clathrin-­‐coated	  pits	  and	   to	   co-­‐fractionate	   with	   clathrin-­‐coated	   vesicles	   [Buss	   et	   al.,	   2001].	   Moreover	  overexpression	   of	   a	   dominant	   negative	   myosin	   VI	   tail	   bearing	   the	   LI	   impaired	  transferrin	  internalization	  at	  the	  plasma	  membrane.	  	   Mechanistically,	   Disabled-­‐2	   (Dab2)	   was	   found	   to	   be	   the	   bridge	   between	  myosin	  VI	  and	  clathrin	  by	  yeast-­‐	   and	  mammalian-­‐two	  hybrid	   screens	   [Morris	  et	  al.,	  2002].	  Dab2	  is	  an	  adaptor	  protein	  able	  to	  recognize	  specific	  cargoes	  or	  receptors	  at	  the	  plasma	  membrane	   [K.Mishra	  et	  al.,	  2002].	  This	  adaptor	  protein	  contains	  αAP-­‐2-­‐	  and	  clathrin-­‐binding	  sites,	  as	  well	  as	  an	  N-­‐terminal	  PTB	  (Phosphotyrosine	  interaction	  domain)	  [K.Mishra	  et	  al.,	  2002]	  and	  a	  PtdIns(4,5)P2	  recognition	  domain	  [Alajlouni	  et	  
al.,	  2011]	  that	  anchors	  the	  molecule	  to	  the	  plasma	  membrane	  (Figure	  8).	  Through	  its	  multiple	   interaction	  surfaces,	  Dab2	  is	  able	  to	  recruit	  the	  endocytic	  machinery	  at	  the	  sites	   of	   internalization	   and	   to	   link	   clathrin-­‐mediated	   endocytosis	   to	   the	   actin	  microfilament	  system	  via	   the	  myosin	  VI	  protein	   [K.Mishra	  et	  al.,	  2002;	  Morris	  et	  al.,	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2001].	   The	   Dab2	   interaction	   surface	   in	   myosin	   VI	   was	   mapped	   on	   the	   relatively	  conserved	  1191WWY1193	  sequence	  [Spudich	  et	  al.,	  2007].	  	  	  
	  
Figure	   8:	   Disabled-­‐2	   domains	   organization.	   Schematic	   representation	   of	   the	   binding	   domains	   in	  mouse	   Dab-­‐2.	   PTB:	   phospho-­‐tyrosine	   binding;	   NPF:	   asparagine-­‐proline-­‐phenylalanine	   bound	   by	   EH	  domains	   (Eps15	   Homology);	   DPF:	   aspartic-­‐proline-­‐phenylalanine	   bound	   by	   EH	   domains.	   From	  [Collaco	  et	  al.,	  2010].	  	   Later	  structural	  studies	  led	  to	  the	  identification	  on	  myosin	  VI	  of	  two	  additional	  interaction	  surfaces	  for	  Dab2,	  centered	  on	  R1160	  and	  L1227.	  On	  the	  Dab2	  molecule,	  the	   interaction	  myosin	  VI	  was	  mapped	  on	   the	   682SYF684	  motif	   [Yu	  et	  al.,	   2009].	   The	  same	   study	   gave	   strong	  molecular	   evidences	   supporting	   the	   hypothesis	   that	   cargo	  binding	  induces	  dimerization	  of	  myosin	  VI,	  thus	  regulating	  the	  processive	  movement	  of	   the	  motor	   protein	   along	   actin	   filaments.	  Nevertheless	   additional	   studies	   showed	  that	   binding	   of	  molecules	   other	   than	   Dab2	   trigger	  myosin	   VI	   dimerization.	   Among	  them	  PtdIns(4,5)P2	  that,	  upon	  binding	  to	  the	  motor	  protein,	  cause	  it	  to	  form	  dimers	  and	  contribute	  to	  myosin	  VI	  localization	  on	  clathrin	  vesicles	  [Spudich	  et	  al.,	  2007].	  	  The	   functional	   role	   of	   myosin	   VI	   in	   clathrin	   mediated	   endocytosis	   was	  demonstrated	  in	  highly	  polarized	  cells	  such	  as	  small	  intestine	  cells,	  polarized	  human	  airway	   epithelial	   cells,	   and	   renal	   proximal	   tubular	   cells.	   In	   the	   first	   two	   models	  endocytosis	  of	  the	  cystic	  fibrosis	  transmembrane	  conductance	  regulator	  (CFTR)	  was	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used	   as	   substrate	   for	   the	   analysis.	   CFTR	   is	   a	   cyclic	   AMP-­‐regulated	   Cl-­‐	   channel	  expressed	  in	  fluid	  transporting	  epithelia,	  and	  localized	  at	  the	  apical	  membrane	  of	  the	  cells	   forming	   the	   tissue.	   In	   polarized	   Calu-­‐3	   cells	   myosin	   VI	   was	   shown	   to	   co-­‐immunoprecipitate	   with	   CFTR,	   Dab2,	   and	   clathrin	   in	   endogenous	   condition.	  Knockdown	  of	  the	  motor	  protein	  was	  also	  shown	  to	  increase	  the	  amount	  of	  CFTR	  at	  the	  apical	  membrane	  of	  the	  cells,	  due	  to	  defects	  in	  endocytosis,	  however	  the	  authors	  claimed	  that	  the	  myosin	  VI+LI	  splice	  variant	  was	  not	  necessarily	  the	  one	  involved	  in	  the	  process.	  Furthermore	  they	  postulated	  the	  role	  of	  αAP-­‐2	  in	  the	  CFTR	  endocytosis	  [Swiatecka-­‐Urban	  et	  al.,	   2004],	  which	  was	   later	   confirmed	   in	   following	   studies	   that	  proved	   a	   direct	   role	   of	   αAP-­‐2	   in	   directing	  myosin	   VI	   to	   CFTR,	   since	   αAP-­‐2	   but	   not	  Dab2	  were	  found	  to	  interact	  directly	  with	  the	  ion	  channel	  [Collaco	  et	  al.,	  2010].	  In	  the	  same	   way	  myosin	   VI-­‐knockout	   mice	   (sv)	   showed	   that	   renal	   proximal	   tubular	   cells	  have	   defects	   in	   morphology	   of	   the	  microvilli	   and	   in	   clathrin-­‐mediated	   endocytosis	  [Gotoh	  et	  al.,	  2010].	  	  Non-­‐canonical	   clathrin-­‐mediated	   endocytosis	   processes	   were	   also	   shown	   to	  depend	   on	  myosin	   VI.	   In	   the	   case	   of	   big	   cargoes	   such	   as	   the	   intracellular	   parasite	  
Listeria	  monocytogenes	  there	  is	  an	  active	  recruitment,	  induced	  by	  the	  bacteria,	  at	  the	  sites	  of	  internalization.	  In	  particular,	  Dab2,	  clathrin	  heavy	  chain,	  clathrin	  light	  chain,	  Huntingtin-­‐interacting	   protein	   1-­‐related	   (Hip1R,	   which	   can	   promote	   actin	  polymerization	   at	   endocytic	   sites	   [Boulant	   et	   al.,	   2011]),	   and	   finally	  myosin	   VI	   are	  recruited	  following	  a	  highly	  regulated	  cascade	  of	  events	  [Bonazzi	  et	  al.,	  2012].	  Myosin	  VI	  was	  shown	  to	  be	  necessary	  for	  the	  successful	  internalization	  of	  the	  cargo	  (Figure	  
9)	   [Bonazzi	   et	  al.,	   2011].	   	   In	   this	   context,	   this	  motor	   protein	   possibly	   provides	   the	  pulling	  force	  needed	  for	  the	  unusual	  membrane-­‐deformation	  event	  at	  the	  basis	  of	  the	  clathrin-­‐mediated	   endocytosis.	   Interestingly,	   the	   same	   molecular	   mechanism	   that	  mediate	   bacteria	   internalization,	   is	   responsible	   for	   reorganization	   of	   E-­‐cadherin	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mediated	  cell-­‐cell	  junctions	  in	  cultured	  monolayers	  [Bonazzi	  et	  al.,	  2012].	  This	  might	  suits	   with	   previous	   evidences	   of	   the	   function	   of	   myosin	   VI	   in	   E-­‐cadherin	   junction	  formation	  and	  stabilization	  [Maddugoda	  et	  al.,	  2007].	  	  
	  
Figure	   9:	   Model	   for	   myosin	   VI-­‐dependent	   bacteria	   internalization.	   Receptors,	   activated	   by	  bacteria,	   recruit	  Dab2,	   clathrin	  heavy	   and	   light	   chains,	   followed	  by	  Hip1R,	   actin	   and	  myosin	  VI.	   The	  motor	  protein	  provides	  the	  pulling	  forces	  necessary	  for	   internalization.	  Adapted	  from	  [Bonazzi	  et	  al.,	  2011].	  	  
1.2.5	  Myosin	  VI	  at	  the	  cell-­‐cell	  and	  cell-­‐matrix	  adhesion	  sites	  The	  active	  involvement	  of	  myosin	  VI	  in	  cell-­‐cell	  adhesion	  (E-­‐cadherin	  mediated)	  was	  demonstrated	   in	   several	   experimental	   setups.	   During	   the	   formation	   of	   mature	  adherens-­‐junctions,	   Myosin	   VI	   bridges	   the	   intracellular	   region	   of	   E-­‐cadherin	   with	  vinculin	  [Maddugoda	  et	  al.,	  2007].	  Again,	  functional	  studies	  performed	  in	  Drosophila	  pioneered	  the	  mammalian	  ones.	  In	  the	  fruit	  fly	  it	  was	  shown	  that	  the	  expression	  level	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of	  E-­‐cadherin,	  myosin	  VI,	  and	  armadillo	  (β-­‐catenin)	   is	  mutually	  dependent,	  and	  that	  the	   motor	   protein	   interacts	   with	   armadillo	   by	   reciprocal	   pulldown	   experiments	  [Geisbrecht	   et	   al.,	   2002].	   In	   mammals,	   myosin	   VI	   knockdown	   resulted	   in	   altered	  junctions	  formation,	  both	  at	  the	  lateral	  and	  apical	  part	  of	  the	  cell	  [Maddugoda	  et	  al.,	  2007].	  The	  interaction	  of	  E-­‐cadherin	  with	  myosin	  VI	  was	  later	  shown	  to	  be	  direct	  by	  
in	  vitro	  pull-­‐down	  experiments	  [Mangold	  et	  al.,	  2012].	  	  Migrating	   cells	   need	   to	   attach	   to	   substrates	   (usually	   extracellular	   matrix	  proteins,	  or	  ECM)	  in	  order	  to	  move	  and	  highly	  regulated	  balance	  of	  force	  of	  adhesion	  is	   of	   paramount	   importance	   in	   this	   context.	   Integrin	   are	   transmembrane	   dimeric	  proteins	  that	  are	  capable	  of	  signal	  across	  the	  membrane	  in	  both	  directions.	  They	  can	  sense	   the	   interaction	   with	   ECM	   components	   and	   transmit	   the	   signal	   to	   the	  cytoskeleton,	  or	  they	  can	  transduce	  an	  intracellular	  signal	  to	  the	  ECM	  [Harburger	  et	  
al.,	   2009].	   In	   endothelial	   cells,	   myosin	   VI	   was	   shown	   to	   regulate,	   together	   with	  neuropilin1	  (Nrp1)	  and	  GAIP-­‐interacting	  protein	  C	  terminus	  (GIPC1),	  integrin	  traffic	  and	   therefore	   adhesion.	   The	   knockdown	   of	  myosin	   VI	   led	   to	   a	   reduced	   number	   of	  active	  (bound	  to	  the	  ECM)	  number	  of	  integrin	  molecules	  [Valdembri	  et	  al.,	  2009].	  The	  investigators	   showed	   that	   Nrp1,	   a	   receptor	   for	   vascular	   endothelial	   growth	   factor	  (VEGF)	  and	  semaphorin	  (SEMA)	  interact	  with	  GIPC	  at	  the	  site	  of	  cell-­‐ECM	  adhesion.	  GIPC-­‐dependent	  myosin	  VI	  recruitment	  on	  integrin	  regulates	  integrin	  activation	  in	  a	  positive	  manner	  [Valdembri	  et	  al.,	  2009].	  	  
1.2.6	  Myosin	  VI	  in	  cell	  migration	  and	  cancer	  Increasing	  evidence	  showed	  that	  myosin	  VI	  contributes	   to	   the	  migrating/metastatic	  potential	  of	  cancer	  cells	  [Chibalina	  et	  al.,	  2009].	  Microarray	  expression	  data	  as	  well	  as	  immunohistochemistry	  analysis	  of	  tumour	  tissues	  from	  independent	  research	  groups	  revealed	  a	  strong	  overexpression	  of	  myosin	  VI	  in	  ovarian	  and	  prostate	  cancer	  tissues	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[Dunn	   et	   al.,	   2006;	   Yoshida	   et	   al.,	   2004]	   that	   positively	   correlates	   with	   a	   clinically	  aggressive	   behavior.	   Notably,	   silencing	   of	   myosin	   VI	   expression	   in	   ovarian	   and	  prostate	  cancer	  cell	  lines	  decreases	  the	  migratory	  potential	  of	  these	  cells	  [Dunn	  et	  al.,	  2006;	   Yoshida	   et	   al.,	   2004].	   Moreover,	   in	   prostate	   cancer	   cells,	   a	   reduction	   in	  clonogenic	   potential	   in	   soft-­‐agar	   was	   also	   observed	   upon	   myosin	   VI	   depletion,	  suggesting	  an	  involvement	  of	  this	  protein	  in	  anchorage-­‐independent	  growth	  [Dunn	  et	  
al.,	  2006].	  Finally,	  myosin	  VI	  was	  identified	  as	  modulator	  of	  androgen	  receptor	  (AR)-­‐dependent	  gene	  expression	  in	  prostate	  cancer	  [Loikkanen	  et	  al.,	  2009].	  	   Chibalina	  and	  colleagues	  have	  showed	  direct	  mechanistic	  evidences	  of	  the	  role	  of	   myosin	   VI	   in	   cell	   migration	   [Chibalina	   et	   al.,	   2010].	   The	   motor	   protein	   was	  described	  to	  confer	  directionality	  to	  cells	  moving	  towards	  an	  epidermal	  growth	  factor	  (EGF)	   gradient.	   This	   phenotype	   is	   due	   to	   the	   concerted	   role	   of	   myosin	   VI	   and	  optineurin	  that	  allow	  the	  delivery	  of	  the	  EGF-­‐receptor	  (EGFR)	  directly	  on	  the	  leading	  edge,	   thus	  sustaining	  signalling	  and	  ultimately	  migration.	   In	  unstimulated	  condition	  myosin	   VI	   knockdown	   was	   also	   described	   to	   reduce	   the	   overall	   number	   and	  dimension	  of	  lamellipodia.	  However,	  in	  such	  condition,	  no	  reduction	  in	  the	  final	  speed	  of	  cells	  was	  scored	  [Chibalina	  et	  al.,	  2010].	  	  	  
1.3	  Clathrin	  and	  clathrin-­‐mediated	  endocytosis	  	  Cells	   exploit	   different	   routes	   of	   endocytosis	   to	   internalize	   plasma	   membrane	  receptors	   and	   small	  molecules	   from	   the	   external	  milieu.	  Among	   them,	   the	   clathrin-­‐mediated	  endocytosis	  or	  CME,	  is	  the	  most	  extensively	  studied	  [McMahon	  et	  al.,	  2011].	  	  Clathrin	   is	   present	   in	   all	   eukaryotic	   cells	   and	   covers	   vesicles	   (CCV)	   that	  internalize	   from	   the	   plasma	  membrane.	   The	   Golgi	   complex	   also	   generates	   vesicles	  that	  present	  a	  clathrin-­‐based	  coat	  [Liu	  et	  al.,	  2001],	  but	  the	  term	  CME	  and	  CCV	  refers	  only	  to	  events	  occurring	  at	  the	  plasma	  membrane.	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Clathrin	  not	  only	  acts	  in	  the	  endocytosis	  of	  a	  wide	  variety	  of	  molecules	  including	  nutrient,	   transporters,	   adhesion	   molecules,	   and	   receptors,	   but	   it	   also	   functions	   in	  mitosis	   [Royle	   et	   al.,	   2005]	   and	   transcription	   regulation	   [Enari	   et	   al.,	   2006].	  Furthermore,	  bacteria	  and	  viruses	  can	  hijack	  clathrin-­‐mediated	  endocytosis	  to	  enter	  the	  cytoplasm	  and	  accomplish	  their	  life	  cycle	  [Humphries	  et	  al.,	  2013].	  	  	  
1.3.1	  Clathrin-­‐coated	  vescicles	  Observed	   for	   the	   first	   time	   in	   1964	   by	   EM,	   clathrin-­‐coated	   vesicles	   were	   isolated	  about	  a	  decade	  later	  when	  Barbara	  Pearse	  fractionated	  pig	  brain	  lysate	  and	  was	  able	  to	  obtain	  pure	  CCVs.	  The	  major	  component	  of	  these	  vesicles	  resulted	  to	  be	  a	  protein	  of	  about	  180	  kDa	  that	  was	  named	  clathrin	  [Pearse,	  1976].	  After	  40	  years	  of	   intense	  studies	   we	   know	   that	   clathrin-­‐coated	   vesicles	   are	   composed	   of	   three	   layers:	   an	  internal	  membrane	  bilayer,	  a	  medial	  layer	  of	  adaptor	  proteins,	  and	  the	  most	  external	  and	   scaffolding	   clathrin	   cage.	   The	   scaffold	   is	   a	   supramolecular	   protein	   complex	  formed	   by	   subunits	   of	   three	   copies	   of	   clathrin	   heavy	   chain	   and	   three	   clathrin	   light	  chain	   that,	   together,	   form	   a	   three-­‐legged	   curled	   and	   pinwheel-­‐like	   triskelion	  [Brodsky,	  2012].	  	  Vesicles	   usually	   form	   and	   are	   filled	   of	   cargos	   in	   a	   tightly	   regulated	   way,	   but	  some	   receptors,	   such	   as	   the	   transferrin	   receptor	   or	   the	   low-­‐density	   lipoprotein	  receptor,	  are	  internalized	  constitutively	  even	  without	  any	  bound	  ligand.	  For	  receptor	  tyrosine	  kinases	  (RTKs)	  or	  G-­‐protein	  coupled	  receptors	  the	   ligand-­‐induced	  clathrin-­‐mediated	   endocytosis	   starts	   after	   a	   conformational	   changed	   induced	   by	   the	   ligand	  activation.	  This	  could	  be	  due	  to	  an	  unmasking	  of	  structural	  signal/s	  already	  present	  in	   the	   tail	   of	   the	   receptors	   or	   by	   post-­‐translational	   modifications	   occurring	   at	   the	  receptor	   (phosphorylation	   and	   ubiquitination	   are	   the	   most	   common	   one,	   see	  [Sigismund	  et	  al.,	  2012]	  for	  a	  review).	  Adaptor	  proteins	  recognize	  these	  signals	  on	  the	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cytoplasmic	  side	  of	  the	  receptors	  and	  allow	  for	  an	  increase	  of	   local	  concentration	  of	  receptors	   at	   the	   site	  where	   clathrin-­‐coat	   start	   to	   assemble.	   Clathrin	   is	   able	   to	   self-­‐assemble	   into	   lattice	   at	   the	   plasma	  membrane	   [Ybe	   et	  al.,	   1999].	  While	   some	   CCPs	  might	  undergo	  spontaneous	  dissolution,	  cargo	  accumulation	  into	  pits	  is	  a	  crucial	  step	  that	  allows	  the	  further	  recruitment	  of	  clathrin	  and	  formation	  of	  a	  productive	  vesicle	  [Loerke	   et	   al.,	   2009].	   The	   successive	   clathrin	   polymerization	   drives	   further	  membrane	   curvature	   and	   the	   final	   step,	   the	   vesicle	   scission,	   is	   due	   to	   dynamin	  GTPases	   [Mettlen	   et	   al.,	   2009].	   A	   schematic	   representation	   of	   a	   pit	   formation,	  maturation	  and	  vesicle	  scission	  is	  reported	  in	  Figure	  10.	  	  
 
 
Figure	  10:	  Clathrin-­‐coated	  vesicle	  formation.	  Clathrin-­‐coated	  vesicles	  (CCVs)	  forms	  from	  productive	  clathrin-­‐coated	   pits	   (CCPs)	   that	   have	   undergone	   the	   maturation	   process.	   The	   maturation	   process	  foresees	   nucleation,	   cargo	   selection,	   coat	   assembly,	   vesicle	   scission,	   and	   uncoating.	   An	   endocytosis	  checkpoint,	  dependent	  on	  the	  concentration	  of	  cargo,	  AP2	  adaptors,	  and	  likely	  other	  factors,	  controls	  progress	   through	   the	   maturation	   process.	   CCPs	   that	   do	   not	   progress	   beyond	   this	   restriction	   point	  abort	  by	  sequential	  disassembly	  of	  AP2	  and	  clathrin.	  From	  [Loerke	  et	  al.,	  2009].	  	  
1.3.2	  The	  clathrin-­‐coat:	  clathrin	  heavy	  chain	  Clathrin	   lattices	   are	   polyhedral	   assembly	   of	   clathrin	   heavy	   and	   light	   chains.	   These	  protein	   are	   quite	   conserved	   among	   eukaryotes	   and	   underwent	   gene-­‐duplication	  during	  evolution	  in	  conjunction	  with	  the	  appearance	  of	  vertebrates	  [Wakeham	  et	  al.,	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2005].	   In	   humans,	   the	   two	   clathrin	   heavy	   chain	   genes	   are	   CLTC	   and	   CLTCL1	   (also	  known	  as	  CHC17	  and	  CHC22),	  positioned	  at	  chromosome	  17	  and	  22,	  respectively.	  The	  two	  proteins	  show	  85%	  of	  sequence	  identity.	  Most	  of	  the	  biochemical,	  functional,	  and	  structural	   data	   in	   literature	   refer	   to	   CLTC	   that	   is	   responsible	   of	   the	   ubiquitous	  clathrin	   coated	   vesicles	   that	  mediate	  membrane	   traffic	   [Brodsky,	   2012].	   CLTCL1	   is	  implicated	  in	  specialized	  membrane	  organization	  in	  skeletal	  muscle	  [Vassilopoulos	  et	  
al.,	   2014],	   is	   involved	   in	   retrograde	   transport	   from	   endosomes	   to	   the	   trans-­‐Golgi	  network	   	   [Liu	   et	   al.,	   2001],	   and	   in	   regulation	   of	   the	   glucose	   transporter	   GLUT4	   in	  muscle	  and	  fat	  cells	  [Vassilopoulos	  et	  al.,	  2009].	  	  Clathrin	   heavy	   chains	   molecules	   are	   quite	   big	   proteins	   (different	   isoforms	  comprise	   from	   1640	   to	   1679	   amino	   acids)	   and	   no	   high-­‐resolution	   full-­‐length	  structures	  are	  up	  to	  now	  available.	  Nonetheless,	  efforts	  from	  different	  groups	  led	  to	  the	   knowledge	   of	   the	   overall	   conformation	   of	   the	   protein	   (see	   Figure	   11	   for	   a	  schematic	   view).	   The	   N-­‐terminus	   of	   CLTC,	   (1-­‐330	   amino	   acids),	   is	   known	   as	   the	  terminal	  domain	  (or	  TD)	  and	  assume	  a	  β-­‐propeller	  conformation	  [Haar	  et	  al.,	  1998],	  which	   allows	   the	   interaction	   with	   several	   adaptor	   proteins.	   Binding	   with	   proteins	  containing	   the	   clathrin	  box	   (generalized	   as	   LΦXΦ[DE])	   usually	   takes	  place	   at	   four	  different	   spots	  on	   the	  propeller.	   	  A	   short	   linker	   separate	   the	  TD	   from	   the	   following	  regions	  named	  ankle,	  distal	  leg,	  knee,	  and	  proximal	  leg.	  All	  these	  parts	  are	  organized	  into	  eight	  CHC	  repeats	  element	  (CHCR),	  α-­‐solenoids	  composed	  of	  10	  helices	  of	  10-­‐12	  residues.	  The	  vast	  majority	  of	  the	  interactions	  that	  allow	  the	  trimerization	  of	  CHC	  are	  mapped	   in	   the	   C-­‐terminal	   region	   of	   the	   molecule,	   in	   the	   trimerization	   domain	   (or	  TxD).	  This	  comprises	  a	  helical	  tripod,	  starting	  from	  CHCR7	  that	  gives	  the	  triskelion	  its	  classical	   orientation	   in	   respect	   to	   the	   plasma	  membrane	   [Wilbur	   et	   al.,	   2010].	   The	  proximal	  leg	  region	  of	  clathrin	  heavy	  chain,	  as	  well	  as	  its	  TxD	  domain,	  are	  involved	  in	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the	  interaction	  with	  clathrin	  light	  chains.	  	  	  	  	  
	  	  
Figure	   11:	  Clathrin	   heavy	   chains.	  a)	   structure	   of	   CHC17,	   derived	   from	  PDBs	   (triskelion-­‐accession	  number	   3IYV;	   trimerization	   domain-­‐accession	   number	   3LVH;	   terminal	   domain-­‐accession	   number	  2XZG;	  proximal	  leg-­‐accession	  number	  1B89).	  The	  four	  numbered	  sites	  on	  the	  TD	  structure	  represent	  the	  binding	  sites	   for	   interacting	  proteins.	  b)	   aligned	  domain	  organization	  of	  CHC17	  and	  CHC22.	  The	  eight	  CHCRs	  (0	  to7)	  in	  CHC17	  are	  reported	  with	  their	  boundaries.	  The	  red	  marks	  highlight	  differences	  between	  the	  CHC17	  and	  CHC22	  proteins.	  From	  [Brodsky,	  2012]	  	  
a)	  
b)	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1.3.3	  The	  clathrin-­‐coat:	  clathrin	  light	  chain	  In	  contrast	  to	  the	  two	  heavy	  chains,	  the	  two	  vertebrate	  clathrin	  light	  chains	  	  (LCa	  or	  CLCa	   and	   LCb	   or	   CLCb)	   have	   more	   divergent	   sequences	   (60%	   identity),	   but	   their	  functions	  are	  more	  similar.	  Within	  the	  cell,	  LCa/b	  binds	  selectively	  to	  CLTC,	  whereas	  CLTCL1	  does	  not	  functionally	  interact	  with	  either	  light	  chain.	  Clathrin	   light	   chains	   are	   polypeptides	   of	   around	   25	   kDa.	   In	   human	   the	   two	  genes	  LCa	  and	  LCb	  are	  positioned	  at	  chromosome	  9	  and	  chromosome	  5,	  respectively.	  The	  two	  proteins	  show	  similar	  domain	  organization	  (see	  Figure	  12	   for	  a	  schematic	  view)..	   Already	   in	   1991,	   Brodsky	   and	   colleagues	   described	   LCs	   as	   linear	   array	   of	  interaction	  surfaces	  [Brodsky	  et	  al.,	  1991],	  and	  indeed,	  several	  proteins	  were	  found	  to	  interact	   with	   them.	   As	   reported	   in	   Figure	   12,	   from	   the	   N-­‐	   to	   the	   C-­‐terminal	   LCs	  present:	   a	   conserved	   region	   of	   23	   aa	  with	   100%	   identity,	   the	   Hip1/Hip1R	   binding	  region	   [Ybe	  et	  al.,	   2007a],	   a	   calcium	   (Ca2+)	   binding	   region,	   the	  heavy	   chain	   binding	  region,	   a	   neuronal-­‐specific	   insert,	   and	   a	   calmodulin-­‐binding	   domain.	   Interestingly,	  some	   features	   are	   exclusively	   present	   in	   one	   of	   the	   two	   genes,	   such	   as	   the	  phosphorylation	  site	  on	  LCb	  and	  the	  Hsc70	   interacting	  surface	  on	  LCa	  (reviewed	   in	  [Brodsky,	  2012]).	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Figure	  12:	  Clathrin	  light	  chains.	  a)	  Domain	  organization	  and	  alignment	  of	  LCa	  and	  LCb.	  EED	  are	  the	  three	   acid	   charged	   residues	   that	   regulate	   clathrin	   assembly	  within	   the	   22-­‐residue	   conserved	   region	  (CON).	  This	  sequence	  includes	  the	  binding	  site	  for	  Hip	  proteins.	  Other	  features	  shared	  by	  the	  two	  LCs	  include	   an	   EF-­‐hand	   that	   binds	   calcium	   (Ca2+),	   the	   heavy-­‐chain-­‐binding	   region	   (HC),	   neuronal-­‐expressed	   intron	   (N),	   and	   a	   calmodulin-­‐binding	   domain	   (CBD)	   at	   the	   C-­‐terminal.	   LCa	   has	   a	   unique	  region	   (Hsc70)	   that	   stimulates	  Hsc70	  activity	   in	  vitro,	   and	  LCb	  has	  a	  unique	   serine	  phosphorylation	  site	  (P).	  b)	  Low-­‐resolution	  structure	  (7.9	  Å)	  of	  LCb	  (in	  yellow)	  bound	  to	  the	  CLTC	  Hub	  region	  (residues	  1074–1675).	  Modified	  from	  [Brodsky,	  2012]	  	   Even	  though	  the	  presence	  of	  LCs	  on	  clathrin	  coats	  has	  been	  known	  for	  long	  now,	  their	   functions	   are	   partly	   unclear	   or	   under	   debate.	   The	   non-­‐rigid	   structure	   of	   LCs	  allows	   the	  molecules	   to	  establish	  wide	   interaction	  surfaces	  on	  CLTC	   that	  goes	   from	  the	  TxD	  domain	  to	  the	  knee	  region	  and	  LC	  is	  thought	  to	  stabilize	  trimerization	  [Ybe	  et	  
al.,	  2007b].	  On	  another	  study,	  LCs	  appear	  to	  fine-­‐tune	  the	  conformation	  of	  triskelia	  by	  assuming	  a	  more	  extended	  or	  retracted	  conformation	  on	  the	  knee	  region	  [Wilbur	  et	  
al.,	   2010].	   While	   this	   interaction	   impacts	   directly	   on	   cages	   formation,	   LC	   can	   also	  
a)	  
b)	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influence	   the	   life	  of	  a	  vesicle	   through	  the	   interaction	  with	   the	  uncoating	   factor	  heat	  shock	  cognate	  70	  (Hsc70),	  that	  is	  activated	  once	  a	  CCV	  is	  pinched	  from	  the	  membrane	  [DeLuca-­‐Flaherty	  et	  al.,	  1990].	  	  In	   spite	   of	   these	   roles	   in	   clathrin-­‐coat	   assembly,	   tuning,	   and	   uncoating,	   the	  knockdown	   of	   LCs	   impact	   on	   clathrin-­‐mediated	   endocytosis	   only	   in	   few	   reported	  cases.	  Ferreira	  and	  colleagues	  reported	  that	  knockdown	  of	  either	  LCa	  or	  LCb	  inhibit	  endocytosis	  of	  some	  G-­‐protein	  coupled	  receptors,	  and	  that	  for	  the	  same	  process	  the	  phosphorylation	  of	  LCb	  residue	  S204	  is	  also	  necessary	  [Ferreira	  et	  al.,	  2012].	  LCs	  are	  also	   critical	   for	   the	   endocytosis	   of	   less-­‐canonical	   cargoes	   such	   as	   Listeria	  
monocytogenes	  [Bonazzi	  et	  al.,	  2011].	  In	  this	  process,	  LCs	  	  re-­‐localize	  Hip1R	  at	  the	  site	  of	   internalization	   and	   this	   event,	   stimulates	   the	   polymerization	   of	   actin	   and	   the	  subsequent	   membrane	   curvature	   of	   the	   clathrin-­‐coated	   pits.	   Interestingly,	   actin	  engagement	   is	   necessary	   to	   complete	   membrane	   deformation	   into	   a	   coated	   pit	   on	  apical	   surfaces	   of	   polarized	   cells	   and,	  more	   generally,	   on	   the	   surface	   of	   any	   cell	   in	  which	   the	  plasma	  membrane	   is	  under	   tension	   from	  osmotic	  swelling	  or	  mechanical	  stretching	   [Boulant	  et	  al.,	   2011].	   In	   this	   context	  where	  membrane	   tension	   seems	   to	  determine	  the	  actin	  dependence	  of	  clathrin-­‐coat	  assembly	  both	  LC	  and	  its	  interactor	  Hip1R	  are	  necessary	  to	  complete	  the	  invagination	  process	  [Boulant	  et	  al.,	  2011].	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2.	  MATERIALS	  AND	  METHODS	  
2.1	  Solutions	  
2.1.1	  10X	  SDS-­‐PAGE	  running	  buffer	  Glycine	   192	  mM	  Tris	  HCl,	  pH	  8.3	  	   250	  mM	  SDS	   1%	  	  	  
2.1.2	  10X	  Western	  transfer	  buffer	  Glycine	   192	  mM	  Tris	  HCl,	  pH	  8.3	  	   250	  mM	  For	  1X	  western	  transfer	  buffer,	  the	  10X	  stock	  was	  diluted	  1:10	  with	  ddH2O	  and	  20%	  v/v	  methanol	  or	  ethanol.	  
	  
2.1.3	  50X	  TAE	  (Tris-­‐Acetate-­‐EDTA)	  Tris	  base	  	   2	  M	  Acetic	  acid	   1	  M	  EDTA,	  pH	  8	   10	  mM	  The	  pH	  was	  adjusted	  to	  8.5	  with	  HCl	  and	  distilled	  H2O	  was	  added	  to	  bring	  the	  volume	  up	  to	  1	  liter.	  	  
2.2	  Protein	  buffers	  
2.2.1	  1X	  JS	  buffer	  HEPES,	  pH	  7.4	   50	  mM	  NaCl	   50	  mM	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Glycerol	   10%	  	  Triton	  X-­‐100	   1%	  MgCl2	   1.5	  mM	  EGTA	  	  	  	   5	  mM	  200X	   Protease	   inhibitor	   cocktail	   from	   Calbiochem,	   sodium	   pyrophosphate	   pH	   7.5	  20mM,	   sodium	   fluoride	   250	   mM,	   PMSF	   2	   mM,	   and	   sodium	   orthovanadate	   10	   mM	  were	  added	  to	  the	  buffer	  just	  before	  use.	  
	  
2.2.2	  1X	  Laemmli	  buffer	  SDS	   2	  %	  Tris	  HCl,	  pH	  6.8	  	   62.5	  mM	  Glycerol	   10%	  	  Bromophenol	  blue	   0.1%	  β-­‐Mercaptoethanol	   5	  %	  (v/v)	  	  
	  
2.3	  Reagents	  
2.3.1	  Antibodies	  Antibodies	   and	   their	   suppliers	   were:	   anti-­‐FLAG	   (F3165,	   Sigma),	   anti-­‐His	   (16B12,	  Babco),	   anti-­‐myosin	   VI	   (MUD-­‐19,	   Sigma),	   anti-­‐myosin	   VI	   (1295,	   generated	   by	  EUROGENTEC	   S.A.),	   anti-­‐Clathrin	   Heavy	   Chain	   antibody	   (MA1-­‐065,	   Pierce),	   anti-­‐Clathrin	  Heavy	  Chain	  (clone	  23,	  610499,	  BD	  bioscience),	  anti-­‐CLINT1	  (NBP1-­‐05991,	  Novus	   biological),	   anti-­‐COPB2	   (sc13332,	   Santa	   Cruz),	   anti	   PI3KC2α	   (611046	   BD	  Biosciences),	   Anti-­‐Dab2	   (610465,	   BD	   Biosciences),	   Anti-­‐GFP	   (G1544,	   Sigma),	   Anti	  GFP	  agarose/GFP-­‐Trap	  (gta-­‐20,	  Chromotek).	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2.3.2	  RNAi	  oligos	  Myosin	  VI	  Oligo#2:	  5’-­‐CAAGGAGTTATGCTGACATAATTCT-­‐3´	  Myosin	  VI	  Oligo#3:	  5’-­‐GAGGCTGCACTAGATACTTTGCTAA-­‐3´	  HeLa	   stably	   knocked	   down	   for	   Myosin	   VI	   were	   generated	   using	   a	   pSUPER	   vector	  carrying	  the	  following	  shRNA,	  targeting	  a	  sequence	  in	  the	  motor	  domain:	  For:	  5’-­‐TGGAATATTGTGCTGAATTATTCAAGAGATAATTCAGCACAATATTCCTTTTTTC-­‐3´	  Rev:	  5’-­‐GAGAAAAAAGGAATATTGTGCTGAATTATCTCTTGAATAATTCAGCACAATATTCC-­‐3´	  	  
	  
2.4	  Cloning	  techniques	  
2.4.1	  Agarose	  gel	  electrophoresis	  DNA	  samples	  were	  loaded	  on	  0.8%-­‐2%	  agarose	  gels	  along	  with	  DNA	  markers	  (1kb	  or	  100bp	   DNA	   Ladder,	   NEB).	   Gels	   were	   made	   in	   TAE	   buffer	   containing	   ethidium	  bromide	   (Sigma),	   according	   to	   manufacturer’s	   instructions,	   and	   run	   at	   80	   V	   until	  desired	  separation	  was	  achieved.	  DNA	  bands	  were	  visualized	  under	  a	  UV	  lamp.	  
	  
2.4.2	  Minipreps	  Individual	   colonies	   were	   used	   to	   inoculate	   2	   ml	   LB	   (containing	   the	   appropriate	  antibiotic)	   and	   grown	   overnight	   at	   37°C.	   Bacteria	   were	   transferred	   to	   Eppendorf	  tubes	  and	  centrifuged	  for	  5	  minutes	  at	  16,000xg	  using	  a	  5415	  R	  centrifuge.	  Minipreps	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were	   performed	   with	   the	   Wizard	   Plus	   SV	   Minipreps	   Kit	   (Promega)	   following	  manufacturer’s	  instructions.	  The	  plasmids	  were	  eluted	  in	  50	  μl	  nuclease	  free	  H2O.	  	  
2.4.3	  Large	  scale	  plasmid	  preparation	  Cells	   containing	   transfected	   DNA	   were	   expanded	   into	   250	   ml	   cultures	   overnight.	  Plasmid	  DNA	  was	  isolated	  from	  these	  cells	  using	  the	  Qiagen	  Maxi-­‐prep	  kit	  according	  to	  manufacturer’s	  instructions.	  	  
2.4.4	  Transformation	  of	  competent	  cells	  An	   aliquot	   of	   competent	   cells	   TOP10	   (Invitrogen)	   were	   thawed	   on	   ice	   for	  approximately	  10	  minutes	  prior	  to	  the	  addition	  of	  plasmid	  DNA.	  Cells	  were	  incubated	  with	  DNA	  on	  ice	  for	  30	  minutes	  and	  then	  subjected	  to	  a	  heat	  shock	  for	  45	  seconds	  at	  42°C.	  Cells	  were	  returned	  to	  ice	  for	  an	  additional	  5	  minutes.	  Then,	  300	  μl	  of	  SOC	  was	  added	  and	  the	  cells	  were	  left	  at	  37°C	  for	  further	  60	  minutes	  before	  plating	  them	  onto	  agar	  plates	  with	  the	  appropriate	  antibiotic.	  Two	  plates	   for	  each	  reaction	  were	  used,	  one	  plated	  with	  100	  μl	  of	  the	  transformed	  bacterial	  cells	  and	  the	  other	  one	  with	  the	  rest.	  Plates	  were	  incubated	  overnight	  at	  37°C.	  	  
2.5	  Constructs	  and	  plasmids	  GFP-­‐PI3KC2a	  was	   kindly	   provided	   by	   Dr.	   Emilio	   Hirsch,	   SFB-­‐DDB1	   by	   Dr.	  Maddika	  Subba	  Reddy,	  GFP-­‐optineurin	  by	  Dr.	  Alain	  Israel,	  FLAG-­‐T6BP	  by	  Dr.	  Folma	  Buss,	  His-­‐GIPC	  by	  Dr.	  Guido	  Serini,	  FLAG-­‐NDP52	  by	  Dr.	  Felix	  Randow.	  	  Human	   myosin	   VI	   cDNA	   KIAA0389	   (isoform	   1)	   was	   obtained	   from	   Kazusa	   DNA	  Research	   Institute	   (Kisarazu,	   Japan);	   PCR	   amplified	   and	   cloned	   into	   pGEX	   6P1	  (Amersham	   Pharmacia	   Biotech),	   pEGFP-­‐C2	   (Clontech).	   Myosin	   VI	   isoform	   2	   and	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isoform	  3	  were	  generated	  by	  mutagenesis	  (deletion	  and	  insertion,	  respectively)	  using	  isoform	  1	  as	  template	  and	  the	  following	  primers:	  iso2	  for:	  5’-­‐GGTACTAAGAAATATGATCTTAGTAAATGG-­‐3´	  iso2	  rev:	  5’-­‐TCTCCGCAGCGCCAGGTCGGC-­‐3´	  iso3	  for:	  5’-­‐CCGGTGACAAGCAAAAATGATGGAACAAGACCCAAAATGA-­‐3´	  iso3	  rev:	  5’-­‐ATAGCTATCCAGGCTCCGCAGCGCCAGGTCGGCC-­‐3´	  All	   other	   constructs	   described	   were	   engineered	   by	   site-­‐directed	   mutagenesis	   or	  recombinant	  PCR	  and	  sequence	  verified.	  	  	  
2.5	  Cell	  culture	  
2.5.1	  Cell	  lines	  HEK293T	  (ILC)	  and	  HEY	  (CELLution	  biosystems)	  cells	  were	  maintained	  in	  monolayer	  cultures	   in	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM,	  Lonza)	  supplemented	  with	  10%	  fetal	  calf	  serum	  and	  2	  mM	  L-­‐glutamine.	  MCF10A	  cells	  (ATCC)	  were	  cultured	  in	  DMEM/F12	   medium	   (Gibco)	   supplemented	   with	   5%	   horse	   serum,	   hydrocortisone	  (0.5	   μg/ml),	   insulin	   (10	   μg/ml),	   cholera	   toxin	   (50	   ng/ml)	   and	   EGF	   (20	   ng/ml).	  OVCAR-­‐3,	   OVCAR-­‐4,	   OVCAR-­‐5,	   OVCAR-­‐8,	   MDA-­‐MB-­‐231	   (NCI-­‐60)	   and	   COLO-­‐704	  (DSMZ)	  cells	  were	  maintained	  in	  RPMI-­‐1640	  (Lonza)	  containing	  10%	  fetal	  calf	  serum	  and	   2	   mM	   L-­‐glutamine.	   SKOV	   3	   cells	   were	   grown	   in	   McCoy’s	   5A	   (Gibco)	   medium	  supplemented	   with	   10%	   fetal	   calf	   serum.	   HeLa	   cells	   (ATCC)	   were	   maintained	   in	  Minimum	  Essential	  Medium	  (MEM,	  Gibco)	  supplemented	  with	  10%	  fetal	  calf	  serum,	  1%	  non-­‐essential	  amino	  acids,	  2	  mM	  L-­‐glutamine	  and	  1	  mM	  Na-­‐Pyruvate.	  All	  cell	  lines	  were	   authenticated	   at	   each	   batch	   freezing	   by	   STR	   profiling	   (StemElite	   ID	   System,	  Promega).	  All	  cell	  lines	  were	  tested	  for	  mycoplasma	  at	  each	  batch	  freezing	  with	  both	  PCR	  and	  a	  biochemical	  test	  (MycoAlert,	  Lonza).	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2.5.2	  Isolation,	  culture	  and	  processing	  of	  primary	  epithelial	  ovarian	  cancer	  cells	  Patient-­‐derived	   tissue	   samples	   were	   collected	   with	   the	   approval	   of	   the	   Ethical	  Committee	   of	   the	   European	   Institute	   of	  Oncology.	   Fresh	   biopsies	   of	   ovarian	   cancer	  were	   obtained	   from	   patients	   with	   high-­‐grade	   epithelial	   ovarian	   serous	   carcinoma	  who	   underwent	   surgical	   tumour	   debulking.	   Fresh	   biopsies	   of	   normal	   ovaries	  were	  obtained	   upon	   informed	   consent	   from	   patients	   undergoing	   adnexectomy	   for	   non-­‐ovarian	  gynaecological	  pathologies.	  All	   tumours	   were	   digested	   in	   DMEM/F12	   medium	   (Gibco)	   containing	   2	   mM	  glutamine,	   1%	   Penicillin/Streptomycin,	   200	   U/ml	   collagenase	   IA	   and	   100	   U/ml	  hyaluronidase.	   Normal	   ovaries	   were	   digested	   in	   5U/ml	   Dispase	   for	   30	   minutes	   at	  37°C	   and	   then	   the	   organ	   surfaces	   were	   scraped	   to	   isolate	   the	   epithelial	   cells.	   The	  derived	  primary	  epithelial	  cells	  were	  maintained	   in	  monolayer	  adherent	  cultures	   in	  collagen	  I	  Cellware	  coated	  flask	  (Corning)	  in	  DMEM/F12	  medium	  (Gibco)	  containing	  1%	   fetal	   bovine	   serum,	   2	   mM	   glutamine,	   1%	   Penicillin/Streptomycin,	   0.2%	  gentamicin,	   0.2%	   amphotericin,	   10	   mg/ml	   transferrin,	   1	   mg/ml	   insulin,	   1	   mg/ml	  hydrocortisone,	  10	  mM	  HEPES	  pH	  7.5,	  50	  mM	  ascorbic	  acid,	  15	  nM	  sodium	  selenite,	  50	  ng/ml	  cholera	  toxin,	  10	  nM	  EGF,	  35	  mg/ml	  bovine	  pituary	  extract,	  10	  nM	  T3,	  10	  nM	  β-­‐estradiol.	  For	  RNA	  extraction,	  5x106	  primary	  cells	  were	  washed	  in	  PBS	  and	  the	  cell	  pellets	  were	  snap	  frozen	  in	  dry	  ice.	  	  
2.5.3	  Transfections	  
RNAi	  transfections	  RNAi	   transfections	   were	   performed	   using	   LipofectAMINE	   RNAi	   MAX	   reagent	   from	  Invitrogen,	  according	  to	  manufacturer’s	  instructions.	  Cells	  were	  subjected	  to	  a	  single	  reverse	  transfection,	  treated	  with	  8	  nM	  RNAi	  oligo	  and	  analyzed	  4	  days	  after	  	  
DNA	  transfections	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For	  biochemical	  purposes	  (i.e.,	  GST-­‐protein	  pull-­‐down	  assay),	  DNA	  transfections	  were	  performed	   using	   Lipofectamine	   2000	   reagent	   from	   Roche,	   according	   to	  manufacturer’s	   instructions.	   Briefly,	   cells	  were	   plated	   at	   80%	   confluency	   on	   10	   cm	  cell	   culture	   dishes.	   The	   day	   after	   cells	   were	   transfected	   with	   5	   μg	   DNA	   and	   20	   μl	  Lipofectamine.	   24	   hours	   after	   transfection	   cells	   were	   lysed	   and	   subjected	   to	   pull-­‐down	  assay.	  For	  immunofluorescence	  studies,	  DNA	  transfections	  were	  performed	  using	  FuGENE	  6	  reagent	   from	   Roche,	   according	   to	   manufacturer’s	   instructions.	   Briefly,	   cells	   were	  plated	   at	   50%	   confluency	   in	   10	   cm	   cell	   culture	   dishes.	   The	   day	   after	   cells	   were	  transfected	  with	  5	  μg	  DNA	  and	  30	  μl	  of	  FUGENE	  6.	  The	  following	  day	  cells	  were	  plated	  on	   28	   mm	   coverslips	   and	   48	   hours	   after	   transfection	   cells	   were	   analyzed	   by	   live	  imaging.	  
	  
2.5.4	  Isoform	  detection	  by	  PCR	  Expression	   of	   myosin	   VI	   isoforms	   in	   various	   cell	   lines	   was	   assessed	   by	   PCR.	  Messenger	  RNA	  was	  isolated	  from	  cells	  grown	  on	  plastic	  dishes	  using	  TRIzol	  reagent	  (Invitrogen)	  and	  RNeasy	  Mini	  Kit	  (Qiagen)	  according	  to	  the	  manufacturer’s	  protocols.	  Genomic	  DNA	  and	  RNA	  retro-­‐transcription	  was	  performed	  with	  QuantiTect	  Reverse	  Transcription	  Kit	   (Qiagen).	   cDNA	  obtained	  was	  used	   in	  PCR	  reactions	  with	  primers	  flanking	  the	  spliced	  region:	  For:	  5´-­‐CCGAGCTCATCAGTGATGAGGC-­‐3´	  	  Rev:	  5´-­‐CCAAGCATGATACACTTTTAGTCTCC-­‐3´	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2.6	  Protein	  procedures	  
2.6.1	  Cell	  lysis	  After	  washing	  with	  PBS	  1X,	   cells	  were	   lysed	   in	   JS	   directly	   in	   the	   cell	   culture	   plates	  using	   a	   cell-­‐scraper	   and	   clarified	   by	   centrifugation	   at	   16,000	   xg	   for	   20	  min	   at	   4ºC	  using	  a	  5415	  R	  centrifuge.	  Protein	  concentration	  was	  measured	  by	  the	  Bradford	  assay	  (Biorad)	  following	  manufacturer’s	  instructions.	  
	  




Separating	  gel	  mix	  
	   	   	  	  	  	  Gel	  %	   	   	  




Separating	  gel	  mix	  Acrylamide	  mix	  (ml)	   1.68	  1M	  Tris	  HCl	  pH	  6.8	  (ml)	  	   1.36	  ddH2O	  (ml)	  	   6.8	  10%	  SDS	  (ml)	  	   0.1	  10%	  APS	  (ml)	  	   0.1	  TEMED	  (ml)	   0.01	  TOTAL	  (ml)	   10	  
	  
	  
2.6.3	  Immunoblot	  (IB)	  Desired	   amounts	   of	   proteins	   were	   loaded	   onto	   1-­‐1.5	   mm	   thick	   SDS-­‐PAGE	   gels	   for	  electrophoresis	   (Biorad).	   Proteins	   were	   transferred	   in	   western	   transfer	   tanks	  (Biorad)	   to	   nitrocellulose	   (Schleicher	   and	   Schnell)	   in	   1X	   Western	   transfer	   buffer	  (supplemented	  with	  20%	  methanol	  or	  ethanol)	  at	  30	  V	  overnight	  or	  100	  V	  for	  1	  hour	  for	   small	   gels	   and	   at	   30	   V	   overnight	   or	   0.8	   A	   for	   2	   hours	   for	   large	   gels.	   Ponceau	  staining	  was	  used	  to	  determine	  the	  efficiency	  protein	  transfer	  onto	  the	  filters.	  Filters	  were	  blocked	  for	  1	  hour	  (or	  overnight)	   in	  5%	  milk	   in	  TBS	  supplemented	  with	  0.1%	  Tween	   (TBS-­‐T).	   After	   blocking,	   filters	   were	   incubated	   with	   the	   primary	   antibody,	  diluted	  in	  TBS-­‐T	  5%	  milk,	  for	  1	  hour	  at	  room	  temperature,	  followed	  by	  three	  washes	  of	   five	   minutes	   each	   in	   TBS-­‐T.	   Filters	   were	   then	   incubated	   with	   the	   appropriate	  horseradish	  peroxidase-­‐conjugated	  secondary	  antibody	  diluted	  in	  TBS-­‐T	  for	  30	  min.	  After	   the	   incubation	  with	   the	   secondary	   antibody,	   the	   filter	  was	  washed	  3	   times	   in	  TBS-­‐T	   (5	  minutes	   each)	   and	   the	  bound	   secondary	   antibody	  was	   revealed	  using	   the	  ECL	  method	  (Amersham).	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2.6.4	  Immunoprecipitation	  For	   co-­‐immunoprecipitation	   experiments,	   HeLa	   cells	   stably	   knocked-­‐down	   for	  myosin	   VI	   were	   transfected	   using	   Lipofectamine	   (Life	   Technologies)	   according	   to	  manufacturer’s	   instruction	   and	   IP	  was	   performed	   using	   500	   μg	   of	   lysate	   and	   GFP-­‐Trap	  (Chromotek)	  in	  JS	  buffer.	  
	  
2.7	  Protein	  production	  and	  purification	  
2.7.1	  GST-­‐fusion	  protein	  production	  GST-­‐fusion	  proteins	  were	  expressed	  in	  E.	  coli	  strain	  BL21	  (DE3)	  Rosetta	  at	  18°C	  for	  16	  hr	  after	  induction	  with	  1	  mM	  IPTG	  at	  an	  OD600	  of	  0.5.	  Cells	  were	  then	  pelleted	  at	  4000	  rpm	  for	  10	  minutes	  at	  4°C	  and	  resuspended	  in	  GST-­‐lysis	  buffer	  (20	  ml/liter	  of	  bacteria).	   Samples	   were	   sonicated	   5	   times	   for	   20	   seconds	   each	   on	   ice	   and	   lysates	  were	   cleared	   by	   centrifugation	   at	   20000	   rpm	   for	   30	   minutes	   at	   4°C.	   1	   ml	   of	  glutathione-­‐sepharose	  beads	   (GE	  healthcare),	   previously	  washed	  3	   times	  with	  GST-­‐lysis	  buffer,	  was	  added	  to	  the	  supernatants	  and	  samples	  were	  incubated	  for	  2	  hour	  at	  4°C	   with	   rocking.	   Beads	   were	   washed	   with	   PBS/0.1%	   Triton	   and	   equilibrated	   in	  storage	  buffer.	  	  	  
GST	  lysis	  buffer	  Hepes,	  pH	  7.5	   50	  mM	  NaCl	   150	  mM	  EDTA	   1	  mM	  Glycerol	   5	  %	  NP40	   0.1%	  Protease	  Inhibitors	  	   1:500	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GST	  maintenance	  buffer	  Hepes,	  pH	  7.5	   50	  mM	  NaCl	   100	  mM	  EDTA	   1	  mM	  Glycerol	   10	  %	  DTT	   1	  mM	  	  
2.7.2	  Cleavage	  of	  GST-­‐fusion	  proteins	  GST-­‐fusion	  proteins	  were	  cleaved	  with	  PreScission	  Protease.	  1	  unit	  of	  enzyme	  for	  100	  μg	   of	   fusion	   protein	   was	   added	   to	   the	   beads	   in	   the	   presence	   of	   GST-­‐maintenance	  solution	  and	  either	   incubated	  overnight	  at	  4°C	  or	   for	  4	  hours	  at	   room	  temperature.	  After	   cleavage	   the	   supernatant	   containing	   the	   cleaved	   protein	   was	   collected	   and	  beads	  were	  washed	  twice	  to	  allow	  the	  complete	  recovery	  of	  the	  cleaved	  protein.	  	  	  
2.7.3	  Fast	  protein	  liquid	  chromatography	  After	   cleavage	   from	   the	   GST	   tag,	   proteins	   were	   purified	   using	   size	   exclusion	  chromatography.	  Prior	  to	  run	  on	  a	  Superdex	  75	  column,	  connected	  to	  an	  ÄKTAFPLC	  system	   (GE-­‐Healthcare),	   samples	   were	   concentrated	   using	   Vivaspin	   concentrators	  (GE-­‐Healthcare)	  and	  centrifuged	  at	  6000	  x	  g	  at	  4°C.	  The	  concentrated	  sample	  was	  run	  onto	  a	  Superdex	  75	  column	  in	  the	  following	  gel	  filtration	  buffer:	  	  	  
Gel	  filtration	  buffer	  20	  	   mM	  	   Tris	  pH	  7	  	  100	  	   mM	  	   NaCl	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1	  	   mM	  	   EDTA	  	   	  1	  	   mM	  	   DTT	  	  5%	  	   	   glycerol	  	  	  Purity	  of	  the	  peak	  was	  assayed	  by	  SDS-­‐PAGE	  gel.	  The	  desired	  fractions	  were	  collected,	  pooled,	  and	  concentrated	  using	  Vivaspin	  tubes.	  The	  final	  concentration	  of	  the	  samples	  was	   obtained	   as	   the	   ratio	   between	   the	   measured	   absorbance	   at	   280	   nm	   and	   the	  theoretical	  molar	  extinction	  coefficient	  at	  280	  nm,	  according	  to	  Lambert–Beer’s	  law.	  	  
2.7.4	  GST	  pull-­‐down	  GST-­‐fusion	  proteins	  immobilized	  onto	  GSH	  beads	  were	  incubated	  for	  2	  h	  at	  4°C	  in	  JS	  buffer	  (50	  mM	  Hepes	  pH	  7.5,	  50	  mM	  NaCl,	  1.5mM	  MgCl2,	  5mM	  EGTA,	  5%	  glycerol	  and	  1%	   Triton	   X-­‐100)	   with	   either	   1	   mg	   of	   HEK293T	   cellular	   lysate	   or	   200	   µg	   of	  transfected	   HEK293T	   cellular	   lysate.	   Detection	   was	   performed	   by	   immunoblotting	  using	   specific	   antibody.	   Ponceau-­‐stained	   membrane	   was	   used	   to	   show	   loading	   of	  GST-­‐fusion	  proteins.	  	  
2.8	  Mass	  spectrometry	  
2.8.1	  Liquid	  chromatography-­‐tandem	  MS	  (LC-­‐MS/MS)	  analysis	  Proteins	   were	   resolved	   by	   SDS-­‐PAGE	   on	   a	   gradient	   gel	   (4-­‐12	   %	   TGX	   Precast	   Gel,	  Biorad)	  and	  stained	  with	  Colloidal	  Blue	  (Colloidal	  Blue	  Staining	  Kit,	  Invitrogen).	  Each	  lane	   was	   divided	   into	   5	   slices	   and	   digested	   with	   trypsin.	   Briefly,	   samples	   were	  subjected	  to	  reduction	   in	  10	  mM	  DTT	  for	  1	  hour	  at	  56ºC.	  Digestion	  was	  carried	  out	  saturating	   the	  gel	  with	  12.5	  ng/μL	  sequencing	  grade	  modified	   trypsin	  (Promega)	   in	  50	  mM	  ammonium	  bicarbonate,	  overnight.	  Peptide	  mixtures	  were	  acidified	  with	  tri-­‐
	  58	  
fluoro	  acetic	  acid	  (TFA,	   final	  concentration	  3%),	  extracted	   from	  gel	  slices	  with	  30%	  acetonitrile	  (ACN)/	  3%	  TFA,	  dried	  in	  a	  Speed-­‐Vac	  and	  resuspended	  in	  20	  µL	  of	  0.1%	  FA.	   Three	   technical	   replicates	   of	   5	   µL	   injected	   for	   each	   sample	  were	   analysed	  on	   a	  Fourier	   transformed-­‐LTQ	   mass	   spectrometer	   (Thermo	   Electron,	   San	   Jose,	   CA).	  Peptides	  separation	  was	  achieved	  by	  a	  linear	  LC	  gradient	  from	  100%	  solvent	  A	  (5	  %	  ACN,	  0.1%	  formic	  acid)	   to	  20%	  solvent	  B	  (ACN,	  0.1%	  formic	  acid)	  over	  33	  min	  and	  from	  20%	  to	  80%	  solvent	  B	  in	  4	  min	  at	  a	  constant	  flow	  rate	  of	  0.3µL/min	  on	  Agilent	  chromatographic	   separation	   system	   1100	   (Agilent	   Technologies,	   Waldbronn,	  Germany)	  equipped	  with	  a	  15	  cm	  fused-­‐silica	  emitter	  of	  75	  µm	  inner	  diameter	  (New	  Objective,	   Inc.	  Woburn,	  MA	  USA),	   packed	   in-­‐house	  with	  ReproSil-­‐Pur	  C18-­‐AQ	  3	  µm	  beads	  (Dr.	  Maisch	  GmbH,	  Ammerbuch,	  Germany)	  using	  a	  high-­‐pressure	  bomb	  loader	  (Proxeon,	   Odense,	   Denmark).	   Survey	   MS	   scans	   were	   acquired	   in	   the	   FT	   from	  m/z	  350-­‐1650	  with	  100,000	  resolution.	  The	  five	  most	   intense	  doubly	  and	  triply	  charged	  ions	  were	  automatically	  selected	  for	  fragmentation.	  	  Target	  ions	  already	  selected	  for	  the	  MS/MS	  were	  dynamically	  excluded	  for	  60s.	  	  
2.8.2	  Data	  processing	  and	  protein	  quantification	  analysis	  Raw	   MS	   files	   were	   converted	   into	   peaklist	   (.msm	   files);	   all	   MS/MS	   samples	   were	  analysed	  using	  Mascot	   (Matrix	  Science,	  London,	  UK;	  version	  2.3.02)	  set	  up	  with	   the	  following	   parameters:	   UniProt_CP_Human_20140416	   database	   (88708	   entries),	  Taxonomy	   Homo	   sapiens,	   enzyme	   Trypsin,	   maximum	   missed	   cleavages	   2,	   fixed	  modification	  carbamidomethyl	  cysteine,	  variable	  modifications	  methionine	  oxidation	  and	  acetyl	  (protein	  N-­‐terminus),	  peptide	  tolerance	  10	  ppm,	  MS/MS	  tolerance	  0.5	  Da,	  instrument	  ESI-­‐TRAP.	  	  	  Interactomics	   results	   were	   generated	   with	   Scaffold_4.3.4	   (Proteome	   Software	   Inc.,	  Portland,	  OR)	  and	  protein	  quantitation	  was	  displayed	  as	  Total	  Spectral	  Count.	  Peptide	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identifications	   were	   accepted	   if	   they	   could	   be	   established	   at	   greater	   than	   95.0%	  probability	   by	   the	   Peptide	   Prophet	   algorithm	   with	   Scaffold	   delta-­‐mass	   correction	  [Keller	  et	  al.,	  2002].	  Protein	  identifications	  were	  accepted	  if	  they	  could	  be	  established	  at	   greater	   than	   99.0%	   probability	   and	   contained	   at	   least	   2	   identified	   peptides.	  	  Protein	  probabilities	  were	  assigned	  by	  the	  Protein	  Prophet	  algorithm	  [Nesvizhskii	  et	  
al.,	   2003].	   Proteins	   that	   contained	   similar	   peptides	   and	   could	   not	   be	   differentiated	  based	  on	  MS/MS	  analysis	  alone	  were	  grouped	  to	  satisfy	  the	  principles	  of	  parsimony.	  Proteins	  sharing	  significant	  peptide	  evidence	  were	  grouped	  into	  clusters.	  Label-­‐free	   quantification	   was	   obtained	   using	   MaxQuant	   software	   (1.4.0.5).	   MS/MS	  peak	   lists	   were	   searched	   against	   the	   Uniprot_cp_human_2013_07	   in	   which	   trypsin	  specificity	   was	   used	   with	   up	   to	   two	   missed	   cleavages	   allowed.	   Searches	   were	  performed	   selecting	   alkylation	   of	   cysteine	   by	   carbamidomethylation	   as	   fixed	  modification,	   and	   oxidation	   of	   methionine	   and	   N-­‐terminal	   acetylation	   as	   variable	  modifications.	  Mass	  tolerance	  was	  set	  to	  20	  ppm	  and	  0.5	  Da	  for	  parent	  and	  fragment	  ions,	  respectively.	  The	  false	  discovery	  rate	  for	  both	  peptides	  and	  proteins	  was	  set	  at	  0.01.	   Additionally,	   we	   required	   at	   least	   two	   peptide	   identifications	   per	   protein,	   of	  which	   at	   least	   one	   unique.	   “LFQ	   intensities”,	   which	   are	   the	   intensity	   values	  normalized	  across	   the	  entire	  dataset,	  were	  used	   for	  quantification	  based	  on	  unique	  plus	  razor	  peptides.	  Statistical	  analysis	  was	  performed	  using	  Perseus.	  Proteins	  were	  filtered	  applying	  Benjamini	  Hochberg	  and	  t-­‐test.	  The	  proteomic	  data	  as	  raw	  files,	  total	  proteins	  and	  peptides	  identified	  with	  relative	  intensities	  and	  search	  parameters	  have	  been	  deposited	  on	  Peptide	  Atlas	  repository	  (accession	  number	  PASS00591).	  
	  
2.9	  NMR	  spectroscopy	  The	   NMR	   experiments	   were	   acquired	   at	   10	   °C	   on	   Bruker	   700,	   800,	   and	   850	   MHz	  spectrometers	   equipped	   with	   gradient	   cryoprobes.	   15N-­‐,	   13C-­‐	   or	   13C,15N-­‐labeled	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samples	   used	   for	   titration	   experiments	   ranged	   from	   0.1	   to	   0.2	   mM,	   whereas	  experiments	   acquired	   for	   structure	   determination	   were	   performed	  with	   0.5	   to	   0.8	  mM	  samples;	  all	  experiments	  were	  conducted	  in	  20	  mM	  sodium	  phosphate	  buffer	  (pH	  6.5),	  50	  mM	  sodium	  chloride,	  2	  mM	  DTT,	  0.01	  %	  NaN3,	  and	  10	  %	  2H2O	  /	  90	  %	  1H2O.	  2D	   [1H,	   15N]-­‐HSQC	   and	   3D	   HNCO,	   HN(CA)CO,	   HNCA,	   HN(CO)CA,	   HNCACB,	   and	  CBCA(CO)NH	  spectra	  were	  used	   for	   	   backbone	  1H,	  15N,	   and	  13C	  assignments.	   Side	  chain	   1H	   and	   13C	   assignments	   were	   obtained	   by	   2D	   [1H,	   13C]-­‐HSQC	   and	   3D	  HBHA(CO)NH,	   H(CCCO)NH,	   (H)CC(CO)NH,	   HCCH-­‐COSY,	   HCCH-­‐TOCSY,	   and	   (H)CCH-­‐TOCSY	   spectra	   .	   Assignments	   were	   checked	   for	   consistency	   with	   3D	   15N/13C	   –NOESY-­‐HSQC	  spectra	  recorded	  with	  mixing	  times	  of	  120	  or	  100	  ms.	  	  
2.9.1	  Structure	  determination	  The	  regions	  for	  Ramachandran	  plot	  statistics	  and	  RMSD	  calculations	  include	  T1054-­‐R1068	  and	  Y1084-­‐S1126.	  NMR	  spectra	  were	  processed	  with	  NMRPipe	  and	  analysed	  with	   KUJIRA	   [Kobayashi	   et	   al.,	   2007]	   and	   SPARKY.	   CYANA2.1	   [Guntert,	   2004]	   was	  used	  for	  automated	  NOE	  assignment	  and	  to	  calculate	  the	  structures	  by	  torsion	  angle	  dynamics;	  each	  NOE	  assignment	  was	  manually	  inspected	  and	  confirmed	  or	  corrected.	  Dihedral	  angle	  restraints	  were	  derived	  by	  TALOS	  [Cornilescu	  et	  al.,	  1999].	  A	  total	  of	  100	   structures	  were	   independently	   calculated	   and	   the	   twenty	   conformers	  with	   the	  lowest	   target-­‐function	   values	   were	   selected	   for	   refinement	   with	   Xplor-­‐NIH.	  Structures	  were	  evaluated	  with	  PROCHECK-­‐NMR	  [Laskowski	  et	  al.,	  1996],	  visualized	  with	   MOLMOL,	   and	   figures	   generated	   by	   PYMOL	   (The	   PyMOL	   Molecular	   Graphics	  System,	  http://www.pymol.org/).	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2.10	  Immunofluorescence	  To	   remove	   soluble	   cellular	   proteins,	   cells	   were	   extracted	   with	   0.03%	   saponin	   in	  cytosolic	  buffer	  (25	  mM	  Hepes-­‐KOH,	  pH	  7.4,	  25	  mM	  KCl,	  2.5	  mM	  magnesium	  acetate,	  5	  mM	  EGTA,	  150	  mM	  K-­‐glutamate)	  for	  1	  min	  prior	  to	  fixation.	  Cells	  were	  fixed	  with	  4%	  paraformaldehyde	  for	  15	  minutes,	  and	  permeabilised	  at	  room	  temperature	  with	  0.1%	  Triton-­‐X100.	  Cells	  were	  incubated	  with	  primary	  antibodies	  for	  1 hour	  followed	  by	   secondary	   antibodies	   (Cy3,	   LifeTechnologies)	   for	   30 minutes,	   at	   room	  temperature.	  Coverslips	  were	  mounted	   in	  a	  glycerol	  solution	  (20%	  glycerol,	  50	  mM	  Tris	  pH=8.4)	  to	  avoid	  mechanical	  deformation	  of	   the	  sample.	   Images	  were	  captured	  using	  a	  Leica	  inverted	  SP2	  microscope	  with	  a	  laser	  scanning	  confocal	  system.	  Analysis	  was	   performed	  with	   ImageJ	   (http://imagej.nih.gov/ij/).	   For	   co-­‐localization	   analysis	  ROIs	   were	   drawn	   around	   individual	   cells	   and	   the	   Pearson’s	   coefficients	   obtained	  using	   JACoP	   plugin	   and	   processed	   for	   statistical	   analysis	   with	   Prism	   (GraphPad	  software).	  	  	  
2.11	  Wound-­‐healing	  assay	  3x104	   cells	   were	   plated	   into	   each	   chamber	   of	   a	   Culture–Insert	   for	   wound	   healing	  (Ibidi)	  48-­‐72	  hours	  before	  the	  beginning	  of	  the	  experiment.	  After	  insert	  removal,	  cells	  pictures	  were	   acquired	   every	  5	  minutes	   for	   24	  hours.	   Live-­‐imaging	  was	  performed	  using	  an	  ORCA-­‐ER	  camera	  (Hamamatsu)	  on	  an	  Olympus	  IX81	  automatic	  microscope	  equipped	   with	   closed	   heating	   and	   CO2	   perfusion	   devices.	   Data	   analysis	   was	  performed	   automatically	   using	   ImageJ	   (http://rsb.info.nih.gov/ij/),	   and	   a	   script	  designed	  in	  order	  to	  distinguish	  and	  measure	  the	  wound	  area	  from	  the	  area	  covered	  by	   cells.	   Wound	   closure	   rate	   values	   correspond	   to	   normalized	   slopes	   of	   linear	  equations	  derived	  from	  regression	  analyses	  of	  the	  area	  over	  time	  plots.	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2.12	  RNAseq	  analysis	  RNA-­‐Seq	   Analysis	   RNA-­‐Seq	   exons	   quantification	   data	   were	   downloaded	   from	   'The	  Cancer	   Genome	   Atlas'	   Data	   Portal	   (https://tcga-­‐data.nci.nih.gov/tcga/dataAccessMatrix.htm).	  Downloaded	  files	  included	  experiments	  which	  were	  analysed	  with	  the	  pipeline	  named	  RNAseq	  and	  conducted	  on	  neoplastic	  cells	  belonging	   to	   ten	  different	   tissues:	  bladder	  urothelial	   carcinoma	  (BLCA),	  breast	  invasive	  carcinoma	  (BRCA),	  esophageal	  carcinoma	  (ESCA),	  head	  and	  neck	  squamous	  cell	  carcinoma	  (HNSC),	  kidney	  renal	  clear	  cell	  carcinoma	  (KIRC),	  liver	  hepatocellular	  carcinoma	   (LIHC),	   lung	   adenocarcinoma	   (LUAD),	   lung	   squamous	   cell	   carcinoma	  (LUSC),	  stomach	  adenocarcinoma	  (STAD),	  and	  uterine	  corpus	  endometrial	  carcinoma	  (UCEC).	  Control	  experiments	  were	  also	  downloaded	  for	  each	  neoplastic	  counterpart.	  Additionally,	   experiment	   files	   relative	   to	   four	   additional	   neoplasic	   tissues	   were	  considered:	   colon	   adenocarcinoma	   (COAD),	   kidney	   renal	   papillary	   cell	   carcinoma	  (KIRP),	   serous	   cystadenocarcinoma	   (OV),	   and	   rectum	   adenocarcinoma	   (READ).	   For	  these	   last	   four	  sets,	  control	  counterparts	  were	  not	  available.	  Despite	  the	  availability	  of	  RNA-­‐Seq	  data	  from	  acute	  myeloid	  leukemia	  (LAML),	  such	  files	  were	  discarded,	  due	  to	   peculiar	   non-­‐comparable	   exon	   notation.	   The	   resulting	   dataset	   consisted	   of	   293	  control	  and	  1646	  tumour	  samples,	  belonging	  to	  14	  different	  tumour	  types.	  For	  each	  experiment,	   the	   exon	  quantification	   file	  was	   considered.	   The	   'raw	   counts'	   (RC)	   and	  'Reads	  Per	  Kilobase	  of	  Exon	  Model	  per	  Million	  Mapped	  Reads’	  (RPKM)	  were	  extracted	  for	  the	  genomic	  positions	  corresponding	  to	  exons	  27	  to	  33	  of	  the	  MYO	  VI	  gene,	  which	  follow	  	  E27:	  	  	  	  	  	  	  chr6:76600945-­‐76601023:+	  	  E28:	  	  	  	  	  	  	  chr6:76602247-­‐76602407:+	  	  E31:	  	  	  	  	  	  	  chr6:76608090-­‐76608128:+	  	  E32:	  	  	  	  	  	  chr6:76617322-­‐76617425:+	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E33:	  	  	  	  	  	  chr6:76618213-­‐76618344:+	  	  All	  the	  positions	  are	  relative	  to	  the	  hg19	  genome	  assembly.	  Exons	  E29	  and	  E30	  were	  not	   individually	   annotated	   due	   to	   the	   presence	   of	   a	   confounding	   overlapping	   first	  exon	   (chr6:76603648-­‐76604977:+).	   Exon	   expression	   changes	   between	   cancer	   and	  normal	   samples	  were	   estimated	  using	  RPKM,	   a	  measure	   of	   expression	   that	   reflects	  the	  molar	  concentration	  of	  a	  transcript	  in	  the	  sample	  by	  normalizing	  read	  counts	  for	  mRNA	   length	   and	   for	   the	   total	   read	   number	   in	   the	   sample.	   Exon	   E31	   relative	  abundances	  (E31RA)	  were	  then	  obtained	  for	  each	  sample	  as	  the	  ratio	  of	  their	  RPKM	  and	   the	   average	   RPKM	   values	   of	   the	   four	   flanking	   constitutive	   exons	   (namely	   E27,	  E28,	  E32	  and	  E33).	  E31	  Normalized	  Relative	  Abundances	   (E31NRA)	  were	  obtained	  for	  each	  cancer	  type	  as	  the	  ratio	  between	  each	  sample	  E31RA	  and	  the	  median	  E31RA	  value	   of	   the	   corresponding	   control	   samples.	   These	   normalized	   values	   can	   be	  compared	  among	  different	  cancer	   types.	   	  For	  cancer	   types	  with	  no	  matched	  control	  set,	  we	  obtained	  E31NRA	  as	   the	  ratio	  between	  each	  sample	  E31RA	  and	   the	  median	  E31RA	  value	  of	  all	   the	  control	  samples.	  Wilcoxon	  test	  has	  been	  performed	  by	  using	  the	  R-­‐package	  (http://www.R-­‐project.org/.)	  to	  verify	  the	  hypothesis	  that	  the	  logRatio	  between	   tumours	   and	   control	   samples	   E31NRA	   values	   is	   negative	   (i.e.	   the	  median	  E31NRA	  is	  less	  in	  tumours	  than	  in	  controls).	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3.	  RESULTS	  
3.1	  Different	  myosin	  VI	  isoforms	  show	  different	  interaction	  partners	  
3.1.1	  Myosin	  VI	  undergoes	  alternative	  splicing	  As	  stated	  in	  the	  introduction,	  myosin	  VI	  can	  exist	   in	  a	  number	  of	  different	  isoforms,	  which	   represent	   splice	   variants	   with	   inserts	   in	   the	   tail	   [Dance	   et	   al.,	   2004].	   The	  number	  of	  isoforms	  differs	  between	  different	  organisms,	  and	  they	  are	  expressed	  in	  a	  tissue-­‐specific	   manner.	   Despite	   certain	   knowledge	   about	   their	   diverse	   functions,	   a	  complete	   understanding	   of	   the	  mechanism	   of	   alternative	   splicing	   regulation	   is	   still	  missing.	  Similarly,	  we	  lack	  studies	  on	  the	  molecular	  mechanism	  that	  determines	  the	  differences	   observed	   between	   the	   various	   myosin	   VI	   isoforms	   [Buss	   et	   al.,	   2001;	  Dance	  et	  al.,	  2004].	  	   We	   attempt	   to	   answer	   these	   questions	   analyzing	   the	   human	   myosin	   VI	  transcripts	   in	   detail.	   The	   protein	   is	   encoded	   by	   36	   exons	   and	   two	   major	   splicing	  events	  were	  described	  close	  to-­‐	  or	  included	  in-­‐	  the	  CBD	  of	  the	  tail.	  Depending	  on	  their	  length	  they	  are	  named	  large-­‐insert	  (LI)	  and	  short-­‐insert	  (SI),	  respectively	  (see	  Figure	  
5	  for	  the	  position	  of	  the	  two	  sites).	  	   We	  focused	  our	  study	  on	  the	  LI.	  Three	  exons	  codify	  for	  it	  (exon	  29,	  30,	  and	  31),	  and	  their	  combination	  give	  rise	  to	  3	  different	  isoforms	  named	  isoform	  2	  (the	  shortest,	  lacking	   all	   the	   three	   exons),	   and	   isoforms	   1	   and	   3	   (which	   differ	   in	   the	   absence	   or	  presence	   of	   exon	   29,	   respectively).	   We	   examined	   the	   level	   of	   conservation	   among	  different	   species,	   of	   the	  myosin	   VI	   sequence	   close	   to	   the	   LI.	  We	   also	   looked	   at	   the	  presence	   of	   known	   protein	   domains	   and	   the	   predicted	   secondary	   structure.	   The	  sequences	   showed	  a	  high	  conservation	   level	   around	   the	  LI	   (colour	   coded	   in	  Figure	  
13),	   the	  presence	  of	   a	  previously	  described	  Ubiquitin-­‐Interacting-­‐Motif	   [Penengo	  et	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al.,	   2006],	   and	   the	   proximity	   of	   the	  well-­‐known	   1116RRL1118	  motif	   that	   accounts	   for	  several	   protein-­‐protein	   interactions	   [Sahlender	   et	   al.,	   2005];	   [Spudich	   et	   al.,	   2007].	  Furthermore,	  the	  secondary	  structure	  prediction	  highlighted	  the	  possible	  presence	  of	  several	  alpha	  helices.	  	  






Figure	  13:	  Myosin	  VI	  undergoes	  alternative	  splicing.	  a)	  position	  of	  the	  alternatively	  spliced	  exons	  of	   the	   large	   insert	   on	   the	   human	  myosin	   VI	   gene.	  b)	   Amino	   acids	   sequence	   alignment	   covering	   the	  region	   used	   for	   the	   following	   experiments,	   color-­‐coded	   according	   to	   sequence	   conservation.	   The	  sequences	  of	  all	  the	  myosin	  VI	  isoforms	  from	  different	  species	  (Hs:	  Homo	  sapiens;	  Mm:	  Mus	  musculus;	  Rn:	  Rattus	   norvegicus;	   Ss:	   Sus	   scrofa;	   Xt:	   Xenopus	   tropicalis;	   Gg:	  Gallus	   gallus;	   Dr:	  Danio	   rerio)	   were	  retrieved	   from	   the	   NCBI	   database	   and	   analysed	   using	   ClustalOmega.	   Secondary	   structure	   elements,	  predicted	   using	   http://www.predictprotein.org	   and	   later	   confirmed	   by	   structural	   data	   are	   depicted	  above	   the	  sequence.	  The	   large	   insert	   corresponds	   to	   the	   linker	   region	   that	  varies	  between	   the	  short	  (iso	  2)	  and	  the	  long	  (iso	  1,	  3)	  isoforms,	  and	  is	  depicted	  in	  orange.	  Numbering	  on	  top	  of	  the	  sequence	  alignment	  refers	  to	  human	  isoform	  3.	  
	  
3.1.2	  Alternative	  splicing	  of	  myosin	  VI	  regulates	  its	  interactome	  To	  verify	  if	  alternative	  splicing	  could	  modify	  the	  interactome	  of	  myosin	  VI,	  and	  thus	  its	   functions,	  we	  performed	   a	  mass	   spectrometry-­‐based	  proteomic	   screen	   aimed	   at	  comparing	   the	   interaction	   profiles	   of	   the	   different	   isoforms.	   Myosin	   VI	   spanning	  amino	   acid	   998-­‐1131	   of	   the	   three	   isoforms	   were	   cloned	   into	   pGEX	   vector.	   The	  corresponding	   purified	   myosin	   VI	   proteins	   were	   used	   in	   pull-­‐down	   assays	   with	  HEK293T	   cellular	   lysates.	   Bound	   proteins	  were	  washes	   and	   resolved	   on	   SDS-­‐PAGE	  gel.	  Notably,	  isoform	  1	  and	  3	  show	  similar	  binding	  pattern	  where	  isoform	  2	  behaves	  differently	   (Figure	   14a).	   	   Bands	  were	   then	   in-­‐gel	   digested	   and	   analysed	   by	  mass-­‐spectrometry.	  A	  label-­‐free	  quantitative	  experiment	  was	  performed	  in	  order	  to	  score	  differences	  between	  the	  constructs.	  Data	  resulting	  from	  this	  approach	  were	  analysed	  by	  MaxQuant	  software	  and	  are	  presented	  in	  Table	  1,	  reported	  as	  total-­‐peptide	  counts	  (TPC).	  Data	  confirmed	  the	  initial	  observations.	  Isoforms	  1	  and	  3	  have	  almost	  identical	  binding	  partners.	  Most	  of	  them	  are	  implicated	  in	  endocytosis	  and	  vesicular	  trafficking	  and	  are	  not	  shared	  by	   isoform	  2.	   In	  particular,	  we	   identified	  clathrin	  heavy	  chain,	  a	  set	  of	  adaptor	  proteins	  that	  form	  the	  AP2	  complex,	  well-­‐known	  endocytic	  adaptors	  of	  the	  ep15/epsin	   family	   (CLINT1	  and	  EPS15),	  and	  a	  COPII	  component	   (SEC16A),	   that	  may	   connect	   myosin	   VI	   to	   the	   anterograde	   transport	   from	   ER	   to	   Golgi.	   Few	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interactors	   common	   to	   all	   three	   isoforms	   were	   identified,	   among	   them	   COPB2	   an	  essential	  component	  of	  the	  Golgi	  vesicles.	  Surprisingly,	  isoform	  2-­‐specific	  interactors	  were	  mostly	  protein	  linked	  to	  the	  DNA	  damage	  response.	  	  	   As	  isoforms	  1	  and	  3	  showed	  no	  difference	  in	  their	  interactome,	  we	  decided	  to	  refer	   to	   them	   collectively	   as	   myosin	   VIlong,	   while	   using	   myosin	   VIshort	   to	   indicate	  isoform	  2.	  	  	   Gene	  name	   	   Iso1	  (TPC)	   Iso2	  (TPC)	   Iso3	  (TPC)	  CLTC	   clathrin,	  heavy	  chain	  	  (CLTC)	   1050	   *153	   1068	  SEC16A	   SEC16	  homolog	  A	  (S.	  cerevisiae)	   175	   0	   145	  AP2B1	   adaptor-­‐related	  protein	  complex	  2,	  beta	  1	  subunit	   91	   0	   107	  AP2A2	   adaptor-­‐related	  protein	  complex	  2,	  alpha	  2	  subunit	   87	   0	   89	  AP2A1	   adaptor-­‐related	  protein	  complex	  2,	  alpha	  1	  subunit	   85	   0	   90	  AP1G1	   adaptor-­‐related	  protein	  complex	  1,	  gamma	  1	  subunit	   28	   0	   32	  AP2M1	   AP-­‐2	  complex	  subunit	  mu	  	   35	   0	   51	  CLINT1	   clathrin	  interactor	  1	  (EPSIN4)	   138	   0	   146	  PIK3C2A	   Class	  2	  phosphatidylinositol-­‐4-­‐phosphate	  3-­‐kinase	   73	   0	   90	  PICALM	   Phosphatidylinositol-­‐binding	   clathrin	   assembly	  protein	  	   15	   0	   19	  EPS15	   Epidermal	  growth	  factor	  receptor	  substrate	  15	  	   6	   0	   5	  REPS	   RalBP1-­‐associated	  Eps	  domain-­‐containing	  protein	  1	  	   10	   0	   5	  COPB2	   Coatomer	  subunit	  beta'	  	   45	   50	   57	  DDB1	   DNA	  damage-­‐binding	  protein	  1	  	   137	   251	   123	  EPRS	   Bifunctional	  glutamate/proline-­‐-­‐tRNA	  ligase	  	   206	   686	   183	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VPRBP	   Vpr	  (HIV-­‐1)	  binding	  protein	  (DCAF)	   0	   140	   0	  DCTN1	   dynactin	  1	   0	   105	   0	  GTPBP4	   Nucleolar	  GTP-­‐binding	  protein	  1	  (NOG1)	   5	   44	   0	  ARHGEF12	   Rho	  guanine	  nucleotide	  exchange	  factor	  12	   6	   64	   0	  YTHDC2	   Probable	  ATP-­‐dependent	  RNA	  helicase	  	   4	   37	   2	  DCTN2	   Dynactin	  subunit	  2	   2	   37	   0	  DOCK7	   Dedicator	  of	  cytokinesis	  protein	  7	  	   2	   32	   4	  
	  
Table	   1	   List	   of	   the	   top	   hits	   of	   interactors	   identified	   by	   label-­‐free	   quantitative	   mass	  
spectrometry.	   Gene	   name,	   description	   and	   total	   peptide	   count	   (TPC)	   is	   reported	   for	   each	   protein.	  	  	  	  	  The	   *	   indicates	   that	   the	   same	   total	   peptide	   count	   was	   reported	   for	   the	   control	   (GST	   alone).	   The	  experiment	  was	  repeated	  once	  in	  the	  label-­‐free	  quantitative	  setup,	  but	  same	  interactors	  were	  found	  in	  three	  different	  non-­‐quantitative	  experiments.	  	  	  	  
	  
Figure	   14:	  Proteomic	   analysis	   of	   myosin	   VI	   isoforms	   reveals	   different	   interactomes.	   a)	   GST-­‐myosin	   VI998-­‐1131	   fusion	   proteins	   representing	   the	   three	   different	   isoform	   variants	   were	   used	   to	  pulldown	  1mg	  of	  HEK293T	  total	  cell	  lysate.	  Bound	  proteins	  were	  washed,	  resolved	  in	  SDS-­‐PAGE,	  and	  Coomassie-­‐stained.	   Numbering	   and	   lines	   refer	   to	   the	   slices	   cut	   for	   the	   mass	   spectrometry	  identification.	   Asterisks	   indicate	   clathrin	   heavy	   chain	   bands,	   being	   one	   of	   the	   most	   abundant	  interactor.	  b)	  Validation	  analysis.	  GST	   fusion	  proteins	  were	   incubated	  with	  HEK293T	  cellular	   lysate.	  Bound	  proteins	  were	  resolved	  by	  SDS-­‐PAGE	  and	  analysed	  by	  immunoblotting	  (IB)	  as	  indicated.	  In	  case	  
a) b) 
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of	  DDB1	  and	  PI3KC2α,	   tagged	  constructs	  were	  transiently	   transfected	   in	  HEK293T	  cells	  and	  IB	  were	  performed	  with	   anti-­‐tag	   antibody.	   Comparable	   loading	   of	  GST-­‐tagged	  proteins	   is	   shown	  by	  Ponceau	  staining	  (bottom	  panel).	  	  	   Experimental	  validation	  confirmed	  the	  most	  abundant	  identified	  interactors	  (5	  out	  of	  5	  tested)	  and	  their	  specificity	  (Figure	  14b).	  Validation	  was	  performed	  through	  the	  same	  experimental	  setting	  used	  for	  the	  mass-­‐spectrometry.	  GST-­‐myosin	  VI998-­‐1131	  were	  used	  to	  pulldown	  HEK293T	  total	  cell	  lysate	  and	  immunoblot	  analysis	  revealed	  a	  selective	   interaction	   of	   myosin	   VIlong	   with	   endogenous	   CLTC,	   CLINT1,	   and	  overexpressed	  PI3KC2α.	  At	   the	   same	   time	  we	  verified	   the	   specific	  binding	  of	  DDB1	  with	  myosin	  VIshort,	  while	  COPB2	  was	   found	   to	   interact	  with	  both	   isoforms	   (Figure	  
14b).	  	  
3.1.3	  Dab2	  is	  not	  necessary	  for	  myosin	  VI998-­‐1131	  interaction	  with	  clathrin	  heavy	  
chain	  Inspection	   of	   the	   gel	   shown	   in	   Figure	   14a,	   revealed	   sharp	   bands	   visible	   in	   the	  isoform	   1	   and	   3	   lanes,	   with	   an	   apparent	   molecular	   weight	   of	   around	   180	   kDa	  (labelled	  with	  an	  asterisk	  in	  the	  figure).	  These	  bands	  represent	  clathrin	  heavy	  chain	  (CLTC),	  an	  exclusive	  and	  abundant	  binding	  partner	  of	  myosin	  VIlong	  	  (Figure	  14b).	  	   It	   has	   been	   previously	   reported	   that	  Disabled-­‐2	   (Dab2)	   is	   the	   critical	   player	  that	  mediates	   the	   interaction	  between	  myosin	  VI	   and	   clathrin	   [Morris	  et	  al.,	   2002].	  Notably,	   the	   1191WWY1193	  motif	  of	  myosin	  VI	   responsible	   for	   this	   interactor	  binding	  [Spudich	   et	   al.,	   2007]	   was	   not	   present	   in	   the	   constructs	   used	   for	   pulldown	  experiments.	  Furthermore	  Dab2,	  which	  is	  a	  96kDa	  protein	  (a	  region	  of	  the	  gel	  that	  we	  analysed	   by	   mass-­‐spectrometry),	   was	   not	   identified	   in	   the	   mass-­‐spectrometry	  analysis.	  We	   reasoned	   that	   this	  might	   be	   due	   to	   the	   low	   level	   of	   expression	   of	   this	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protein	  in	  HEK293T	  cells	  (Figure	  15a).	  To	  better	  understand	  the	  role	  of	  Dab2	  in	  our	  experimental	  settings,	  HeLa	  cells	  were	  chosen	  as	  a	  second	  cellular	  system	  since	  they	  are	   positive	   for	   Dab2	   expression	   (Figure	   15a).	   Also	   in	   this	   case,	   we	   easily	   scored	  specific	   binding	   of	   myosin	   VIlong	   constructs	   to	   clathrin	   heavy	   chain	   while	   no	  interaction	   with	   Dab2	   was	   detected	   (Figure	   15b).	   We	   repeated	   the	   experiment	  transfecting	  GFP-­‐Dab2	  in	  HEK293T	  cells	  with	  identical	  results	  (Figure	  15c).	  Thus,	  we	  identified	  a	  novel	  surface	  of	  interaction	  between	  myosin	  VI	  and	  clathrin.	  Whether	  the	  binding	   is	   direct	   or	   mediated	   by	   the	   presence	   of	   a	   third	   molecule	   remains	   to	   be	  investigated.	  	  	  
	  	  
Figure	   15:	   Dab2	   does	   not	   interact	   with	   myosin	   VI998-­‐1131.	   a)	   Immunoblot	   analysis	   aimed	   at	  comparing	  the	  level	  of	  expression	  of	  Dab2	  in	  different	  cell	  lines.	  25µg	  of	  HeLa,	  CaCO-­‐2,	  and	  HEK293T	  total	  cell	  lysate	  were	  resolved	  in	  SDS-­‐PAGE	  and	  analysed	  by	  immunoblot	  with	  a	  monoclonal	  anti-­‐Dab2	  antibody.	   Anti-­‐Tubulin	   was	   used	   as	   loading	   control.	   	   b)	   GST-­‐myosin	   VI998-­‐1131	   fusion	   proteins	   were	  incubated	  with	  HeLa	   cellular	   lysate	   (endogenous	  Dab2).	   Bound	   protein	  were	   resolved	   in	   SDS-­‐PAGE	  and	  analysed	  by	  immunoblot	  (IB)	  as	  indicated.	  Comparable	  loading	  of	  GST-­‐tagged	  proteins	  is	  shown	  by	  
b) c) 
a) 
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Ponceau	  staining	  (bottom	  panel).	  c)	  same	  as	  in	  b)	  but	  GFP-­‐Dab2	  was	  transfected	  in	  HEK293T	  and	  IB	  was	  performed	  with	  anti-­‐GFP	  antibody.	  	   	  
3.1.4	   Clathrin	   heavy	   chain	   C-­‐terminus	   is	   necessary	   for	   the	   interaction	   with	  
myosin	  VI	  In	   order	   to	   unravel	   the	   nature	   of	   this	   novel	   interaction	   we	   searched	   the	   binding	  surface	  on	  CLTC.	  We	  exploited	  three	  GFP-­‐tagged	  clathrin	  constructs	  bearing	  different	  truncations	   at	   the	  C-­‐terminus	  of	   the	  molecule	   (aa	  1-­‐479,	   aa	  1-­‐1074	  and	  aa	  1-­‐1675,	  respectively,	   see	   Figure	   16a,	   and	   the	   Material	   and	   Methods	   section).	   Transfected	  HEK293T	   cellular	   lysates	   were	   used	   in	   pulldown	   experiments,	   using	   GST-­‐myosin	  VI998-­‐1131	  fusion	  proteins	  as	  bait	  representing	  the	  three	  isoforms.	  Bound	  protein	  were	  analysed	  in	  immunoblot	  using	  an	  antibody	  raised	  against	  the	  N-­‐terminus	  of	  clathrin	  heavy	   chain.	   This	   antibody	   was	   able	   to	   recognize	   simultaneously	   GFP-­‐tagged	   and	  endogenous	  CLTCs,	  allowing	  a	  direct	  comparison	  between	  the	  overexpressed	  and	  the	  endogenous	   proteins.	   As	   shown	   in	   Figure	   16b	   only	   the	   full-­‐length	   GFP-­‐CLTC	  construct	  was	  able	  to	  bind	  specifically	  GST-­‐myosin	  VIlong	  but	  not	  GST-­‐myosin	  VIshort,.	  None	  of	  the	  other	  fragments,	  even	  if	  expressed	  at	  the	  same	  level,	  were	  able	  to	  do	  the	  same.	  	  	   These	   results	   indicate	   that	   the	   critical	   determinant	   for	   myosin	   VI	   binding	  resides	  in	  the	  1074-­‐1675	  region	  of	  CLTC,	  at	  its	  C-­‐terminus.	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Figure	  16:	  Full-­‐length	  clathrin	  heavy	  chain	  is	  needed	  for	  the	  interaction	  with	  myosin	  VI998-­‐1131.	  
a)	  Scheme	  of	  the	  different	  GFP-­‐tagged	  clathrin	  heavy	  chain	  constructs	  used	  in	  the	  experiment	  together	  with	  their	  ability	  to	  interact	  with	  myosin	  VIlong.	  b)	  GST-­‐myosin	  VI998-­‐1131	  fusion	  proteins	  were	  incubated	  with	  total	  cell	   lysates	  (TCL)	  from	  HEK293T	  transfected	  either	  with	  GFP	  alone,	  GFP-­‐CLTC	  1-­‐479,	  GFP-­‐CLTC	   1-­‐1074	   or	   GFP-­‐CLTC	   1-­‐1675	   (full-­‐length).	   Bound	   proteins	   were	   resolved	   in	   SDS-­‐PAGE	   and	  analysed	  by	  immunoblot	  using	  anti-­‐CLTC	  antibody.	  Pale-­‐green	  arrows	  highlight	  bands	  accounting	  for	  GFP-­‐CLTC	   fusion	  proteins.	  Comparable	   loading	  of	  GST-­‐tagged	  proteins	   is	  shown	  by	  Ponceau	  staining	  (bottom	  panel).	  	  
3.1.5	  Myosin	  VI998-­‐1131	  does	  not	  interact	  directly	  with	  clathrin	  heavy	  chain	  To	  verify	  a	  possible	  direct	  interaction	  between	  clathrin	  heavy	  chain	  and	  myosinVI998-­‐
1131,	  we	  decided	  to	  purify	  GST-­‐clathrin	  fusion	  proteins	  from	  bacteria.	  The	  full-­‐length	  protein	   spans	   1675	   amino	   acids,	   making	   difficult	   to	   express	   it	   in	   a	   good	   amount.	  Therefore,	  we	  choose	   to	  purify	  different	   regions	  of	   the	  protein	   separately.	  The	   full-­‐length	   clathrin	   is	   composed	   of	   several	   domains,	   which	   differ	   functionally	   and	  structurally	   [Brodsky,	   2012]	   and	   can	   appropriately	   fold	   on	   their	   own.	  We	   selected	  three	  GST-­‐tagged	  constructs,	  a	  first	  encompassing	  aa	  1-­‐479,	  a	  second	  spanning	  aa	  1-­‐1074,	   and	   a	   third	   which	   contained	   aa	   1075-­‐1675	   (see	   Figure	   17a).	   The	   three	  together	  cover	  the	  entire	  length	  of	  the	  protein.	  The	  fusion	  proteins	  were	  used	  in	  an	  in	  
b) 
a) 
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vitro	  pulldown	  against	  increasing	  amount	  of	  a	  GST-­‐cleaved	  and	  purified	  myosin	  VI998-­‐
1131	  polypeptide.	  As	  visible	  from	  Figure	  17b,	  no	  specific	  binding	  was	  scored	  between	  the	  clathrin	  constructs	  and	  the	  myosin	  fragment	  even	  at	  the	  highest	  concentration	  (1	  μM	  bait	  vs.	  12	  μM	  prey).	  	  	   These	   results	   led	   us	   to	   investigate	   the	   possibility	   that	   an	   additional	   protein	  could	  mediate	  the	  interaction.	  	  
	  
Figure	   17:	   Purified	   clathrin	   heavy	   chain	   and	   myosin	   VI998-­‐1131	   do	   not	   interact	   in	   vitro.	   a)	  Schematic	  representation	  of	   the	  different	  GST-­‐tagged	  clathrin	  heavy	  chain	   fusion	  protein	  used	   in	   the	  experiment	  together	  with	  their	  ability	   to	  bind	  myosin	  VI	  998-­‐1131.	  b)	  1	  µM	  of	  bacterially	  purified	  GST-­‐tagged	  proteins	  (bait)	  were	  incubated	  with	  the	  indicated	  amount	  of	  purified	  myosin	  VI	  998-­‐1131	  (prey).	  Bound	  proteins	  were	  resolved	  in	  SDS-­‐PAGE	  and	  Coomassie	  stained.	  	  	  




produced	   and	   purified	   from	   bacteria	   GST-­‐tagged	   LC	   that	   was	   used	   as	   bait	   against	  purified	  myosin	  VI998-­‐1131	  polypeptides,	  representing	  the	  long	  and	  short	   isoforms.	  As	  shown	  in	  Figure	  18,	  we	  found	  that	  myosin	  VIlong	  but	  not	  myosin	  VIshort	  interacts	  with	  clathrin	  light	  chain.	  	  	   These	  results	  validate	  the	  isoform	  specific	  binding	  of	  myosin	  VIlong	  to	  clathrin	  that	  we	   found	   in	  mass-­‐spectrometry	  and	   led	  us	   to	   conclude	   that	  we	   identify	   a	  new	  direct	  binding	  partner	  of	  myosin	  VI.	  
	  
Figure	  18:	  Purified	  clathrin	  light	  chain	  and	  myosin	  VI998-­‐1131	  interact	  in	  vitro.	  1	  µM	  GST-­‐tagged	  LC	  were	   incubated	  with	   3	   µM	   cleaved	   and	   purified	  myosin	  VI	   998-­‐1131.	   Bound	  proteins	  were	   resolved	   in	  SDS-­‐PAGE	  and	  Coomassie	  stained.	  	  
	  
3.1.7	  Mapping	  the	  clathrin	  light	  chain	  interaction	  surface	  Once	  we	  defined	  clathrin	  light	  chain	  as	  a	  new	  interactor	  of	  myosin	  VI,	  we	  performed	  a	  structure/function	   analysis	   aimed	   at	   elucidating	   the	   region	   of	   LC	   involved	   in	   the	  binding.	  Clathrin	  light	  chains	  are	  translated	  from	  2	  different	  genes	  (LCa	  and	  LCb),	  and	  even	  though	  no	  functional	  differences	  are	  known	  between	  LCa	  and	  LCb	  proteins,	  their	  primary	  sequences	  show	  some	  differences	  (see	  Figure	  19)	  [Brodsky,	  2012].	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Figure	  19:	  Alignment	  of	  LCa	  and	  LCb.	  Scheme	  of	  the	  domain	  organization	  of	  LCs	  as	  in	  Figure	  12a,	  numbering	  of	  the	  amino	  acids	  on	  top.	  The	  black	  vertical	  lines	  on	  the	  bottom	  represent	  site	  of	  identity	  between	  the	  two	  primary	  sequences.	  Alignment	  was	  performed	  using	  ClustalOmega	  and	  modified	  with	  JalView.	   	  	   We	  exploited	  the	  two	  genes	  coding	  for	  similar	  proteins	  to	  gather	  a	  first	  set	  of	  information	   about	   the	   possible	   site	   of	   interaction.	   Thus,	  we	   cloned	   also	   LCb	   into	   a	  pGEX	  vector	  and	  we	  used	  purified	  GST-­‐LCs	  fusion	  proteins	  to	  pulldown	  cleaved	  and	  purified	  myosin	  VI998-­‐1131	   fragment.	   As	   reported	   in	  Figure	   20,	  we	  detected	   specific	  binding	   of	   GST-­‐LCa	   with	   myosin	   VI,	   while	   no	   interaction	   was	   found	   with	   the	   LCb	  counterpart.	  	  	  
	  
Figure	  20:	  LCa	  and	  LCb	  differ	   in	  their	  ability	  to	  interact	  with	  myosin	  VI998-­‐1131.	  1	  µM	  of	  GST	  and	  GST-­‐tagged	  LCs	  were	  used	  to	  pulldown	  3	  µM	  myosin	  VI998-­‐1131	  representing	   long	  and	  short	   isoforms.	  Bound	  proteins	  were	  resolved	  in	  SDS-­‐PAGE	  and	  Coomassie	  stained.	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Next,	   we	   performed	   structure/function	   analysis	   by	   cloning	   different	  truncation	  constructs	  of	  LCa	   (refer	   to	  Figure	   19a	   for	  a	   scheme).	   	   In	  order	   to	  avoid	  possible	  misfolding,	  we	   considered	   the	  boundaries	   of	   known	   functional	   domains	  of	  the	  protein.	  Various	  fragments	  were	  successfully	  expressed	  in	  bacteria,	  purified	  and	  used	   to	   pulldown	   cleaved	   and	   purified	   myosin	   VI998-­‐1131	   polypeptides	   of	   long	   and	  short	   myosin	   VI	   isoforms.	   This	   analysis	   allowed	   us	   to	   identify	   the	   region	   of	   LCa	  spanning	  between	  aa	  47	  and	  aa	  97	  as	  the	  minimal	  surface	  required	  for	  the	  interaction	  (Figure	  21).	  Not	  surprisingly,	  this	  region	  shows	  the	  poorest	  sequence	  similarity	  with	  LCb,	   explaining	   the	  differences	   scored	   in	   the	  myosin	  VI	   binding.	   Through	   the	   same	  region,	   LCa	  was	   shown	   to	   bind	   Hsc70,	   an	   interaction	   that	   is	   not	   conserved	   in	   LCb	  [DeLuca-­‐Flaherty	  et	  al.,	  1990].	   	  
	  
Figure	  21:	  Myosin	  VI998-­‐1131	  directly	  interact	  in	  vitro	  with	  LCa47-­‐97.	  a)	  Scheme	  of	  the	  different	  fusion	  proteins	  together	  with	  their	  ability	  to	  bind	  myosin	  VI998-­‐1131.	  b)	  1	  µM	  GST	  alone,	  GST-­‐LCa,	  GST-­‐LCb,	  as	  
b) 
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well	   as	  different	  GST-­‐LCa	   truncations	  were	  used	  as	  bait	   to	  pulldown	  6	  µM	  purified	  myosin	  VI998-­‐1131	  isoform	  1	  in	  an	  in	  vitro	  pulldown.	  Bound	  proteins	  were	  resolved	  in	  SDS-­‐PAGE	  and	  Coomassie	  stained.	  	   To	   better	   understand	   this	   interaction,	   we	   investigated	   whether	   the	   two	  proteins	  were	   able	   to	   form	   a	   stable	   complex	   in	   solution.	   To	   this	   purpose,	  we	   used	  analytical	   size	   exclusion	   chromatography	   (SEC).	   Myosin	   VI998-­‐1131	   fragment	   from	  isoform	  1	  was	  cleaved	  and	  purified	  through	  ion	  exchange	  chromatography	  (data	  not	  shown).	  The	  purified	  protein	  eluted	  in	  a	  S75	  column	  as	  a	  single,	  narrow	  peak	  (red	  line	  in	  Figure	   22)	  between	   the	  14kDa	  and	   the	  29kDa	  molecular	  weight	   (MW)	  markers.	  The	  same	  behaviour	  was	  observed	   for	   the	  LCa47-­‐97	   (green	   line	   in	  Figure	   22)	   that	   is	  actually	  run	  aberrantly,	  possibly	  due	  to	  its	  elongated	  and	  unfolded	  structure	  [Wilbur	  
et	  al.,	   2010].	   The	   two	   proteins	  were	   then	  mixed	   at	   1:1	  molar	   ratio	   and	   allowed	   to	  interact	  for	  15	  min	  at	  4	  °C.	  After	  injection,	  the	  pre-­‐formed	  complex	  eluted	  in	  a	  single	  peak	  in	  correspondence	  of	  the	  29	  kDa	  marker	  (blue	  line	  in	  Figure	  22),	  confirming	  the	  formation	  of	  a	  stable	  complex	  in	  solution.	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Figure	   22:	   LCa47-­‐97	   and	   myosin	   VI998-­‐1131	   form	   a	   stable	   complex	   in	   solution.	   Analytical	   size	  exclusion	  chromatography	  of	  50	  µM	  purified	  LCa	  47-­‐97	  fragment	  (green	  line),	  50	  µM	  myosin	  VI998-­‐1131	  (red	   line)	   and	   the	   complex	   of	   the	   two	   polypeptides	   (blue	   line).	   The	   two	   fragments	  were	   incubated	  together	  for	  15	  min	  at	  4	  °C	  to	  allow	  interaction.	  Fractions	  from	  9-­‐14	  ml	  were	  separated	  by	  gradient	  (4-­‐20%)	  SDS-­‐PAGE	  and	  stained	  with	  Coomassie.	  	  
	   Based	   on	   the	   these	   results,	   we	   attempted	   to	   solve	   the	   crystal	   structure	   of	  myosin	   VI:LCa	   using	   the	   protein	   complex	   purified	   as	   in	   Figure	   22	   (LCa47-­‐97	   and	  myosin	   VI998-­‐1131).	   First,	   we	   used	   static	   light	   scattering	   (SLS)	   to	   determine	   the	  effective	   molecular	   weight	   of	   the	   two	   proteins	   singularly	   and	   in	   complex.	   The	  proteins	  (16kDa	  for	  myosin	  and	  5	  kDa	  for	  LCa)	  and	  their	  complex	  (21kDa)	  weighted	  exactly	  as	  predicted	  (data	  not	  shown).	  Proteins	  resulted	  monodisperse	  and	  therefore	  suitable	  for	  crystallization	  attempts.	  We	  exploited	  several	  crystallization	  trays	  at	  4	  °C	  and	  20	  °C	  (i.e.	  PACT	  and	  JCSG-­‐Plus),	  with	  the	  complex	  at	  a	   final	  concentration	  of	  20	  mg/mL	  and	  40	  mg/mL.	  Unfortunately,	  most	  of	  the	  drops	  were	  clear,	  testifying	  a	  high	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solubility	  of	  the	  complex.	  Difficulties	  in	  the	  crystallization	  of	  clathrin	  light	  chain	  were	  already	  reported	  in	  the	  past	  and	  ascribed	  to	  the	  lack	  of	  a	  proper	  secondary	  structure	  [Wilbur	  et	  al.,	  2010].	  	  	   To	  define	   the	  minimal	   interaction	   surface	   on	  LCa,	  we	  prepared	   a	  new	   set	   of	  GST-­‐tagged	   constructs,	   shortening	   either	   the	   C-­‐	   or	   the	   N-­‐terminus	   of	   the	   LCa47-­‐97	  fragment.	   Four	   different	   constructs	   were	   assessed	   for	   their	   ability	   to	   bind	  myosin	  VIlong	  in	  vitro	  and	  none	  of	  them	  resulted	  impaired	  in	  this	  ability	  (Figure	  23).	  Thus,	  we	  concluded	  that	  the	  interaction	  with	  myosin	  VI	  is	  restricted	  to	  the	  thirty	  amino	  acids	  of	  the	  LCa51-­‐80	  fusion	  protein.	  	  	  
	  




two	  constructs,	  namely	  GST-­‐LCa51-­‐60	  and	  GST-­‐LCa51-­‐70	  (Figure	  24a),	  were	  used	  again	  in	  a	  in	  vitro	  pulldown	  with	  purified	  myosin	  VIlong.	  GST-­‐LCa	  full-­‐length	  (FL),	  GST-­‐LCa47-­‐
97	   and	   GST-­‐LCa51-­‐80	   were	   used	   as	   positive	   controls.	   As	   reported	   in	   Figure	   24b,	  trimming	  of	  LCa	  down	  to	  a	  stretch	  of	  ten	  amino	  acids	  didn’t	  show	  any	  impairment	  in	  myosin	  VI	  binding.	  	  We	   also	   designed	   GST-­‐LCa	   full-­‐length	   constructs	   with	   deletion	   of	   the	   51-­‐60	  and	   51-­‐70	   regions,	   namely	   GST-­‐LCaΔ51-­‐60	   and	   GST-­‐LCaΔ51-­‐70	   (Figure	   24a).	  Corroborating	  our	  previous	  findings,	  using	  LCaΔ51-­‐60	  and	  LCaΔ51-­‐70	  fusion	  proteins	  the	  interaction	   with	   myosin	   VI	   was	   reduced	   to	   background	   level	   (Figure	   24c).	   We	  concluded	   that	   the	   region	   spanning	   aa	   51	   to	   aa	   60	   of	   LCa	   is	   both	   necessary	   and	  sufficient	  for	  the	  interaction	  with	  myosin	  VIlong.	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Before	  embarking	  in	  new	  crystallization	  trails	  a	  more	  precise	  quantitation	  of	  the	  affinity	   between	   LCa	   and	   myosin	   VI	   would	   be	   of	   help.	   To	   this	   end,	   we	   recently	  obtained	   fluorescently	   labelled	  LCa	   fragments	  encompassing	   the	   region	  between	  aa	  51	  and	  aa	  60	  that	  will	  be	  used	  to	  perform	  fluorescent	  polarization	  assay.	  	  
3.1.8	  Structure/function	  analysis	  of	  the	  myosin	  VIlong	  binding	  region	  for	  clathrin	  We	  also	   attempted	   to	   define	   the	  minimal	   clathrin	   interaction	   surface	   on	  myosin	  VI	  molecule.	  To	  this	  purpose,	  we	  designed	  and	  generated	  a	  panel	  of	  GST-­‐tagged	  myosin	  VI	  constructs,	  trimming	  either	  the	  C-­‐	  or	  the	  N-­‐terminus	  of	  the	  isoform	  3	  myosin	  VI998-­‐
1131	  construct,	  which	  was	  used	  for	  the	  proteomic	  screen.	  As	  these	  experiments	  were	  performed	  before	  the	  identification	  of	  the	  clathrin	  light	  chain	  as	  the	  direct	  interactor,	  the	   read	   out	   of	   these	   experiments	   was	   clathrin	   heavy	   chain	   binding	   detected	   by	  immunoblot.	  This	  can	  be	  considered	  as	  a	  proxy	  of	  the	  LCa	  binding	  ability	  of	  myosin	  VI.	  A	  schematic	  representation	  of	  the	  different	  constructs	  used	  is	  reported	  on	  top	  of	  each	  panel	  of	  Figure	  25.	  	  
Regions deleted from the C-terminal end did not show any clathrin interaction (Figure	   25b),	   thus	   proving	   the	   requirement	   of	   this	   region	   for	   the binding.	    As	  expected,	  by	  itself,	  the	  region	  following	  the	  alternative	  splicing	  was	  not	  sufficient	  for	  the	   interaction.	   The	   construct	   bearing	   only	   myosin	   VI	   aa	   1080-­‐1131	   failed	   to	  pulldown	  clathrin	  while	  the	  binding	  was	  retained	  by	  other	  fusion	  proteins	  carrying	  a	  longer	  N-­‐terminus	  that	  includes	  at	  least	  part	  of	  the	  LI	  (Figure	  25c).	  	  To	   conclusively	   define	   the	   determinants	   of	  myosin	   VI:clathrin	   interaction,	  we	  designed	  deletion	  constructs	  that	  remove	  part	  of	  the	  LI	  region	  of	  myosin	  VI	  (myosin	  VI	  Δ1045-­‐1069	  and	  myosin	  VI	  Δ1055-­‐1069).	  As	  shown	  in	  Figure	  25d,	  these	  constructs	  loose	  the	  ability	  to	  pulldown	  clathrin.	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Figure	  25:	  Myosin	  VI1055-­‐1131	  is	  the	  minimal	  region	  required	  for	  clathrin	  binding.	  a)	  scheme	  of	  the	  myosin	  VI	   region	  used	   in	   the	   following	  experiments.	   In	  b),	  c),	   and	  d)	  500	  μg	  of	  HEK293T	  TCL	  were	  incubated	   with	   the	   GST-­‐tagged	   myosin	   VI	   schematized	   on	   top	   of	   every	   single	   panel	   to	   allow	  interaction.	   Bound	   proteins	   were	   then	   resolved	   in	   SDS-­‐PAGE	   and	   assessed	   for	   CLTC	   presence	   by	  immunoblot	   using	   monoclonal	   anti-­‐CLTC	   antibody.	   Comparable	   loading	   of	   GST-­‐tagged	   proteins	   is	  shown	  by	  Ponceau	  staining	  (bottom	  panel).	  	  	  
3.2	   “RRL-­‐interactors”	   and	   clathrin	   are	   mutually	   exclusive	   binding	  
partners	  of	  myosin	  VI	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We	   therefore	   tested	   if	   the	   motif	   was	   directly	   involved	   in	   clathrin	   binding.	   To	   this	  purpose,	  we	   generated	   single	   point	  mutations	   of	   the	   1116RRL1118	  motif	   as	  well	   as	   a	  triple	  AAA	  mutation	  previously	  described	   in	   literature	   to	   validate	   interactions	  with	  known	  myosin	  VI	  binders.	  As	   shown	   in	  Figure	   26,	   GST-­‐tagged	  myosin	  VIlong	   fusion	  proteins	   carrying	   R1117A	   (RAL),	   L1118A	   (RRA)	   and	   the	   triple	   AAA	   mutation	   are	  impaired	   in	   clathrin	   binding	   from	   cell	   lysates.	   In	   the	   same	   experiment	   the	  R1116A	  (ARL)	  mutant	  behaved	  as	  the	  wild	  type.	  	  
	  
Figure	  26:	  The	  1116RRL1118	  motif	  is	  crucial	  for	  clathrin	  binding.	  GST-­‐tagged	  myosin	  VIlong	  (aa	  998-­‐1131)	  wild-­‐type	  or	   1116RRL1118	  mutants	  were	  used	   against	   500	  μg	  of	  HEK293T	  TCL.	  Bound	  proteins	  were	   then	   resolved	   in	   SDS-­‐PAGE	   and	   assessed	   for	   CLTC	  presence	   by	   immunoblot	   using	  monoclonal	  anti-­‐CLTC	  antibody.	  Comparable	  loading	  of	  GST-­‐tagged	  proteins	  is	  shown	  by	  Ponceau	  staining	  (bottom	  panel).	  	  	  	   During	   our	   subsequent	   structural	   analysis	  we	   found	   that	   the	   residue	  R1117	  makes	   important	   contact,	   required	   for	   the	   structural	   integrity	   of	   this	   myosin	   VI	  region	   (data	   not	   shown).	   Indeed,	   the	   R1117A	   mutant	   protein	   is	   unfolded,	   as	  demonstrated	   by	   circular-­‐dichroism	   data	   (Figure	   27).	   Thus,	   for	   the	   following	  functional	  studies	  we	  focused	  on	  the	  L1118A	  mutant	  that	  retains	  a	  correct	  fold.	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Figure	  27	  Myosin	  VI	  R1117A	  mutation	  causes	  unfolding	  of	  the	  protein.	  Circular	  dichroism	  data	  of	  the	  myosin	  VI998-­‐1131	  R117A	  fragment,	  ellipticity	  of	  the	  fragment	  is	  perturbed	  in	  the	  R1117A	  mutant.	  	  	   To	   corroborate	   our	   biochemical	   results	   regarding	   the	   interaction	   between	  myosin	  VIlong	  and	  clathrin,	  we	  generated	  GFP-­‐tagged	  versions	  of	  the	  tail	  of	  myosin	  VI	  (Δ1-­‐834	   constructs).	   Truncated	   myosin	   VI	   constructs	   (lacking	   the	   motor-­‐domain)	  have	  been	  extensively	  used	   in	  previous	  studies	  as	   they	  retain	   the	  ability	   to	   interact	  with	  the	  known	  partners	  and	  they	  are	  easier	  to	  express	  in	  cell	  lines.	  We	  cloned	  wild-­‐type	   (Taillong)	   and	   L1118A	   mutant	   (TaillongRRA)	   as	   well	   as	   Tailshort.	   As	   our	   results	  showed	  that	  Dab2	  might	  be	  dispensable	  for	  myosin	  VI998-­‐1131	  and	  clathrin	  to	  interact	  in	   our	   setup,	   we	   decided	   to	   clone	   a	   GFP-­‐fusion	   construct	   bearing	   the	   TaillongWLY	  mutant	  since	  the	  W1192L	  mutation	  was	  reported	  to	  abrogate	  Dab2	  binding	  [Spudich	  
et	  al.,	  2007].	  To	  avoid	  any	  influence	  due	  to	  the	  possible	  dimerization	  of	  the	  GFP-­‐tails	  constructs	   with	   the	   endogenous	   myosin	   VI,	   we	   transfected	   them	   into	   HeLa	   cells	  where	  endogenous	  myosin	  VI	  had	  been	  stably	  knocked-­‐down.	  First,	  we	  looked	  at	  the	  co-­‐localization	   of	   the	   different	   myosin	   VI	   tails	   with	   clathrin	   heavy	   chain	   in	  immunofluorescence	   studies.	   As	   previously	   reported,	   Taillong	   strongly	   co-­‐localized	  with	  clathrin,	  whereas	  Tailshort	  exhibited	  no	  significant	  co-­‐localization	  (Figure	  28a,b)	  in	   confocal	   slices.	   Notably,	   both	   the	   RRA-­‐	   and	   WLY-­‐	   Taillong	   mutants	   failed	   to	   co-­‐localize	  with	  clathrin,	  similarly	  to	  Tailshort	  (Figure	  28a,b).	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Figure	   28:	   Myosin	   VI	   L1118A	   mutant	   fails	   to	   colocalize	   with	   clathrin	   heavy	   chain.	   a)	   Co-­‐localization	   of	   GFP-­‐tagged	  myosin	   VI	   tail	   constructs	   transfected	   into	   HeLa	   and	   endogenous	   clathrin	  heavy	   chain.	   On	   the	   right	   of	   each	   sample	   slice	   we	   enlarged	   a	   region	   of	   the	   cell	   and	   reported	   the	  normalized	  intensity-­‐plot	  of	  the	  red	  and	  green	  pixels	  along	  the	  yellow	  line.	  b)	  Diagram	  reporting	  the	  average	  ±SE	  of	  Pearson’s	   coefficient	   calculated	   from	  at	   least	  15	   cells	   for	   each	   transfected	   constructs	  from	  three	  independent	  experiments.	  	   	  We	  confirmed	  these	  results	  through	  co-­‐immunoprecipitation	  experiments.	  GFP-­‐myosin	   VI	   tails	   were	   transiently	   transfected	   into	   HeLa	   cells	   lacking	   endogenous	  myosin	   VI	   and	   immunoprecipitated	   using	   an	   anti-­‐GFP	   nanobody.	   As	   reported	   in	  






Figure	  29:	  Myosin	  VI	  L1118A	  mutant	   fails	   to	  co-­‐immunoprecipitate	  clathrin	  heavy	  chain	   from	  
cell	   lysate.	   a)	   HeLa	   cells	   stably	   expressing	   shRNA	   against	  myosin	   VI	   (lacking	   endogenous	   protein)	  were	  transiently	  transfected	  with	  wild-­‐type	  and	  mutants,	  shRNA-­‐resistant,	  GFP-­‐myosin	  VI	  tails.	  Anti–GFP	  nanobodies	  were	  used	   to	   immunoprecipite	  1	  mg	  of	  TCL.	  Bound	  proteins	  were	  resolved	  by	  SDS-­‐PAGE	   and	   immunoblotted	   using	   anti-­‐CLTC	   and	   anti-­‐Dab2	   monoclonal	   antibodies	   (the	   two	   proteins	  were	  expressed	  at	  endogenous	  level).	  A	  polyclonal	  anti-­‐GFP	  antibody	  was	  used	  in	  immunoblot	  to	  check	  the	  equal	  amount	  of	  immunoprecipitated	  protein	  (panel	  b).	  
	  
This	   observation	   led	   us	   to	   further	   analyse	   the	   effect	   of	   mutations	   of	   the	  
1116RRL1118	  motif	  towards	  known	  interactors	  of	  myosin	  VI,	  such	  as	  optineurin,	  T6BP,	  NDP52,	   and	   GIPC.	   As	   probed	   for	   clathrin	   (Figure	   26),	   binding	   to	   partners	   was	  impaired	   by	   the	   structure-­‐destabilizing	   R1117A	   mutation	   either	   alone	   or	   in	   the	  context	   of	   the	   triple	   AAA	   mutant	   (Figure	   30).	   Analysis	   performed	   with	   the	   other	  single	   point	  mutants	   demonstrate	   that	   R1116	   and	   L1118	   are	   critical	   for	   GIPC	   and	  optineurin	   binding	   whereas	   T6BP	   and	   NDP52	   associate	   with	   myosin	   VI	   in	   fashion	  which	  not	  only	  depends	  on	  1116RRL1118	  (Figure	  30).	  These	  two	  latter	  molecules	  might	  extend	  their	  interaction	  with	  myosin	  VI	  to	  a	  larger	  surface	  that	  encompass	  but	  is	  not	  limited	  to	  the	  RRL	  motif.	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Figure	   30:	   Effect	   of	   myosin	   VI	   L1118A	  mutation	   on	   the	   “RRL-­‐interactors”.	   GST-­‐tagged	  myosin	  VI1080-­‐1131	   wild-­‐type	   and	   1116RRL1118	   mutants	   were	   used	   against	   500	   μg	   of	   TCL	   from	   HEK293T	  transfected	   with	   GFP-­‐optineurin,	   His-­‐GIPC,	   Flag-­‐NDP52,	   and	   Flag-­‐T6BP.	   Bound	   proteins	   were	   then	  resolved	  by	  SDS-­‐PAGE	  and	  assessed	  for	  the	  presence	  of	  the	  different	  interactors	  through	  immunoblot	  using	   anti-­‐tag	   antibodies.	   Comparable	   loading	   of	   GST-­‐tagged	   proteins	   is	   shown	  by	   Ponceau	   staining	  (bottom	  panel).	  	  	  
3.2.2	  The	  presence/absence	  of	  the	  LI	  dictates	  myosin	  VI	  interactors	  Our	  previous	  results	  demonstrated	  that	  for	  the	  clathrin	  heavy	  chain	  binding	  we	  need	  both	  the	  LI	  and	  1116RRL1118	  motif.	  	  This	  prompted	  us	  to	  re-­‐examine	  the	  interaction	  of	  Myosin	   VI	   with	   the	   previously	   characterized	   “RRL-­‐interactors”	   respect	   to	   the	  alternative	   splicing	   of	   the	   LI.	   No	   direct	   and	   specific	   binding	   towards	   Myosin	   VI	  isoforms	  has	  been	  previously	  tested	  in	  vitro.	  	   To	   get	   insights	   into	   this	   issue,	   GST-­‐myosin	  VI998-­‐1131	   constructs	   representing	  the	  three	  isoforms,	  together	  with	  the	  GST-­‐myosin	  VI1080-­‐1131	  constructs	  that	  contains	  the	   1116RRL1118	   motif	   but	   not	   the	   LI	   were	   analysed	   against	   HEK293T	   cell	   lysate.	  Surprisingly,	  all	  four	  interactors,	  optineurin,	  GIPC,	  NDP52,	  and	  T6BP	  selectively	  bind	  to	  myosin	  VIshort,	   similar	   to	  myosin	  VI1080-­‐1131	   construct	   (Figure	   31).	   Thus,	   clathrin	  and	  “RRL-­‐interactors”	  have	  different	  binding	  specificity	  and	  the	  presence/absence	  of	  the	   LI	   appears	   to	   dictate	   the	  myosin	   VI	   interactors. A	   possible	   explanation	   for	   the	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above-­‐described	   data	   implies	   that	   the	   different	   isoforms	   might	   assume	   different	  conformations	  and	  that,	  in	  the	  context	  of	  Myosin	  Vlong,	  the	  1116RRL1118	  motif	  necessary	  for	  interactor	  binding	  is	  not	  available.	   	  
	  
Figure	  31:	  Mutually	  exclusive	  binding	  of	  myosin	  VI	  to	  clathrin	  and	  “RRL-­‐interactors”.	  GST-­‐tagged	  myosin	   VI998-­‐1131	   and	  myosin	   VI1080-­‐1131	   constructs	  were	   used	   against	   500	   μg	   of	   TCL	   from	  HEK293T	  transfected	   with	   GFP-­‐optineurin,	   His-­‐GIPC,	   Flag-­‐NDP52,	   and	   Flag-­‐T6BP.	   Bound	   proteins	   were	   then	  resolved	  in	  SDS-­‐PAGE	  and	  assessed	  for	  the	  presence	  of	  the	  different	  interactors	  through	  immunoblot	  using	   anti-­‐tag	   antibodies,	   except	   for	   CLTC.	   Comparable	   loading	   of	   GST-­‐tagged	   proteins	   is	   shown	   by	  Ponceau	  staining	  (bottom	  panel).	  
	  
3.2.3	  Structure	  of	  the	  myosin	  VI	  clathrin-­‐binding	  domain	  	  To	  shed	  light	  on	  the	  different	  behaviour	  of	  myosin	  VI	  we	  started	  a	  collaboration	  with	  the	  Kylie	  Walters	  group	  at	  NIH	  (Bethesda,	  USA).	  We	  used	  modern	  NMR	  techniques	  to	  solve	  the	  structure	  of	  the	  myosin	  VIlong	  fragment	  responsible	  for	  clathrin	  binding;	  this	  region	  spans	  R1050-­‐R1131	  and	  includes	  the	  isoform-­‐specific	  LI	  region	  (in	  orange	  in	  
Figure	   25). Twenty	   calculated	  NMR	   structures	  with	   lowest	   energy	   converged	  well	  with	   a	   backbone	   root	   mean	   square	   deviation	   (RMSD)	   of	   0.18	   Å.	   The	   structure	  confirmed	   the	   predicted	   α2-­‐linker	   helix	   (shown	   Figure	   25).	   The	   LI	   region	  encompassing	   P1055	   to	   R1068	   residues	   forms	   an	   amphipathic	   α-­‐helix	   that	   packs	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against	  two	  other	  helices	  present	  in	  all	  isoforms	  (Figure	  32a).	  A	  hydrophobic	  surface	  of	   α2-­‐linker	   formed	   by	   M1058,	   M1062,	   and	   L1066	   inserts	   into	   cleft	   at	   the	   α3/α4	  interface	  for	  interaction	  with	  hydrophobic	  residues	  Y1091,	  F1114,	  L1118,	  and	  Y1121	  (Figure	  3.20a).	  	  Notably	   the	   residue	   L1118,	   critical	   for	   clathrin	   binding	   (RRA	  mutant,	   Figure	  
26),	   is	   buried	   in	   the	   interface	   between	   α2-­‐linker	   and	   α3/α4	   (Figure	   32b).	   	   Thus,	  leucine	   to	   alanine	   substitution	   in	   this	   position	   most	   likely	   acts	   changing	   the	  configuration	  of	   the	  domain	   rather	   than	  directly	  affecting	   the	   surface	  of	   interaction	  with	  clathrin.	  As	  visible	  in	  the	  structure,	  R1117	  forms	  a	  salt	  bridge	  with	  S1087	  of	  the	  α3	   (Figure	   32b)	   and	   this	   clarifies	   the	   importance	   of	   this	   residue	   to	   maintain	   the	  structural	  integrity	  of	  this	  region.	  These	  structural	  details	  proved	  that	  the	  1116RRL1118	  motif	   remains	   inaccessible	   for	   interactors	  binding	   in	   the	   case	  of	  myosin	  VIlong.	   This	  validates	   our	   observation	   that	   all	   four	   “RRL-­‐binders”	   have	   a	   clear	   preference	   for	  myosin	   VIshort	   when	   tested	   in	   pull-­‐down	   assay	   (Figure	   31)	   and	   the	   idea	   of	   a	  conformational	  difference	  between	  the	  myosin	  VI	   isoforms	  induced	  by	  the	  presence	  of	  the	  LI.	  	  
	  
Figure	  32:	   Structure	   of	   the	  myosin	  VI	   clathrin-­‐binding	  domain.	   a)	  Ribbon	  representation	  of	   the	  myosin	  VI	  R1050-­‐R1131	  structure.	  The	  isoform	  specific	  α-­‐2	  linker	  is	  in	  orange,	  α-­‐3	  and	  α-­‐4	  helices	  in	  cyan.	  b)	  Expanded	  view	  of	  a	  that	  illustrates	  the	  position	  of	  the	  RRL	  motif	  residues.	  
a) b) 
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Taken	   together,	   these	   data	   imply	   that	   packing	   of	   the	   α2-­‐linker	   against	   the	  α3/α4	  helices	  in	  myosin	  VIlong	  determines:	  i)	  its	  exquisite	  clathrin-­‐binding	  ability	  and	  ii)	  its	  impairment	  in	  RRL-­‐mediated	  binding	  (i.e.	  optineurin).	  Thus,	  myosin	  VI	  isoforms	  have	  mutually	  exclusive	  association	  with	  clathrin	  and	  RRL	  interactors	  (i.e.	  optineurin,	  as	  schematise	  in	  Figure	  33).	  	  
	  
Figure	   33:	  Model	   representation	   of	   the	   interaction	   of	  myosin	   VIlong	   and	  myosin	   VIshort.	   a)	  The	  	  	  α2-­‐linker	   (orange)	   packs	   against	   the	   α3/α4	   helices	   and	   mask	   the	   RRL	   motif	   in	   myosin	   VIlong	  contemporarily	  allowing	  clathrin	  to	  interact.	  b)	  Absence	  of	  the	  α2-­‐linker	  unmasks	  the	  RRL	  motif,	  thus	  permitting	  the	  interaction	  of	  myosin	  VIshort	  with	  the	  “RRL-­‐interactors”.	  	   We	   endeavoured	   to	   validate	   the	   functional	   impact	   of	   the	   myosin	   VIlong	  conformation	   testing	   point	   mutation/s	   capable	   of	   disrupting	   interaction	   between	  α3/α4	  and	  the	  α2-­‐linker	  (Figure	  34a).	  M1062,	  which	  is	  sandwiched	  between	  α3	  and	  α4,	   was	   replaced	   with	   glutamine,	   and	   this	   variant,	   as	   well	   as	   the	   previously	  characterized	  L1118A	  mutant	  (Figure	  26	  and	  Figure	  30),	  were	  evaluated	  for	  binding	  to	   RRL-­‐specific	   interactors	   in	   pull-­‐down	   assays.	   As	   shown	   in	  Figure	   34b,	  M1062Q	  was	   impaired	   in	  clathrin	  binding,	   similarly	   to	  L1118A.	  GIPC	  and	  optineurin	  showed	  increased	  binding	   to	  M1062Q,	  but	  not	   to	  L1118A,	  consistent	  with	   the	  evidence	   that	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L1118	   belongs	   to	   their	   interaction	   surface.	   Finally,	   NDP52	   and	   T6BP	   bind	   to	   both	  mutants	  at	  levels	  similar	  to	  myosin	  VIshort.	  	  
	  
Figure	  34:	  Structural-­‐based	  mutagenesis	  of	  the	  α-­‐2	  linker	  of	  myosin	  VIlong.	  a)	  enlarged	  view	  of	  the	  ribbon	   representation	   of	   the	  myosin	   VI1050-­‐1131	   structure	   that	   illustrate	   the	   position	   of	   the	   residues	  important	  for	  the	  tertiary	  structure.	  The	  isoform	  specific	  α-­‐2	  linker	  is	  in	  orange,	  α-­‐3	  and	  α-­‐4	  helices	  in	  cyan.	  b)	   GST-­‐tagged	  myosin	  VI998-­‐1131	  wild	   type	   and	  mutants	   constructs	  were	  used	   against	   500μg	  of	  TCL	   from	   HEK293T	   transfected	   with	   GFP-­‐optineurin,	   His-­‐GIPC,	   Flag-­‐NDP52,	   and	   Flag-­‐T6BP.	   Bound	  proteins	  were	  then	  resolved	  in	  SDS-­‐PAGE	  and	  assessed	  for	  the	  presence	  of	  the	  different	  interactors	  by	  immunoblot	  using	  anti-­‐tag	  antibodies,	  except	  for	  CLTC.	  Comparable	  loading	  of	  GST-­‐tagged	  proteins	  is	  shown	  by	  Ponceau	  staining	  (bottom	  panel).	   	  	   These	   results	   confirmed	   the	   conformational	   differences	   between	   the	  myosin	  VI	  isoforms	  induced	  by	  the	  presence	  of	  the	  α2-­‐linker,	  and	  established	  the	  molecular	  mechanism	   underlying	   their	   mutually	   exclusive	   association	   with	   clathrin	   and	   RRL	  interactors.	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3.3	   The	   exon	   31	   of	   myosin	   VI,	   which	   encodes	   for	   the	   α2-­‐linker,	   is	  
frequently	  skipped	  in	  cancer	  
3.3.1	  Ovarian	  cancer	  predominantly	  express	  myosin	  VIshort	  Overexpression	   of	   myosin	   VI	   has	   emerged	   in	   ovarian	   and	   prostate	   cancer	   and	  confidently	  linked	  to	  metastatic	  aggressiveness	  and	  worsening	  of	  prognosis	  [Dunn	  et	  
al.,	   2006;	   Yoshida	   et	   al.,	   2004].	  While	   this	   information	   was	   available,	   there	   are	   no	  evidences	   regarding	   the	  myosin	  VI	   isoform	  expressed	   in	  malignant	   tumours.	   In	   the	  last	  few	  years,	  the	  contribution	  of	  deregulated	  splicing	  in	  human	  disease,	  particularly	  in	   cancer,	   has	   been	   widely	   recognized	   [Singh	   et	   al.,	   2012].	   To	   gain	   insight	   into	  possible	  differential	   expression	  of	  myosin	  VI	   isoforms	   in	   tumours,	  we	   concentrated	  our	  efforts	  on	  ovarian	  cancer,	  analyzing	  the	  isoform	  expression	  in	  high-­‐grade	  primary	  ovarian	   cancer	   cells	   cultured	   in	   vitro	   for	   two	   passages.	   We	   designed	   PCR-­‐primers	  positioned	   on	   exons	   28	   and	   33	   (flanking	   the	   LI	   region,	   Figure	   35a)	   in	   order	   to	  perform	  RT-­‐PCR	  starting	  from	  cDNA	  of	  tumour	  and	  control	  samples.	  In	  this	  way	  we	  could	   discriminate	   between	   the	   different	   isoforms,	   as	   demonstrated	   in	   the	   control	  lanes	   of	   Figure	   35b.	   Surprisingly,	   while	   normal	   ovarian	   samples	   (ovarian	   surface	  epithelium,	   OSE)	   express	   different	   myosin	   VI	   isoforms,	   all	   the	   tumours	   samples	  analysed	  (ten	  out	  of	  ten),	  showed	  almost	  exclusively	  expression	  of	  myosin	  VIshort.	  	  	   This	   result	   suggests	   a	   possible	   positive	   selection	   for	   this	   isoform	   in	   tumour	  progression	  and	  metastasis.	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Figure	   35:	   Myosin	   VIshort	   is	   prevalently	   expressed	   in	   ovarian	   cancer	   cells.	   a)	   Schematic	  representation	  of	  the	  region	  amplified	  by	  RT-­‐PCR.	  Grey	  boxes	  represent	  coding	  exons	  and	  alternative	  splicing	  events	  are	  depicted.	  Exon	  31	   that	   codifies	   for	   the	  α2-­‐linker	   is	   represented	   in	  orange.	  Oligos	  used	  for	  the	  PCR	  mapped	  in	  Exon	  28	  and	  Exon	  33	  and	  are	  indicated	  by	  arrows.	  b)	  RT-­‐PCR	  from	  cDNA	  prepared	  from	  the	  indicated	  primary	  cells.	  PCR	  controls	  are	  from	  plasmids	  carrying	  myosin	  VI	  of	  the	  different	  isoforms.	  Samples	  were	  loaded	  on	  a	  2%	  agarose	  gel	  and	  stained	  with	  ethidium	  bromide.	  Cells	  from	   normal	   tissue	   (OSE-­‐Ovarian	   Surface	   Epithelium),	   were	   used	   as	   control	   to	   compare	   cancer	   vs.	  normal	  myosin	  VI	  isoform	  expression.	  	  
3.3.2	   Cells	   that	   express	   only	  myosin	   VIshort	   are	   addicted	   to	  myosin	   VI	   for	   cell	  





Figure	   36:	   Most	   ovarian	   cell	   lines	   selectively	   express	   Myosin	   VIshort	   in	   cultured	   conditions.	  Myosin	  VI	   isoform	  expression	  was	  assessed	  by	  RT-­‐PCR	   from	  cDNA	  prepared	   from	   the	   indicated	   cell	  line.	  PCR	  controls	  are	  from	  plasmids	  carrying	  myosin	  VI	  of	  the	  different	  isoforms.	  Samples	  were	  loaded	  on	  a	  2%	  agarose	  gel	  and	  stained	  with	  ethidium	  bromide.	  	   Next,	   we	   wondered	   whether	   there	   could	   be	   differences	   among	   cells	   that	  express	  only	  the	  short	  isoform	  o	  myosin	  VI	  and	  cells	  that	  express	  also	  the	  longer	  ones.	  To	   this	  purpose	  we	  challenged	  the	  cell	   to	  express	  myosin	  VIlong	  by	  growing	  them	  in	  confluent	   condition	   for	   2	   to	   4	   days.	   It	  was	  previously	   reported	   that	   during	   in	   vitro	  epithelial	  cell	  polarization	  a	  myosin	  VI	  isoform	  switch	  occurs	  toward	  longer	  isoforms	  [Buss	  et	  al.,	  2001].	  Of	  the	  selected	  cell	  lines,	  SKOV-­‐3	  and	  HEY	  did	  not	  show	  any	  switch	  in	  the	  expression	  of	  myosin	  VI	  isoform,	  as	  visible	  in	  Figure	  37.	  On	  the	  other	  hand,	  we	  could	   score	   a	   different	   behaviour	   for	   OVCAR-­‐5	   cell	   line,	   which	   increased	   the	  expression	  of	  myosin	  VIlong	  upon	  confluency	  (Figure	  37).	  
	  
Figure	  37:	   Isoform	  switch	  of	  ovarian	  cell	   lines	  upon	  polarization.	  Myosin	  VI	  isoform	  expression	  was	  assessed	  by	  RT-­‐PCR	  from	  cDNA	  prepared	  from	  the	  indicated	  cell	  line	  grown	  in	  normal	  (no	  mark)	  and	  confluent	   condition	   (marked	  with	  C).	  PCR	  controls	  are	   from	  plasmids	  carrying	  myosin	  VI	  of	   the	  different	  isoforms.	  Samples	  were	  loaded	  on	  a	  2%	  agarose	  gel	  and	  stained	  with	  ethidium	  bromide.	  	   It	   was	   previously	   reported	   that	   knocking-­‐down	   myosin	   VI	   substantially	  inhibits	   migration	   in	   vitro	   and	   reduces	   dissemination	   of	   ovarian	   tumour	   cells	  propagated	  in	  nude	  mice	  [Yoshida	  et	  al.,	  2004].	  Wound-­‐healing	  assay	   in	  vitro	  can	  be	  considered	  as	  a	  proxy	  for	  cancer	  metastasis.	  Thus,	  we	  analysed	  the	  effect	  of	  myosin	  VI	  depletion	   in	  a	  wound-­‐healing	  assay,	  comparing	   the	  behaviour	  of	   the	  ovarian	  cancer	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Figure	   38:	   Ovarian	   cell	   lines	   that	   express	   only	  myosin	   VIshort	   need	  myosin	   VI	   for	   proper	   cell	  
migration.	  Same	  for	  a)	  -­‐	  e):	  Wound-­‐healing	  assay.	  The	  indicated	  cell	  lines	  were	  transiently	  transfected	  with	  different	  siRNA	  targeting	  myosin	  VI	  to	  achieve	  knockdown	  of	  the	  protein	  (marked	  as	  KD)	  or	  mock	  treated	   (marked	  as	  Mock).	  Left	  panel,	   sample	   images:	  T0	   first	   frame,	  T1	  and	  T2	  arbitrary	   time-­‐points	  identical	   for	  Mock	   and	  KD	  of	   the	   same	   cell	   lines.	   Central	   panel:	   quantification	   of	   the	  wound	   closure	  speed	  relative	  to	  control	  that	  represents	  the	  average	  of	  6	  different	  measures	  from	  three	  independent	  experiments	   +/-­‐	   SD.	   Right	   panel:	   anti-­‐myosin	   VI	   IB	   and	   anti-­‐Vinculin	   IB	   performed	   at	   T0	   to	   allow	  quantification	  of	  the	  efficiency	  of	  the	  knockdown.	  
	  
3.3.3	  Exon	  31	  skipping	  is	  a	  common	  event	  in	  many	  cancer	  types	  Previous	  results	  prompted	  us	  to	  extend	  our	  analyses	  of	  myosin	  VI	  isoform	  expression	  to	  other	  cancer	  types	  using	  an	  in	  silico	  approach,	  in	  collaboration	  with	  Uberto	  Pozzoli	  (IRCCS E.MEDEA, Italy). As	   a	   source	   of	   data,	   we	   used	   The	   Cancer	   Genome	   Atlas	  (TCGA)	   database	   and	   included	   all	   of	   the	   experiments	   performed	   using	   RNAseq	  technology.	  The	  resulting	  dataset	  consisted	  of	  293	  control	  and	  1646	  tumour	  samples,	  belonging	  to	  14	  different	  tumour	  types.	  	  	   Exon	  31	  encodes	  for	  the	  α2-­‐linker	  that	  we	  proved	  being	  the	  necessary	  for	  the	  isoform-­‐specific	   conformation.	   For	   this	   reason,	   as	   discriminating	  marker	   of	  myosin	  VIlong	   isoforms	   the	   relative	   expression	   of	   exon	   31	   was	   evaluated.	   The	   relative	  abundance	   of	   exon	   31	   (E31RA)	   was	   obtained	   as	   the	   ratio	   of	   its	   RPKM	   (Reads	   Per	  Kilobase	   of	   Exon	  Model	   per	  Million	  Mapped	   Reads,	   see	  Materials	   and	  Methods	   for	  details)	  and	  the	  average	  RPKM	  values	  of	  the	  four	  flanking	  constitutive	  exons	  (namely	  E27,	  E28,	  E32	  and	  E33).	  The	  box	  plot	  relative	   to	   the	  analysis	   (Figure	   39)	   indicates	  that	   exon	   31	   skipping	   is	   a	   common	   event	   occurring	   with	   significantly	   increased	  frequency	  in	  tumour	  compared	  to	  normal	  samples.	  Thus,	  myosin	  VIshort	  is	  selectively	  expressed	   in	  many	   tumour	   types.	   The	   analysis	   conducted	   at	   the	   single	   cancer	   type	  level	   showed	   that	   exon	   skipping	   is	  highly	   frequent	   among	   certain	   tumours,	  but	  not	  others,	   and	   suggested	   that	   myosin	   VIshort	   functions	   may	   be	   critical	   and	   positively	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selected	  only	   in	   specific	   types	  of	   cancers.	  Of	  note,	   in	   the	   case	  of	   ovarian	   cancer,	   no	  “normal”	   controls	   were	   present	   in	   the	   database,	   but	   compared	   to	   the	   average	   of	  normal	   samples,	   exon	  E31RA	   is	  barely	  measurable	   (Figure	   40),	   further	   confirming	  the	  data	  obtained	  in	  primary	  tumours.	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Figure	  39:	  Exon	  E31	  relative	  abundance	  in	  different	  cancer	  types.	  Exon	  E31	  relative	  abundance	  at	  the	  single	  tumour	  level	  compared	  with	  their	  normal	  counterparts.	  E31RA	  has	  been	  calculated	  for	  each	  sample	  dividing	  E31	  RPKMS	  by	  the	  average	  of	  the	  flanking	  constitutive	  exons	  (i.e.	  E27,	  E28,	  E32,	  E33).	  All	   values	   have	   been	   normalized	   by	   their	   median	   in	   the	   tumour	  matched	   control	   samples.	   Bladder	  urothelial	   carcinoma	  (BLCA),	  breast	   invasive	  carcinoma	  (BRCA),	  esophageal	   carcinoma	  (ESCA),	  head	  and	   neck	   squamous	   cell	   carcinoma	   (HNSC),	   kidney	   renal	   clear	   cell	   carcinoma	   (KIRC),	   liver	  hepatocellular	  carcinoma	  (LIHC),	  lung	  adenocarcinoma	  (LUAD),	  lung	  squamous	  cell	  carcinoma	  (LUSC),	  stomach	  adenocarcinoma	  (STAD),	  and	  uterine	  corpus	  endometrial	  carcinoma	  (UCEC).	  	  
	  
	  
Figure	   40:	   Exon	   31	   expression	   is	   barely	   detectable	   in	   ovarian	   cancer.	   Exon	   E31	   relative	  abundance	   in	   ovarian	   cancer	   compared	   to	   the	   average	   of	   normal	   samples	   from	   all	   available	   cancer	  types.	  P-­‐value	  is	  reported.	  	  	   	  
As	  proof	  of	  principle,	  we	  selected	  two	  breast	  cell	  lines,	  MCF10A	  (normal	  cells)	  and	  MDA-­‐MB-­‐231.	   This	   latter	   cancer	   cell	   line	   showed	   high	   levels	   of	  myosin	   VIshort-­‐only,	   in	   both	   sparse	   and	   confluent	   conditions,	   while	   MCF10A	   could	   switch	   the	  expression	  to	  all	   the	   three	   isoforms	  (Figure	   41a).	  Upon	  myosin	  VI	  depletion,	  MDA-­‐MB-­‐231	   cells	   displayed	   a	   clear	   impairment	   in	   wound	   closure	   (Figure	   41b)	   while	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MCF10A	   cells	   were	   unaffected	   (Figure	   41c).	   Thus,	   also	   breast	   cancer	   cells	   that	  selectively	  express	  myosin	  VIshort-­‐only	  are	  addicted	  to	  myosin	  VI	  for	  cell	  migration.	  	  
	  






Phosphorylation,	   dimerization,	   and	   alternative	   splicing	   have	   been	   suggested	   to	   be	  crucial	  for	  myosin	  VI	  activity	  [Buss	  et	  al.,	  2008].	  In	  this	  thesis,	  we	  focused	  on	  myosin	  VI	   isoforms	   and	   in	   particular	   on	   the	   large	   insert,	   codified	   by	   exons	   29,30,31.	   In	  literature	  it	  is	  known	  that	  the	  alternatively	  spliced	  isoforms	  of	  myosin	  VI	  are	  targeted	  to	  different	  intracellular	  locations	  through	  a	  yet	  undefined	  mechanism	  [Tumbarello	  et	  
al.,	   2013].	   Here,	   by	   studying	   the	   interactomes	   and	   the	   conformational	   structure	   of	  myosin	   VI	   isoforms,	   we	   provide	  mechanistic	   insights	   into	   how	  myosin	   VI	   function	  becomes	   pathological	   in	   human	   cancers,	   and	   demonstrate	   the	   importance	   of	   an	  isoform-­‐specific	  helix	  in	  assigning	  myosin	  VI	  to	  distinct	  functional	  roles.	  	  
4.1	   Myosin	   VI	   isoforms	   (long	   and	   short)	   have	   different	   interactomes,	  
among	  which	  clathrin	  is	  selective	  for	  the	  long	  The	  subcellular	   localization	  of	  any	  given	  protein	  correlates	  with	   its	   function.	   In	   this	  framework,	  myosin	  VI	  has	  been	  seen	  at	  the	  apical	  membrane	  of	  highly	  polarized	  cells	  exerting	  a	  role	  in	  endocytosis	  [Ameen	  et	  al.,	  2007],	  shaping	  the	  microvilli	  [Buss	  et	  al.,	  2001],	   colocalizing	   with	   intracellular	   coated	   and	   uncoated	   vesicles	   [Dance	   et	   al.,	  2004],	   or	   at	   the	   leading	   edge	   of	   migrating	   cells	   [Chibalina	   et	   al.,	   2010].	   Although	  myosin	   VI	   is	   widely	   expressed	   in	   most	   tissues,	   isoforms	   containing	   the	   LI	   are	  specifically	  found	  in	  polarized	  epithelial	  cells.	  Up	  to	  now,	  isoforms	  lacking	  the	  LI	  were	  shown	  to	   localize	   in	  Rab5/APPL1-­‐positive	  endosomes	  [Tumbarello	  et	  al.,	  2012],	  are	  required	   for	  polarized	   transport	  of	   tyrosine	  motif	  containing	  basolateral	  membrane	  proteins	  [Au	  et	  al.,	  2007],	  and	  for	  the	  maintaining	  an	  active	  pool	  of	  secretory	  granules	  near	   the	   plasma	  membrane	   of	   neurosecretory	   cells	   [Tomatis	   et	  al.,	   2013].	  How	   the	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presence	  of	  LI	  in	  the	  tail	  influences	  the	  functions	  and	  intracellular	  targeting	  of	  myosin	  VI	  is	  not	  known.	  	  In	  our	  studies	  we	  specifically	  investigated	  how	  alternative	  splicing	  of	  the	  large	  insert	  of	  myosin	  VI	  regulates	  the	  structural	  and	  functional	  properties	  of	  the	  molecule.	  Many	  of	   the	  binding	  partners	  of	  myosin	  VI	  were	   found	   in	  yeast-­‐two	  hybrid	  screens	  where	  chicken	  myosin	  VI	  tail+LI	  was	  the	  bait	  [Morris	  et	  al.,	  2002;	  Morriswood	  et	  al.,	  2007;	  Sahlender	  et	  al.,	  2005].	  To	  identify	  specific	  interactors	  of	  the	  various	  isoforms,	  we	  undertook	   a	   different	   approach	   coupling	  GST-­‐pulldown	  of	   a	  HEK293T	   total	   cell	  lysate	  to	  a	  quantitative	  mass-­‐spectrometry	  analysis.	  The	  results	  presented	  in	  Table	  1	  demonstrate	  that	  the	  presence	  or	  the	  absence	  of	  the	  large	  insert	  dictates	  specific	  myosin	  VI	   interactors.	  Lack	  of	  the	  LI	  (see	  Figure	  
13b),	  generates	  the	  isoform	  2	  that	  we	  named	  myosin	  VIshort,	  that	  appears	  to	  bind	  a	  set	  of	  previously	  undescribed	  interactors.	  Isoform	  1	  and	  3	  that	  differs	  for	  the	  presence	  or	  the	  absence	  of	  exon	  29,	  show	  basically	  no	  difference	  in	  terms	  of	  interactors.	  This	  led	  us	  to	  name	  them	  collectively	  as	  myosin	  VIlong.	  	  Interestingly,	   myosin	   VIshort	   interact	   with	   many	   nuclear-­‐resident	   proteins	  related	  to	  the	  DNA	  damage	  response	  pathway.	  In	  our	  immunofluorescence	  studies	  we	  failed	   to	   see	   a	   nuclear	   localization	   of	   myosin	   VIshort,	   but	   additional	   studies	   are	  required	   to	   evaluate	   possible	   re-­‐localization	   of	   the	   protein	   upon	   DNA	   damage.	  Nonetheless,	  our	  data	  corroborate	  previous	  reports	  on	  the	  role	  of	  myosin	  VI	  in	  RNA	  polymerase-­‐II	   dependent	   transcription	   and	   p53-­‐mediated	   DNA	   damage	   response	  [Cho	   et	   al.,	   2010;	   Jung	   et	   al.,	   2006;	   Vreugde	   et	   al.,	   2006].	   On	   the	   other	   hand,	   the	  identification	   of	  myosin	   VIlong	   interactors	   such	   as	   clathrin	   heavy	   chain	   and	   clathrin	  adaptors	   (APs)	   are	   in	   accordance	   with	   the	   role	   of	   myosin	   VI	   in	   clathrin-­‐mediated	  endocytosis	  [Ameen	  et	  al.,	  2007;	  Buss	  et	  al.,	  2001;	  Kravtsov	  et	  al.,	  2012].	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Previous	  studies	  have	  considered	  Dab-­‐2	  as	  the	  adaptor	  that	  links	  myosin	  VI	  to	  clathrin-­‐mediated	   function	   [Inoue	   et	   al.,	   2002;	   Morris	   et	   al.,	   2002;	   Spudich	   et	   al.,	  2007].	  The	  Dab-­‐2:myosin	  VI	   	   interaction,	  however,	  fails	  to	  explain	  the	  myosin	  VIlong-­‐specific	   interaction	  with	  clathrin,	  as	   the	  Dab-­‐2	  binding	  region	   is	  remote	   from	  the	  LI	  [Morris	   et	   al.,	   2002;	   Yu	   et	   al.,	   2009].	   Our	   pulldown	   assays	   (Figure	   15)	   suggested	  either	  a	  direct	  binding	  with	  clathrin	  heavy	  chain	  or	  an	  indirect	  binding	  mediated	  by	  an	  alternative	  adaptor.	  Clathrin	   heavy	   chain	   truncation	   constructs	   have	   been	   exploited	   for	   both	  biochemical	   and	   cell-­‐biological	   studies.	   The	   molecule’s	   tertiary	   structure	   allow	   to	  divide	  it	  into	  a	  terminal,	  leg,	  and	  trimerization	  domains	  that	  can	  exert	  their	  functions	  even	   when	   isolated	   from	   the	   rest	   of	   the	   molecule.	   We	   used	   GST-­‐	   and	   GFP-­‐tagged	  clathrin	  heavy	  chain	  truncations,	  kindly	  given	  from	  SJ	  Royle	  (Division	  of	  Biomedical	  Cell	  Biology,	  Warwick	  Medical	  School,	  Gibbet	  Hill	  Road,	  Coventry),	   to	  determine	  the	  possible	  site	  of	  interaction	  of	  myosin	  VI	  on	  the	  CLTC	  molecule.	  As	  only	  the	  full-­‐length	  was	   able	   to	   bind	   to	   myosin	   VIlong	   (Figure	   16),	   we	   concluded	   that	   the	   critical	  determinant	  for	  the	  interaction	  with	  myosin	  VI	  is	  at	  the	  C-­‐terminus	  of	  clathrin	  heavy	  chain.	   Intriguingly,	   even	   though	   expressed	   at	   the	   same	   level	   of	   the	   endogenous,	  transfected	  GFP-­‐CLTC	  full-­‐length	  did	  not	  show	  the	  same	  stoichiometry	  of	  interaction	  of	   endogenous	   CLTC	   to	  myosin	   VIlong,	   arguing	   against	   the	   complete	   functionality	   of	  the	   overexpressed	   protein	   (Figure	   16).	   When	   we	   tested	   the	   direct	   binding	   with	  bacterially	   purified	   proteins,	   none	   of	   the	   GST-­‐CLTC	   fusion	   proteins	   was	   able	   to	  interact	  with	  a	  myosin	  VI998-­‐1131	  (Figure	  17b).	  As	  the	  isolated	  clathrin	  hubs	  that	  we	  used	  in	  experiment	  are	  reported	  to	  self-­‐assemble	  into	  trimeric	  units	  [Liu	  et	  al.,	  1995]	  we	  can	  exclude	  a	  requirement	  of	  triskelion	  for	  myosin	  VI	  interaction.	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4.2	  Myosin	  VIlong	  binds	  directly	  to	  clathrin	  light	  chain	  A	  The	   evidences	   described	   above	   prompted	   us	   to	   hypothesize	   a	   direct	   binding	   of	  myosin	  VI998-­‐1131	  with	   the	  only	  known	  protein	   capable	  of	  binding	   the	  C-­‐terminus	  of	  CLTC,	  namely	  clathrin	  light	  chains.	  The	  direct	  binding	  of	  purified	  LC	  and	  myosin	  VI998-­‐
1131	  protein	  (Figure	  18)	  definitely	  confirmed	  our	  idea.	  Thus,	  we	  can	  add	  a	  new	  player	  in	  the	  myosin	  VI	  activity	  towards	  clathrin-­‐mediated	  endocytosis.	  The	  elevated	  affinity	  of	  clathrin	   light	  chains	   towards	  their	  heavy	  counterpart	  (KD≈10-­‐11	  M	  [Winkler	  et	  al.,	  1983])	  can	  account	  for	  high	  amount	  of	  CLTC	  we	  scored	  in	  our	  initial	  pulldown	  using	  GST-­‐myosin	  VI998-­‐1131	  against	  cell	  lysates.	  We	  did	  not	  score	  LC	  in	  the	  mass	  spec	  data	  as	  proteins	  with	   a	  molecular	  mass	   lower	   than	  50	  kDa	  were	   automatically	   excluded	  from	  the	  analysis	  (we	  cut	  slices	  higher	  than	  immunoglobulins	  heavy	  chain).	  	  Although	  clathrin	  light	  chain	  and	  myosin	  VI	  have	  never	  been	  directly	  linked	  to	  each	   other	   in	   clathrin-­‐mediated	   endocytosis,	   they	  were	   both	  demonstrated	   to	   have	  critical	   role	   in	   this	   process.	   CME	   of	   the	  most	   studied	   cargoes,	   such	   as	   transferrin-­‐receptor	   (TfnR)	   or	   epidermal	   growth-­‐factor	   receptor	   (EGFR)	   is	   not	   influenced	   by	  depletion	   clathrin	   light	   chain	   [Huang	   et	   al.,	   2004],	   nor	   by	   depletion	   of	   myosin	   VI	  (previous	  unpublished	  results	  of	  our	  lab).	  Nevertheless,	  recent	  evidences	  have	  shown	  that	  LCs	  are	  involved	  in	  the	  trafficking	  of	  mannose-­‐6-­‐phosphate	  receptor	  [Poupon	  et	  
al.,	  2008]	  and	  G-­‐protein-­‐coupled	  receptor	  [Ferreira	  et	  al.,	  2012].	  The	  finding	  of	  a	  Hip1	  and	  Hip1R	  binding	  site	  on	  LCs	  [Chen	  et	  al.,	  2005]	  laid	  the	  foundations	  for	  a	  novel	  link	  between	  clathrin-­‐mediated	  endocytosis	  and	  the	  actin	  cytoskeleton.	  Altogether	   these	  evidences	  drive	  to	  hypothesize	  a	  broader	  list	  of	  functions	  of	  LCs,	  yet	  to	  be	  studied.	  In	  the	  very	  same	  way,	  a	  critical	   role	  of	  myosin	  VI	   in	  CME	  has	  been	  suggested,	  but	   few	  direct	  evidences	  have	  been	  reported.	  Alterations	  of	  myosin	  VI	  activity	  were	  shown	  to	  inhibit	   CFTR	   internalization	   in	   several	   cellular	   systems	   [Swiatecka-­‐Urban	   et	   al.,	  2004];	   [Ameen	   et	   al.,	   2007];	   [Collaco	   et	   al.,	   2010].	   Interestingly,	   CFTR	   endocytosis	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occurs	   via	   	   CME	   [Bradbury	   et	   al.,	   1999].	   The	   regulation	   of	   surface	   sodium	   type-­‐IIa	  cotransporter	   (NaPi2a)	  at	   the	  apical	  membrane	  of	   renal	  proximal	   tubular	   cells	   also	  appears	   to	   depend	   on	   myosin	   VI	   and	   clathrin-­‐mediated	   endocytosis	   [Blaine	   et	   al.,	  2009];	  [Chen	  et	  al.,	  2014].	  In	  such	  kind	  of	  highly	  polarized	  cells,	  endogenous	  myosin	  VIlong	  is	  enriched	  at	  the	  apical	  membrane,	  together	  with	  clathrin-­‐rich	  structures	  [Buss	  
et	  al.,	  2001].	  Notably,	  clathrin	  light	  chains	  and	  their	  binding	  partner	  Hip1/Hip1R	  are	  also	   needed	   at	   the	   apical	  membrane	   of	   polarized	   cells	   to	   achieve	   efficient	   clathrin-­‐coated	   vesicle	   fission	   [Boulant	   et	   al.,	   2011].	   It	   is	   therefore	   tempting	   to	   speculate	   a	  coordinate	   function	   of	   myosin	   VI	   and	   LCs	   in	   such	   location,	   where	   tensile	   strength	  might	  rigidify	  the	  membrane,	  making	  it	  less	  prone	  to	  invagination.	  	  Our	   study	   also	   offers	   a	   new	   perspective	   on	   the	   molecular	   mechanism	   that	  regulates	   the	   monomer-­‐dimer	   conversion	   of	   this	   anchor-­‐motor	   protein	   [Lu	   et	   al.,	  2014b;	  Sweeney	  et	  al.,	  2010].	  It	  is	  tempting	  to	  speculate	  that	  the	  existence	  of	  distinct	  interaction	   surfaces	   for	   clathrin	   and	   Dab-­‐2,	   both	   required	   for	   co-­‐localization	   with	  clathrin-­‐coated	   pits	   (Figure	   28)	   may	   provide	   critical	   synergy	   that	   regulates	   the	  myosin	  VI	  motor	  ability.	  Clathrin	  binding	  may	  recruit	  and	  concentrate	  myosin	  VI	  at	  clathrin-­‐coated	  pits	  where	  Dab2	  could	  tether	  it	  into	  a	  stable	  and	  active	  dimer,	  crucial	  to	  convert	  myosin	  VI	  in	  a	  processive	  cellular	  transporter	  [Yu	  et	  al.,	  2009].	  Our	   hypothesis	   might	   introduce	   a	   new	   layer	   of	   complexity	   in	   the	   endocytic	  processes,	   required	   in	   specific	   situation	   where	   the	   plasma	   membrane	   is	   under	  tension	  or	  in	  the	  case	  of	  endocytosis	  of	  larger	  cargoes	  such	  as	  Listeria	  monocytogenes	  [Bonazzi	  et	  al.,	   2011],	  which	   resemble	  adherens	   junctions	   rearrangements	   [Bonazzi	  
et	  al.,	  2012],	  a	  process	  where	  myosin	  VI	  was	  demonstrated	  to	  play	  a	  role	  [Maddugoda	  
et	  al.,	  2007].	  Committed	   to	   the	   idea	   that	   a	   complete	   mechanistic	   and	   structural	  understanding	   of	   the	   myosin	   VI:clathrin	   light	   chain	   interaction	   is	   of	   paramount	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importance	   for	   further	   studies,	   we	   exploited	   several	   GST-­‐pulldown,	   using	   purified	  proteins.	   A	   first	   identification	   of	   the	   specific	   interaction	   of	   myosin	   VIlong	   with	   LCa,	  compared	  to	  the	  unbound	  LCb	  (Figure	  20),	  led	  us	  to	  investigate	  the	  binding	  surface	  using	   truncated	  LCa	   fusion	  proteins.	  This	  analysis	  allowed	  us	   to	   identify	  LCa47-­‐97	   as	  the	  minimal	   region	   (Figure	   21).	   LCs	   show	   a	   tendency	   to	   be	   unstructured	  while	   in	  solution	   but	   can	   fold	   upon	   the	   establishment	   of	   partner	   interaction	   [Wilbur	   et	   al.,	  2010].	   Size	   exclusion	   chromatography	   analysis	   proved	   that	   the	   two	   proteins	   could	  form	  a	  stable	  complex	   in	  solution,	  even	  at	   low	  concentration	  (10	  μM	  each,	  data	  not	  shown).	  Unfortunately,	  we	  were	  not	  able	  to	  obtain	  crystals.	  Further	  trimming	  of	  the	  molecule	   led	  us	   to	   conclude	   that	   the	  LCa51-­‐60	   is	   the	  minimal	   surface	  needed	   for	   the	  interaction	   (Figure	   23	   and	  Figure	   24).	   A	   LCa	   protein	   deleted	   of	   this	   latter	   region	  (GST-­‐LCaΔ51-­‐60),	   resulted	   to	   be	   impaired	   in	   myosin	   VIlong	   binding	   (Figure	   24),	  univocally	  proving	  that	  LCa51-­‐60	   fragment	   is	  both	  necessary	  and	  sufficient	  to	  contact	  the	  motor	  protein.	  We	  calculated	  the	  isoelectric	  points	  of	  the	  two	  proteins:	  LCa51-­‐60	  	  pI	  ≈	   4;	   myosin	   VI998-­‐1131	   pI	   ≈	   8.	   Thus,	   we	   hypothesize	   an	   interaction	   mediate	   by	  electrostatic	  interaction	  and	  we	  intend	  to	  perform	  mutant	  analysis	  to	  prove/disprove	  this	  hypothesis.	  	  
4.3	  Due	   to	   the	  disparate	  conformations	  adopted	  by	  myosin	  VI	   isoforms,	  
clathrin	  and	  “RRL”	  interactors	  are	  mutually	  exclusive	  partners.	  Using	  point	  mutants	  of	  myosin	  VI	  we	  investigated	  the	  effect	  of	  the	  1116RRL1118	  motif	  in	  regulating	   the	   interaction	  with	   clathrin,	   since	   this	   has	   been	   prove	   to	   be	   one	   of	   the	  major	  hub	  for	  myosin	  VI	  interactors	  [Tumbarello	  et	  al.,	  2013].	  The	  triple	  1116AAA1118	  mutant,	   as	  well	   as	   the	  R1117A	  and	   the	  L1118A	  single	  mutants,	   showed	  a	   complete	  impairment	  of	  the	  binding	  to	  the	  coat	  protein	  (Figure	  26).	  R1117A	  mutation	  disrupts	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the	   salt	   bridge	   that	   this	   amino	   acid	   establishes	  with	   the	   S1087	   side	   chain	   (Figure	  
32b).	  Circular	  dichroism	  analysis	  confirmed	  unfolding	  of	  the	  myosin	  VI998-­‐1131	  bearing	  the	   R1117A	   mutation	   (Figure	   27).	   Thus,	   the	   previously	   characterized	   1116AAA1118	  triple	  mutant	  has	  to	  be	  unfolded	  as	  well	  and	  the	  mapping	  of	  the	  binding	  site	  for	  T6BP	  and	   NDP52	   [Morriswood	   et	   al.,	   2007]	   is	   questionable.	   Indeed,	   binding	   of	   both	  proteins	  to	  myosin	  VI	  were	  unaffected	  by	  R1116A	  or	  L1118A	  mutation	  (Figure	  30)	  We	   selected	   the	   L1118A	   mutant	   to	   further	   study	   the	   myosin	   VI:clathrin	  interaction.	   This	   mutation	   negatively	   affect	   myosin	   VI	   binding	   to	   clathrin	   in	   co-­‐immunoprecipitation	   and	   co-­‐localization	   experiments,	   as	   shown	   in	   Figure	   28	   and	  
Figure	   29.	   In	   these	   experiments,	  myosin	   VIshort	   and	  myosin	   VIlong	  W1192L	  mutant	  were	   used	   to	   check	   isoform	   specificity	   of	   the	   clathrin	   binding	   as	   well	   as	   Dab2	  interaction.	   While	   myosin	   VIshort	   failed	   to	   localize	   and	   coimmunoprecipitate	   with	  clathrin,	  it	  still	  retained	  the	  ability	  to	  bind	  Dab2	  (Figure	  28	  and	  Figure	  29).	  W1192L	  mutant	   did	   not	   colocalize	   with	   clathrin	   but	   could	   still	   bind	   the	   coat	   protein	   by	  coimmunoprecipitation.	   We	   ascribed	   these	   behaviors	   to	   a	   transient	   nature	   of	   the	  interactions	   between	   these	   three	   proteins	   at	   the	   level	   of	   clathrin	   coated	   pits	   and	  vesicles	   and	   to	   a	   redundant	   actions	   of	   Dab2	   and	   clathrin	   light	   chain	   in	   recruiting	  myosin	  VI	  at	  the	  CME	  sites.	  To	   better	   investigate	   this	   possibility	   dynamics	   studies	   are	   needed.	   Recent	  advantages	  in	  high-­‐resolution	  time-­‐lapse	  imaging	  techniques	  [Kural	  et	  al.,	  2015;	  Li	  et	  
al.,	   2015]	  may	  allow	   to	   resolve	   in	   time	  and	  space	   the	  appearance	  of	  Dab2,	   clathrin,	  and	  myosin	   VI	   at	   the	   site	   of	   endocytosis.	   Possibly,	   this	   approach	  will	   be	   combined	  with	   gene	   substitution	   techniques	   (CRISPR/Cas9	   knock-­‐in),	   in	   order	   to	   avoid	  overexpression	  of	  fluorescent	  proteins,	  which	  have	  already	  been	  shown	  to	  influence	  their	  behavior	  [Dance	  et	  al.,	  2004].	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By	  NMR	  we	  structurally	  characterized	  the	  novel	  myosin	  VIlong-­‐specific	  clathrin-­‐binding	  domain	  that	  we	  identified.	  From	  the	  structure	  we	  learned	  that	  the	  α2-­‐linker	  marks	  the	  specific	  conformation	  of	  myosin	  VIlong.	  and	  prevents	  interaction	  with	  other	  functional	   adaptors	   that	   utilize	   the	   previously	   identified	   ‘RRL’	   motif.	   This	   motif,	  embedded	   in	   the	  clathrin-­‐binding	  domain,	   is	  masked	   in	   the	  structural	  configuration	  adopted	   by	   the	   myosin	   VIlong.	   Consequently,	   the	   previously	   identified	   interactors	  (optineurin,	  GIPC,	  NDP52,	  and	  T6BP)	  show	  selective	  binding	  to	  myosin	  VIshort	  (Figure	  
31).	  Thus,	  the	  different	  isoform	  structural	  architectures	  establish	  mutual	  exclusivity	  of	  myosin	  VI	  binding	  partners,	  clathrin	  versus	  RRL	  interactors,	  and	  in	  turn,	  function.	  The	   tertiary	   structure	   is	   maintained	   through	   a	   series	   of	   hydrophobic	   interaction	  (highlighted	   in	   Figure	   34a)	   that	   we	   abolished	   introducing	   mutation	   of	   L1118	   to	  alanine	  and	  M1062	  to	  glutamine.	  With	   these	  mutations	  we	  obtained	  a	  myosin	  VIlong	  protein	   that	   behaves	   like	   myosin	   VIshort	   in	   terms	   of	   interactors	   selectivity	   (Figure	  
34b).	  	  Taken	  together	  our	  data	  showed	  a	  clear	  preference	  of	  RRL	  interactors	  towards	  myosin	  VIshort.	  Structural	  data	  provide	  a	  detailed	  rationale	  for	  optineurin	  and	  GIPC	  as	  R1116	   and	   L1118,	   which	   belong	   to	   their	   interaction	   surface,	   are	   masked	   in	   the	  myosin	   VIlong	   conformation.	  A	   similar	   explanation	   could	   also	   apply	   for	   NDP52	   and	  T6BP,	  although	  their	  precise	  interaction	  surface	  remains	  to	  be	  established.	  	  Whatever	  the	   case,	   our	   data	   suggest	   that	  myosin	   VIshort	   is	   the	  myosin	   VI	   isoform	   specifically	  involved	  in	  the	  functional	  interaction	  with	  these	  adaptor	  proteins	  while	  myosin	  VIlong	  is	   specifically	   involved	   in	   CME.	   These	   findings	   opens	   interesting	   scenario	   in	  which	  myosin	  VI	  isoforms	  exerts	  their	  specific	  cellular	  functions	  through	  their	  cargo	  adaptor	  proteins	  [Tumbarello	  et	  al.,	  2013].	  Whether	  myosin	  VIshort	   is	   the	   isoform	  specifically	  involved	   in	   autophagy	   and	   Golgi	   morphology	   and	   secretion	   requires	   further	  investigations.	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4.4	  Myosin	  VIshort	  is	  critically	  involved	  in	  cancer	  cells	  migration	  Several	   studies	   reported	   overexpression	   of	   myosin	   VI	   in	   prostate	   and	   ovarian	  cancers,	  which	  positively	  correlates	  with	  their	  grade	  and	  metastatic	  potential	  [Dunn	  
et	  al.,	   2006;	  Yoshida	  et	  al.,	   2004].	  Though,	  no	   information	  was	  available	   concerning	  the	  specificity	  of	  isoform	  expression.	  We	  examined	  expression	  of	  myosin	  VI	  isoforms	  in	  primary	  tumours	  from	  ovarian	  cancer	  patients	  to	  find	  that	  myosin	  VIshort	  was	  the	  only	  isoform	  upregulated	  (Figure	  35).	  	  With	  an	  unbiased	  approach,	  we	  evaluated	  the	  relative	  abundance	  of	  the	  myosin	  VI	  exons.	  This	  analysis	  revealed	  that	  selective	  skipping	  of	  the	  exon	  31,	  encoding	  the	  long	  isoform-­‐specific	  helix,	  frequently	  occurs	  in	  specific	  tumours	  but	  not	  in	  others	  or	  in	  normal	  samples	  (Figure	  39).	   Importantly,	  cancer	  cell	   lines	  selectively	  expressing	  the	  myosin	  VIshort	  isoform	  exhibit	  severe	  migration	  defects	  when	  myosin	  VI	  is	  knocked	  down	  (Figure	  38	  and	  Figure	  41).	  	  In	   essence,	  we	   found	   that	   the	   isoform	   switch,	   a	   physiological	   event	   occurring	  during	  epithelial	  polarization	  [Buss	  et	  al.,	  2001;	  Dance	  et	  al.,	  2004],	  is	  deregulated	  in	  a	  large	   proportion	   of	   cancers.	   Exon	   skipping	   determines	   the	   expression	   of	   myosin	  VIshort	  only	  in	  these	  cancer	  cells	  that	  become	  addicted	  to	  myosin	  VIshort	  for	  tumour	  cell	  migration.	  	  Myosin	  VI	   has	   been	  previously	   implicated	   in	   cell	  migration	   in	  Drosophila	   and	  mammals	   (reviewed	   in	   [Chibalina	   et	  al.,	   2009]).	  However,	   published	   data	   led	   to	   an	  intriguing	   conundrum.	   On	   the	   one	   hand,	   myosin	   VI	   depletion	   from	   epithelial	   cells	  leads	   to	   loss	   of	   vinculin	   from	   adhesion	   sites,	   and	   weakens	   E-­‐cadherin	   complexes	  [Maddugoda	   et	   al.,	   2007].	   Such	   rearrangement	   results	   in	   loss	   of	   cohesive	   forces	   in	  epithelial	  layers,	  a	  well-­‐known	  prerequisite	  for	  invasive	  cancer	  cell	  migration.	  On	  the	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other	   hand,	   myosin	   VI	   is	   significantly	   upregulated	   in	   prostate	   and	   ovarian	   cancer	  cells,	  where	  its	  overexpression	  correlates	  with	  clinically	  aggressive	  behaviour	  [Dunn	  
et	  al.,	  2006;	  Yoshida	  et	  al.,	  2004].	  In	  this	  context,	  silencing	  of	  myosin	  VI	  expression	  in	  ovarian	  and	  prostate	  cancer	  cell	  lines	  decreases	  the	  migratory	  potential	  of	  these	  cells	  
in	  vitro,	   and	  ovarian	   tumour	  dissemination	   in	  vivo	   [Dunn	  et	  al.,	  2006;	  Yoshida	  et	  al.,	  2004].	  	  Our	  results	  provide	  a	  molecular	  explanation	   for	   this	  conundrum,	  ascribing	  the	  cohesive	   and	  migratory	   defects	   to	   the	   two	   different	  myosin	   VI	   isoforms.	  We	   found	  that	  myosin	  VIshort	  is	   overexpressed	   in	   ovarian	   and	  other	   invasive	   cancers,	  whereas	  myosin	  VIlong	  is	  expressed	  in	  polarized	  epithelial	  cells,	  in	  which	  it	  likely	  promotes	  E-­‐cadherin	   stabilization	   at	   cell-­‐cell	   junctions	   and,	   possibly,	   their	   rearrangements	  through	  clathrin-­‐mediated	  endocytosis.	  	  The	   border	   cell	   migration	   occurring	   during	   oogenesis	   in	   Drosophila	   is	  reminiscent	  of	   tumour	   cell	   invasion	   [Yoshida	  et	  al.,	   2004].	   Initially,	   the	  border	   cells	  are	   polarized	   epithelial	   cells	   with	   strong	   cell-­‐cell	   contacts.	   To	   start	   migration,	   cell	  polarity	   changes	   from	   apico-­‐basal	   to	   front-­‐rear,	   and	   proteins	   found	   at	   cell-­‐cell	  junctions	  reorganize	  at	  the	  invasive	  edge	  of	  the	  cell	  to	  facilitate	  motility	  and	  invasion	  [Pinheiro	  et	  al.,	  2004].	  During	  these	  events,	  myosin	  VI	  changes	  localization,	  from	  the	  baso-­‐lateral	  membrane	  to	  membrane	  ruffles	  at	  the	  front	  of	  moving	  cells	  [Pinheiro	  et	  
al.,	  2004].	  An	   interesting	  possibility	   is	   that	  at	   the	  onset	  of	  border	  cell	  migration,	  an	  isoform	  switch	   towards	   the	   shorter	  myosin	  VI	   isoform	  occurs.	  Nothing	   is	  known	  of	  the	   differential	   expression	   and	   functions	   of	   myosin	   VI	   isoforms	   in	   Drosophila.	  However,	   we	   noticed	   that	   different	   splicing	   variants	   also	   exist	   in	   the	   fly	   gene.	  Secondary	  structure	  prediction	  analysis	  suggested	  that,	  even	  if	  the	  primary	  sequence	  is	  not	  conserved,	  the	  exon	  that	  is	  skipped	  in	  the	  shortest	  isoforms	  encodes	  an	  alpha	  helix	  with	  length	  and	  position	  similar	  to	  the	  α2-­‐linker	  in	  mammals.	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In	  the	  last	  few	  years,	  the	  contribution	  of	  alternative	  splicing	  in	  human	  disease,	  particularly	   in	   cancer,	   has	   been	  widely	   recognized	   [Singh	   et	  al.,	   2012].	   Unbalanced	  expression	  of	   splicing	   variants	   or	   failure	   to	  properly	   express	   the	   correct	   isoform	   is	  clearly	   part	   of	   the	   biology	   of	   cancer	   cells	   [Biamonti	  et	  al.,	   2014].	   Cancer-­‐associated	  alternative	   splicing	   variants	   are	   now	   considered	   new	   tools	   for	   the	   diagnosis	   and	  classification	   of	   cancers	   and	   could	   become	   targets	   for	   innovative	   therapeutic	  interventions	  based	  on	  highly	  selective	  splicing	  correction	  approaches.	  The	  selective	  expression	  of	  myosin	  VIshort	   in	  several	  types	  of	  cancer,	  which	  we	  reported	  in	  Figure	  
39	   and	   40,	   may	   very	   well	   fit	   in	   this	   context.	   Our	   data	   suggest	   that	   cancer	   cells	  positively	  select	  myosin	  VIshort	  because	   it	   confers	   them	  with	  a	  migratory	  advantage.	  Although	  more	  work	   is	   required	   to	   understand	   how	   exon	   skipping	   of	  myosin	   VI	   is	  occurring	   in	   cancer	   cells,	   our	   findings	   reveal	   an	   unappreciated	   function	   for	   the	  regulation	  of	  alternative	  splicing	  of	  myosin	  VI	  in	  cancer	  biology.	  The	  identification	  of	  myosin	   VIshort	   as	   a	   regulator	   of	   cancer	   cell	   migration	   provides	   an	   exciting	   starting	  point	  to	  understand	  and	  therapeutically	  exploit	  novel	  key	  events	  in	  pathological	  cell	  migration.	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